0001437749-13-006114.txt : 20130515 0001437749-13-006114.hdr.sgml : 20130515 20130515161136 ACCESSION NUMBER: 0001437749-13-006114 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20130331 FILED AS OF DATE: 20130515 DATE AS OF CHANGE: 20130515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO KEY INTERNATIONAL INC CENTRAL INDEX KEY: 0001019034 STANDARD INDUSTRIAL CLASSIFICATION: COMPUTER COMMUNICATIONS EQUIPMENT [3576] IRS NUMBER: 411761861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-13463 FILM NUMBER: 13847117 BUSINESS ADDRESS: STREET 1: 3349 HIGHWAY 138 STREET 2: BUIDING D, SUITE B CITY: WALL STATE: NJ ZIP: 07719 BUSINESS PHONE: 6516870414 MAIL ADDRESS: STREET 1: 3349 HIGHWAY 138 STREET 2: BUIDING D, SUITE B CITY: WALL STATE: NJ ZIP: 07719 FORMER COMPANY: FORMER CONFORMED NAME: SAC TECHNOLOGIES INC DATE OF NAME CHANGE: 19961115 10-Q 1 bkyi_10q-033113.htm FORM 10-Q bkyi_10q-033113.htm
 
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q
 
x
QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended March 31, 2013
 
o
TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT
 
 
For the Transition Period from              to
 
Commission file number 1-13463
 
BIO-KEY INTERNATIONAL, INC.
(Exact Name of registrant as specified in its charter)
 
DELAWARE
 
41-1741861
(State or Other Jurisdiction of
Incorporation of Organization)
 
(IRS Employer
Identification Number)
 
3349 HIGHWAY 138, BUILDING D, SUITE B, WALL, NJ  07719
(Address of Principal Executive Offices)
 
(732) 359-1100
(Registrant’s telephone number, including area code)
 
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  x    No  o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x    No  o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer  o
 
Accelerated filer  o
     
Non-accelerated filer  o
 
Smaller Reporting Company  x
 
Indicate by check mark whether the registrant is a shell company (as defined by rule 12b-2 of the Exchange Act)  Yes  o   No  x
 
Number of shares of Common Stock, $.0001 par value per share, outstanding as of May 12, 2013 was 87,182,348
 
 
 

 
BIO-KEY INTERNATIONAL, INC.
 
INDEX
 
PART I. FINANCIAL INFORMATION
           
 
Item 1
Condensed Consolidated Financial Statements:
   
     
Balance Sheets as of March 31, 2013 (unaudited) and December 31, 2012
 
3
     
Statements of Income for the three months ended March 31, 2013 and 2012 (unaudited)
 
4
     
Statements of Cash Flows for the three months ended March 31, 2013 and 2012 (unaudited)
 
5
     
Notes to Condensed Consolidated Financial Statements (unaudited)
 
7
           
 
Item 2
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
11
           
 
Item 4
Controls and Procedures
 
16
           
PART II. OTHER INFORMATION
   
           
 
Item 6
Exhibits
 
16
           
Signatures
 
17
 
 
2

 
 
PART I — FINANCIAL INFORMATION
 
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
 
   
March 31,
2013
   
December 31,
2012
 
   
(Unaudited)
       
ASSETS
           
Cash and cash equivalents
  $ 451,748     $ 83,989  
Accounts receivable, net of allowance for doubtful accounts of $20,526 at March 31, 2013 and December 31, 2012
    449,110       604,784  
Due from factor
    94,380       189,904  
Inventory
    4,351       4,186  
Prepaid expenses and other
    59,303       25,088  
Total current assets
    1,058,892       907,951  
Equipment and leasehold improvements, net
    18,531       24,267  
Deferred finance costs
    55,521       -  
Deposits and other assets
    8,712       8,712  
Intangible assets—less accumulated amortization
    193,093       195,911  
Total non-current assets
    275,857       228,890  
TOTAL ASSETS
  $ 1,334,749     $ 1,136,841  
                 
LIABILITIES
               
Accounts payable
  $ 649,308     $ 931,276  
Accrued liabilities
    385,623       593,599  
Deferred revenue
    467,108       508,520  
Note payable – related party
    -       321,428  
Total current liabilities
    1,502,039       2,354,823  
Note Payable
    497,307       -  
Total non-current liabilities
    497,307       -  
TOTAL LIABILITIES
  $ 1,999,346     $ 2,354,823  
                 
                 
STOCKHOLDERS’ DEFICIENCY:
               
Common stock — authorized, 170,000,000 shares; issued and outstanding; 87,182,348 of $.0001 par value at March 31, 2013 and 78,155,413 December 31, 2012
    8,718       7,815  
Additional paid-in capital
    51,930,685       51,062,624  
Accumulated deficit
    (52,604,000 )     (52,288,421 )
TOTAL STOCKHOLDERS’ DEFICIENCY
    (664,597 )     (1,217,982 )
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY
  $ 1,334,749     $ 1,136,841  

 
The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.
 
 
3

 
 
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
 
   
Three months ended
March 31,
 
   
2013
   
2012
 
             
Revenues
           
Services
  $ 276,960     $ 395,854  
License fees and other
    527,683       1,014,573  
      804,643       1,410,427  
Costs and other expenses
               
Cost of services
    40,715       124,017  
Cost of license fees and other
    77,098       57,413  
      117,813       181,430  
Gross Profit
    686,830       1,228,997  
                 
Operating Expenses
               
Selling, general and administrative
    732,076       604,884  
Research, development and engineering
    262,809       254,487  
Total Operating Expenses
    994,885       859,371  
Operating (loss) income
    (308,055 )     369,626  
Other expenses
               
Interest expense
    (7,524 )     (6,128 )
Total Other expenses
    (7,524 )     (6,128 )
Net (loss) income
  $ (315,579 )   $ 363,498  
                 
Basic (Loss) Income per Common Share
  $ 0.00 *   $ 0.00 *
Diluted (Loss) Income per Common Share
  $ 0.00 *   $ 0.00 *
* Represents less than $0.01
               
                 
Weighted Average Shares Outstanding:
               
Basic
    81,465,289       78,155,413  
Diluted
    81,465,289       78,156,172  
 
 
The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.
 
 
4

 
 
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 
   
Three Months Ended March 31,
 
   
2013
   
2012
 
             
CASH FLOW FROM OPERATING ACTIVITIES:
           
Net (loss) income
  $ (315,579 )   $ 363,498  
Adjustments to reconcile net (loss) income to cash (used for) provided by operating activities:
               
Depreciation
    5,736       7,970  
Amortization
               
Intangible assets
    2,818       2,817  
Deferred costs
    1,682       -  
Share-based compensation
    12,447       20,741  
Change in assets and liabilities:
               
Accounts receivable trade
    155,674       100,290  
Due from factor
    95,524       -  
Inventory
    (165 )     1,129  
Prepaid expenses and other
    (34,215 )     (8,176 )
Accounts payable
    (281,968 )     (272,814 )
Accrued liabilities
    (207,976 )     18,016  
Deferred revenue
    (41,412 )     (65,905 )
Net cash (used for) provided by operating activities
    (607,434 )     167,566  
CASH FLOW FROM FINANCING ACTIVITIES:
               
Issuance of common stock
    902,693       -  
Repayment of note payable – related party
    (321,428 )     -  
Proceeds from issuance of note payable
    497,307       -  
Costs to issue common stock
    (46,176 )     -  
Financing costs for note payable
    (57,203 )     -  
Net cash provided by financing activities
    975,193       -  
NET INCREASE IN CASH AND CASH EQUIVALENTS
    367,759       167,566  
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
    83,989       43,437  
CASH AND CASH EQUIVALENTS, END OF PERIOD
  $ 451,748     $ 211,003  
 
 
The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.
 
 
5

 
 
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 
SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION

 
 
Three Months Ended March 31,
 
 
2013
 
2012
 
         
Cash paid for:
       
Interest
  $ 51,494     $  
 
 
The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.
 
 
6

 
 
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARY
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 
March 31, 2013 (Unaudited)
 
1.                      BASIS OF PRESENTATION
 
The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiary (collectively, the “Company”) and are stated in conformity with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).  The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Significant intercompany accounts and transactions have been eliminated in consolidation.
 
In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company’s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at December 31, 2012 was derived from the audited financial statements, but does not include all of the disclosures required by accounting principles generally accepted in the United States of America. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012 (the “Form 10-K”), filed on April 1, 2013.
 
Recently Issued Accounting Pronouncements
 
Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.
 
 
2.                      GOING CONCERN
 
The Company has incurred significant losses to date and at March 31, 2013,  had an accumulated deficit of approximately $53 million. In addition, broad commercial acceptance of the Company’s technology is critical to the Company’s success and ability to generate future revenues. At March 31, 2013, the Company’s total cash and cash equivalents were approximately $452,000, as compared to approximately $84,000 at December 31, 2012.
 
The Company has financed itself in the past through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. The Company currently requires approximately $390,000 per month to conduct  operations, a monthly amount that we have been unable to achieve through revenue generation.

During the three months ended March 31, 2013, the Company raised proceeds of $1,297,000 net of fees through the issuance of a senior secured promissory note and shares of common stock . See Notes 5 and 6.

If the Company is unable to generate sufficient revenue to meet our goals, it will need to obtain additional third-party financing to (i) conduct the sales, marketing and technical support necessary to execute its plan to substantially grow operations, increase revenue and serve a significant customer base; and (ii) provide working capital. No assurance can be given that any form of additional financing will be available on terms acceptable to the Company, that adequate financing will be obtained by the Company, in order to meet its needs, or that such financing would not be dilutive to existing shareholders.

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The matters described in the preceding paragraphs raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to meet its financing requirements on a continuing basis, and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.
 
 
7

 
 
3.                      SHARE BASED COMPENSATION
 
The following table presents share-based compensation expenses for continuing operations included in the Company’s unaudited condensed consolidated statements of operations:
 
   
Three Months Ended March 31,
 
   
2013
   
2012
 
             
             
Selling, general and administrative
  $ 11,121     $ 2,223  
Research, development and engineering
    1,326       18,518  
    $ 12,447     $ 20,741  
 
 
4.                      EARNINGS PER SHARE (“EPS”)
 
The Company’s basic EPS is calculated using net income available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of convertible notes and preferred stock.
 
The reconciliation of the numerator of the basic and diluted EPS calculations was as follows for the three month periods ended March 31, 2013 and 2012:
 
   
Three Months ended
March 31,
 
   
2013
   
2012
 
             
Basic Numerator:
           
             
Net (loss) income
  $ (315,579 )   $ 363,498  
                 
Basic Denominator:
    81,465,289       78,155,413  
Per Share Amount
  $ 0.00     $ 0.00  
 
The following table summarizes the potential weighted average shares of common stock that were included in the diluted per share calculation for the three months ended March 31, 2013 and 2012.
 
   
Three Months Ended
March 31,
 
   
2013
   
2012
 
             
Stock Options
    -       759  
 
   
Three Months ended
March 31,
 
   
2013
   
2012
 
             
Dilutive Numerator:
           
             
Net (loss) income
  $ (315,579 )   $ 363,498  
                 
Dilutive Denominator:
    81,465,289       78,156,172  
Per Share Amount
  $ 0.00*     $ 0.00*  
 
* Represents less than $0.01 per share
 
 
8

 
 
The following table sets forth the options and warrants which were excluded from the diluted per share calculation even though the exercise prices were  less than the average market price of the common shares because the effect of including these potential shares was antidilutive due to the net losses for the three months ended March 31, 2013 and 2012:
 
   
Three Months Ended
March 31,
 
   
2013
   
2012
 
             
Stock options
    647,660       -  
Warrants
    -       -  
                 
Total
    647,660       -  
 
The following table sets forth options and warrants which were excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:
 
   
Three Months Ended
March 31,
 
   
2013
   
2012
 
             
Stock options
    3,025,000       4,588,560  
Warrants
    8,250,000       8,250,000  
                 
Total
    11,275,000       12,838,560  
 

5.                      NOTES PAYABLE
 
The 2010 Exchange Agreement
 
Effective as of December 31, 2010, the Company entered into a Securities Exchange Agreement (the “2010 Exchange Agreement”) with Thomas Colatosti (“Colatosti”), the Company’s Chairman of the Board. Pursuant to the 2010 Exchange Agreement, Mr. Colatosti agreed to exchange all of his outstanding shares of Series D Convertible Preferred Stock, including all accrued and unpaid dividends thereon, and the 7% Convertible Promissory Note dated as of December 28, 2009 issued by the Company to Mr. Colatosti in the original principal amount of $64,878 for a new non-convertible 7% Secured Promissory Note in the original principal amount of $350,804 (the “Colatosti Note”).

The principal and interest under the Colatosti Note was scheduled to be repaid by the Company in cash on December 31, 2012. Pursuant to a Note Amendment and Extension Agreement effective as of December 31, 2012, the maturity date of the Colatosti Note was extended to March 31, 2013. In February 2013, the principal balance and accrued interest owing under the Colatosti Note was repaid from the proceeds of the new financing (see Note 2).  At March 31, 2013 and December 31, 2012, the amount payable under the Colatosti Note  was $0 and $321,428, respectively.

2013 Note Purchase Agreement
 
Pursuant to a Note Purchase Agreement dated February 26, 2013 by and between the Company and DRNC (the “InterDigital NPA”). Pursuant to the InterDigital NPA, the InterDigital Note was issued in a principal amount of $497,307 and bears interest at a rate of 7% per annum, with a default rate of 9% per annum while a nonpayment default is continuing. The InterDigital Note matures on December 31, 2015, is secured by a security interest in all of the tangible and intangible assets of the Company and is subject to acceleration upon an event of default. Under the InterDigital NPA, commencing July 1, 2013, the Company is required to comply with certain financial covenants, including a leverage ratio covenant and an annual limit on capital expenditures other than in the ordinary course of business.. A portion of the proceeds from the sale of the InterDigital Note were used to repay the Colatosti Note in full, with the remaining proceeds to be used for other general corporate purposes.  At March 31, 2013, the amount payable under the InterDigital Note was $497,307.
 
 
9

 

In connection with the InterDigital NPA and InterDigital Note, the Company incurred costs totaling $57,203.  Such costs were capitalized and are being amortized over the term of the InterDigital Note on the effective interest method.
 
 
6.                      STOCKHOLDERS’ DEFICIENCY

Issuances of Common Stock
 
Pursuant to a Securities Purchase Agreement dated February 26, 2013 by and between the Company and DRNC (the “InterDigital SPA”), the Company issued 4,026,935 shares of its common stock at a purchase price $0.10 per share, for an aggregate purchase price of $402,693. DRNC has anti-dilution rights under the InterDigital SPA that would require the Company to issue additional shares to DRNC on a full-ratchet basis if the Company, within the nine months following February 26, 2013, sells or issues any common stock or common stock equivalents (other than sales or issuances to directors, officers, employees or independent contractors in the ordinary course of business for compensation purposes and stock splits and stock dividends payable in respect of the Company’s common stock) having a purchase, exercise or conversion price per share of less than $0.10.

Concurrently with the closing of the transactions described above, the Company closed an equity financing with a number of private investors pursuant to a Securities Purchase Agreement dated February 26, 2013 by and between the Company and such private and institutional investors (the “Private Investor SPA”). Pursuant to the Private Investor SPA, the Company issued 5,000,000 shares of its common stock at a purchase price $0.10 per share, for an aggregate purchase price of $500,000.

In connection with the share issuances described above, the Company incurred costs of $46,176 which were offset against additional paid-in capital.
 
Issuances of Stock Options
 
For the three months ended March 31, 2013 and 2012, 2,300,000 and 1,125,000 stock options were granted, respectively. Terms of the options issued in 2013 include the following: term - 7 years, excercise price - $0.17, vesting - 3 years.
 
Derivative Liabilities

In connection with the issuances of equity instruments or debt, the Company may issue options or warrants to purchase common stock. In certain circumstances, these options or warrants may be classified as liabilities, rather than as equity. In addition, the equity instrument or debt may contain embedded derivative instruments, such as conversion options or listing requirements, which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative liability instrument. The Company accounts for derivative liability instruments under the provisions of FASB ASC 815, “Derivatives and Hedging.”
 
As discussed above, the Company issued shares to DRNC that contain anti-dilution rights.  The Company determined that the anti-dilution rights are embedded derivatives that must be bifurcated and recorded as derivative liabilities. In addition, the Company would be required to revalue the derivative liabilities at the end of each reporting period with the change in value reported on the statement of operations. The Company did not account for these derivative liabilities in its financial statements as it was determined to not be material.

 
7.                      SEGMENT INFORMATION
 
The Company has determined that its continuing operations are one discrete segment consisting of Biometric products. Geographically, North American sales accounted for approximately 98% and 97% of the Company’s total sales for the three months ended March 31, 2013 and 2012, respectively.
 
 
8.                      FAIR VALUES OF FINANCIAL INSTRUMENTS                                                                                                                      

Cash and cash equivalents, accounts and notes receivable, accounts payable, accrued liabilities, and notes payable, are carried at, or approximate, fair value because of their short-term nature.


9.                      MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLES

For the three months ended March 31, 2013 and 2012, three customers accounted for 61% and 76% of revenue, respectively.  At March 31, 2013, one customer accounted for 56% of accounts receivable.  At December 31, 2012, two customers accounted for 88% of accounts receivable.
 
 
10

 
 
ITEM 2.           MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS
 
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
 
The information contained in this Report on Form 10-Q and in other public statements by the Company and Company officers include or may contain certain forward-looking statements. All statements other than statements of historical facts contained in this Report on Form 10-Q, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generally identify forward-looking statements. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements.  Although we believe that our plans, intentions and expectations reflected in the forward-looking statements are reasonable, we cannot be sure that they will be achieved.  Particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: our history of losses and limited revune; our ability to raise additional capital; infringement on our intellectual propery; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition between us and other companies in the biometric technology industry; market acceptance of our products under development; delays in the development of products and statements of assumption underlying any of the foregoing, as well as other factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission.  All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing.  Except as required by law, we assume no duty to update or revise our forward-looking statements based on changes in internal estimates or expectations or otherwise.  Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. 
 
OVERVIEW
 
BIO-key International, Inc. (the “Company,” “BIO-key,” “we,” or “us) was founded in 1993 as a fingerprint biometric technology company. Biometric technology is the science of analyzing specific human characteristics which are unique to each individual in order to identify a specific person from a broader population. First incorporated as BBG Engineering, the company became SAC Technologies in 1994. The BIO-key name was introduced in 2002.
 
We develop and market advanced fingerprint biometric identification and identity verification technologies, cryptographic authentication-transaction security technologies, as well as related Identity Management and Credentialing software solutions. We were pioneers in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit card, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing.  Advanced BIO-key® technology has been and is used to improve both the accuracy and speed of competing finger-based biometrics.
 
In partnerships with OEMs, integrators, and solution providers, we provide biometric software solutions to private and public sector customers.  We provide the ability to positively identify and authenticate individuals before granting access to valuable corporate resources, web portals or applications in seconds.  Powered by our patented Vector Segment Technology™ our VST™, WEB-key® and BSP development kits are fingerprint biometric solutions that provide true interoperability with all major reader manufacturers, enabling application developers and integrators to seamlessly integrate fingerprint biometrics into virtually any application. 
 
We have developed what we believe is the most discriminating and effective commercially available finger-based biometric technology. Our primary focus is in marketing and selling this technology into commercial logical and physical Privilege Entitlement & Access Control markets.  Our primary market focus includes Mobile Payments & Credentialing, Online Payments and Credentialing, and Healthcare record and payment data security, among other things.  Our secondary focus includes government markets, primarily law enforcement forensic investigation and Homeland Security.
 
 
11

 
 
We continue to research and develop advancements in our capabilities, as well as exploring and developing potential strategic relationships, including potential business combinations and acquisitions, which could help us leverage our capability to deliver our solutions. We have built a direct sales force of professionals, and also team with resellers, integrators and partner networks with substantial experience in selling technology solutions to government and corporate customers.
 
STRATEGIC OUTLOOK
 
Historically, our largest market has been access control within highly regulated industries such as healthcare.  However, we believe the mass adoption of advanced smart-phone and hand-held wireless devices have caused commercial demand for advanced user authentication to emerge as viable.  The introduction of smart-phone capabilities, like Mobile Payments and Credentialing, could effectively require biometric user authentication on mobile devices to reduce risks of identity theft, payment fraud and other forms of fraud in the mobile or cellular based World Wide Web. As more services and payment functionalities, like Mobile Wallets and Near Field Communication (NFC), migrate to smart-phones, the value and potential risk associated with such systems should grow and drive demand and adoption of advanced user authentication technologies, including fingerprint biometrics and BIO-key solutions.
 
We believe there is potential for significant market growth in three key areas:
 
 
·
Corporate Network Access Control, including corporate campuses, computer networks and applications;
 
 
·
Consumer Mobile Credentialing, including mobile payments, credit and payment card programs, data and application access, and commercial loyalty programs; and.
 
 
·
Government Services and highly regulated industries, including Medicare, Medicaid, Social Security, drivers licenses, campus and school ID, passports/visas.
 
In the near-term, we expect to grow our business within the government services and  highly-regulated industries which we have historically had a strong presence, such as the healthcare industry.  We believe that continued heightened security and privacy requirements in these industries will generate increased demand for security solutions, including biometrics.
 
Over the longer term, we intend to expand our business into the Cloud and mobile computing industries. The emergence of Cloud computing and mobile computing are primary drivers of commercial and consumer adoption of advanced authentication applications, including biometric and BIO-key authentication capabilities.  As the value of assets, services and transactions increases on such networks, we expect that security and user authentication demand will rise proportionately.
 
CRITICAL ACCOUNTING POLICIES
 
For detailed information on our critical accounting policies and estimates, see our financial statements and notes thereto included in this Report and in our Annual Report on Form 10-K, for the year ended December 31, 2012.  There have been no material changes to our critical accounting policies and estimates from those disclosed in our most recent Annual Report on Form 10-K.
 
RECENT ACCOUNTING PRONOUNCEMENTS
 
Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.
 
 
12

 
 
RESULTS OF OPERATIONS
 
THREE MONTHS ENDED MARCH 31, 2013 AS COMPARED TO MARCH 31, 2012
 
INTRODUCTION
 
Consolidated Results of Operations - Percent Trend
 
   
Three Months Ended March 31,
 
   
2013
   
2012
 
Revenues
           
Services
    34 %     28 %
License fees and other
    66 %     72 %
Total Revenues
    100 %     100 %
Costs and other expenses
               
Cost of services
    5 %     9 %
Cost of license fees and other
    10 %     4 %
Total Cost of Goods Sold
    15 %     13 %
Gross profit
    85 %     87 %
                 
Operating expenses
               
Selling, general and administrative
    91 %     43 %
Research, development and engineering
    33 %     18 %
Total Operating Expenses
    124 %     61 %
Operating (loss) income
    -38 %     26 %
                 
Other income (expenses)
    -1 %     0 %
                 
Net (loss) income
    -39 %     26 %
 
 
Revenues and cost of goods sold
 
   
Three months ended
             
   
March 31,
             
   
2013
   
2012
   
$ Change
   
% Change
 
                         
Revenues
                       
Service
  $ 276,960       395,854     $ (118,894 )     -30 %
License & other
    527,683       1,014,573       (486,890     -48 %
Total Revenue
  $ 804,643     $ 1,410,427     $ (605,784 )     -43 %
                                 
Cost of goods sold
                               
Service
  $ 40,715       124,017       (83,302 )     -67 %
License & other
    77,098       57,413       19,685       34 %
Total COGS
  $ 117,813     $ 181,430     $ (63,617 )     -35 %
 
Revenues
 
For the three months ended March 31, 2013 and 2012, service revenues were $276,960 and $395,854, respectively, a decrease of $118,894, or 30%.  The decrease is due to lower non-recurring custom services revenue of approximately $120,000.  Recurring maintenance and support revenue remained relatively constant at $174,000 as compared to $173,000 during the three months ended March 31, 2012.
 
For the three months ended March 31, 2013, license and other revenue (comprised of third party hardware and royalty) decreased as a result of several contributing factors.  Core software license revenue decreased by approximately $545,000, or 60%, primarily as a result of no new large implementation in a blood center in 2013. For the three months ended March 31, 2013 and 2012, we continued to ship products to McKesson Corporation for the continued deployment of our identification technology in its AccuDose® product line, and for continued expansion of biometric ID deployments with commercial partners ChoicePoint /LexisNexis, Educational Biometric Technology, and Identimetrics. Third-party hardware sales increased by approximately $57,000, or 78%, due to continued expansions from existing customers.  Our royalty income for the three months ended March 31, 2013 and 2012 was derived primarily from an OEM agreement and increased from approximately $25,000 to approximately $26,000.
 
 
13

 
 
Costs of goods sold
 
For the three months ended March 31, 2013 cost of service decreased approximately $83,000 as a result of reduced costs associated with lower non-recurring custom services revenue. For the three months ended March 31, 2013, license and other costs increased $19,685 as a result of increases in third party hardware and third party license costs.
 
Selling, general and administrative
 
   
Three months ended
             
   
March 31,
             
   
2013
   
2012
   
$ Change
   
% Change
 
                         
Selling, general and administrative
  $ 732,076     $ 604,884     $ 127,192       21 %
 
Selling, general and administrative costs for the three months ended March 31, 2013 increased 21% from the corresponding period in 2012.  The increase was related to fees associated with  the InterDigital agreements, personnel costs and factoring fees, offset by a decrease in channel marketing expense related to decreased non-recurring custom services revenue, and a decrease in commission expense related to lower revenue.
 
Research, development and engineering
 
   
Three months ended
             
   
March 31,
             
   
2013
   
2012
   
$ Change
   
% Change
 
                         
Research, development and engineering
  $ 262,809     $ 254,487     $ 8,322       3 %
 
For the three months ended March 31, 2013, research, development and engineering costs increased 3% from the corresponding period in 2012 as a result of additional temporary outside services, offset by reduced travel and reduced share-based compensation expenses.
 
Other income and expense
 
   
Three months ended
             
   
March 31,
             
   
2013
   
2012
   
$ Change
   
% Change
 
                         
Interest expense
  $ (7,524 )   $ (6,128 )   $ (1,396     23 %
 
Interest expense during the three months ended March 31, 2013 was comprised of accrued interest on promissory notes issued in 2010 and 2013 (see Note 5 to our financial statements contained elsewhere in this report), and the amortized portion of the deferred financing costs for the promissory note issued in 2013. Interest expense for the three months ended March 31, 2012 consisted of accrued interest on the promissory note issued in 2010.

Off-Balance Sheet Arrangements
 
As of March 31, 2013, we did not have any relationships with unconsolidated entities or financial partners, such as entities often referred to as structured finance or variable interest entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.  As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.
 
 
14

 
 
LIQUIDITY AND CAPITAL RESOURCES
 
Cash Flows
 
Net cash used for operations during the three months ended March 31, 2013 was approximately $607,000 which includes a one time fees of approximately $133,000 related to the transactions with InterDigital . The cash used in operating activities was primarily attributable to the following items:
 
    Positive cash flows related to an decrease in accounts receivable of approximately $156,000 due to one large order received and paid for in the first quarter and approximately $96,000 in payments received from factored receivables;
     
    Negative cash flows related to a decrease in accounts payable and accrued expenses of approximately $490,000, attributable to working capital management, an increase in prepaid expenses of approximately $34,000, attributable to retaining specialized consultants,  and a decrease of approximately $41,000 in deferred revenue.
 
Net cash provided by financing activities during the three months ended March 31, 2013 was approximately $975,000 from the following activities :
 
    Positive cash flow from the issuance of 9,026,935 shares of common stock  for an aggregate purchase price of $902,693 and the issuance of a 2013 Note payable in the principal amount of $497,307
     
   
Negative cash flows of $321,000 from the repayment of a 2010 Note payable and approximately $46,000 for the one time fees associated with the stock issuance and approximately $57,000 for one time fees associated with the Note payable.
 
 
Net working capital deficit at March 31, 2013 was approximately $443,000 as compared to approximately $1,447,000 at December 31, 2012. The improvement was driven mainly by the financing activities in the first quarter of 2013.
 
Capital Resources
 
Since January 7, 1993 (date of inception), our capital needs have been principally met through proceeds from the sale of equity and debt securities.
 
 We expect capital expenditures to be less than $100,000 during the next twelve months.
 
 We do not currently maintain a line of credit or term loan with any commercial bank or other financial institution.
 
The following sets forth our primary sources of capital during the previous two years:

Effective December 31, 2010, Thomas Colatosti (“Colatosti”), our Chairman of the Board agreed to exchange all of his outstanding shares of Series D Convertible Preferred Stock, including all accrued and unpaid dividends thereon, and the 7% Convertible Promissory Note dated as of December 28, 2009 in the original principal amount of $64,878, for a new non-convertible 7% Secured Promissory Note in the original principal amount of $350,804 (the “Colatosti Note”).  In February 2013, the principal balance and accrued interest owing under the Colatosti Note was repaid in full from the proceeds of the financing with InterDigital described below.

On February 26, 2013, we issued a promissory note in the principal amount of $497,307 (the “InterDigital Note”) to DRNC Holdings.  The InterDigital Note accrues interest at a rate of 7% per annum, with a default rate of 9% per annum while a nonpayment default is continuing, matures on December 31, 2015, is secured by all of our tangible and intangible assets, and is subject to acceleration upon an event of default.  Commencing July 1, 2013, we are required to comply with certain financial covenants, including a leverage ratio covenant and an annual limit on capital expenditures other than in the ordinary course of business.  A portion of the proceeds from the sale of the InterDigital Note was used to repay the Colatosti Note in full, with the remaining proceeds to be used for general corporate purposes.  At March 31, 2013, $497,307 remained payable under the InterDigital Note.

On February 26, 2013, we issued 4,026,935 shares of common stock to DRNC for an aggregate purchase price of $402,963.  DRNC has anti-dilution rights that require us to issue additional shares to DRNC on a full-ratchet basis if, within the nine months following February 26, 2013, we sell or issue any common stock or common stock equivalents (other than sales or issuances to directors, officers, employees or independent contractors in the ordinary course of business for compensation purposes and stock splits and stock dividends payable in respect of our common stock) at a purchase, exercise or conversion price per share less than $0.10.

On February 26, 2013, we also issued 5,000,000 shares of common stock to a limited number of investors for an aggregate purchase price of $500,000.
 
 
15

 
 
As of December 2011, we entered into a 24-month accounts receivable factoring arrangement with a financial institution (the “Factor”). Pursuant to the terms of this arrangement,  from time to time, we sell to the Factor certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor  remits 75% of the accounts receivable balance to us (the “Advance Amount”), with the remaining balance, less fees payable by us, once the Factor collects the full accounts receivable balance from the customer. Factoring fees range from 2.75% to 15% of the face value of the invoice factored and are determined by the number of days required for collection of the invoice. In April 2012, the terms were updated from monthly to quarterly, and the 24-month arrangement was extended to August 1, 2014.  We expect to continue to use this factoring arrangement periodically to assist with our general working capital requirements.
 
Liquidity outlook
 
At March 31, 2013, our total cash and cash equivalents were approximately $452,000, as compared to approximately $84,000 at December 31, 2012.
 
As discussed above, we have historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and recently through factoring receivables. We currently require approximately $390,000 per month to conduct our operations, a monthly amount that we have been unable to consistently achieve through revenue generation.  During the first quarter of 2013, we generated approximately $805,000 of revenue, which is below our average monthly requirements.

If we are unable to generate sufficient revenue to meet our goals, we will need to obtain additional third-party financing to (i) conduct the sales, marketing and technical support necessary to execute our plan to substantially grow operations, increase revenue and serve a significant customer base; and (ii) provide working capital. Therefore, we may need to obtain additional financing through the issuance of debt or equity securities, or to restructure our financial position through transactions similar to those consummated during the 2009 to 2013 period.

Due to several factors, including our history of losses and limited revenue, our independent auditors have included an explanatory paragraph in their opinion related to our annual financial statements as to the substantial doubt about our ability to continue as a going concern. Our long-term viability and growth will depend upon the successful commercialization of our technologies and our ability to obtain adequate financing. To the extent that we require such additional financing, no assurance can be given that any form of additional financing will be available on terms acceptable to us, that adequate financing will be obtained to meet our needs, or that such financing would not be dilutive to existing stockholders. If available financing is insufficient or unavailable or we fail to continue to generate sufficient revenue, we may be required to further reduce operating expenses, delay the expansion of operations, be unable to pursue merger or acquisition candidates, or continue as a going concern.

 
ITEM 4. CONTROLS AND PROCEDURES
 
Disclosure Controls and Procedures
 
Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2013. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of March 31, 2013, our CEO and CFO concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
 
Changes in Internal Control Over Financial Reporting
 
No change in our internal control over financial reporting occurred during the fiscal quarter ended March 31, 2013, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 
PART II — OTHER INFORMATION
 
ITEM 6. EXHIBITS
 
The exhibits listed in the Exhibits Index immediately preceding such exhibits are filed as part of this Report.
 
 
16

 
 
SIGNATURES
 
In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 

 
BIO-Key International, Inc.
   
Dated: May 15, 2013
/s/ MICHAEL W. DEPASQUALE
 
Michael W. DePasquale
 
Chief Executive Officer
   
   
Dated: May 15, 2013
/s/ CECILIA C. WELCH
 
Cecilia C. Welch
 
Chief Financial Officer
 
 
17

 
 
EXHIBIT INDEX
 
Exhibit No.
 
Description
10.1
 
Note Purchase Agreement dated February 26, 2013 by and between the Company and DRNC Holdings, Inc.
     
10.2
 
Senior Secured Term Promissory Note dated February 26, 2013
     
10.3
 
Securities Purchase Agreement dated February 26, 2013 by and between the Company and DRNC Holdings, Inc.
     
10.4
 
Form of Securities Purchase Agreement dated February 26, 2013 by and between the Company and certain investors
     
31.1
 
Certificate of CEO of Registrant required under Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended
     
31.2
 
Certificate of CFO of Registrant required under Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended
     
32.1
 
Certificate of CEO of Registrant required under 18 U.S.C. Section 1350
     
32.2
 
Certificate of CFO of Registrant required under 18 U.S.C. Section 1350
     
101.INS**
 
XBRL Instance
     
101.SCH**
 
XBRL Taxonomy Extension Schema
     
101.CAL**
 
XBRL Taxonomy Extension Calculation
     
101.DEF**
 
XBRL Taxonomy Extension Definition
     
101.LAB**
 
XBRL Taxonomy Extension Labels
     
101.PRE**
 
XBRL Taxonomy Extension Presentation



 
 
18

 

 

 

 

 

 
EX-10.1 2 ex10-1.htm EXHIBIT 10.1 ex10-1.htm
 
Exhibit 10.1
 


 
 












$497,306.50 Senior Secured Note
 

 

 





____________________
 
NOTE PURCHASE AGREEMENT
____________________
 


February 26, 2013
 
 




 
 

 

BIO-key International, Inc.
3349 Highway 138, Building D, Suite A
Wall, New Jersey 07719
 
February 26, 2013
 
DRNC Holdings, Inc.
200 Bellevue Parkway, Suite 300
Wilmington, DE 19809

Ladies and Gentlemen:
 
BIO-key International, Inc., a Delaware corporation (the “Company”), agrees with you as follows.
 
1.             Definitions.
 
1.1.           Definitions of Capitalized Terms.  The terms defined in this Section 1.1, whenever used in this Agreement, shall, unless the context otherwise requires, have the following respective meanings:
 
1933 Act” shall have the meaning set forth in the Securities Purchase Agreement.
 
1934 Act” shall have the meaning set forth in the Securities Purchase Agreement.
 
Affiliate” shall have the meaning set forth in the Securities Purchase Agreement.
 
Attributable Debt” shall mean, on any date, (a) in respect of any Capitalized Lease of any Person, the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP, (b) in respect of any Synthetic Lease Obligation, the capitalized amount of the remaining lease or similar payments under the relevant lease or other applicable agreement or instrument that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP if such lease or other agreement or instrument were accounted for as a Capitalized Lease and (c) all Synthetic Debt of such Person.
 
beneficial ownership” shall be determined in the manner set forth in Rule 13d-3 of the Commission under the 1934 Act.
 
Capital Expenditures” shall mean, with respect to any Person for any period, any expenditure in respect of the purchase or other acquisition of any fixed or capital asset (excluding normal replacements and maintenance which are properly charged to current operations).
 
Capitalized Leases” shall mean all leases that have been or should be, in accordance with GAAP, recorded as capitalized leases.
 
 
 

 
 
Change of Control” shall mean any event or transaction or series of events or transactions occurring at any time after the Closing Date for whatever reason following which (i) any person or group of persons (within the meaning of the 1934 Act) (other than the Restricted Subsidiaries (or any of its Affiliates)) (a) shall acquire beneficial ownership or control of more than 50% of the outstanding Shares of the Company or any Restricted Subsidiary or (b) shall have the right or ability by voting power, contract or otherwise to direct or cause the direction of the management and policies of the Company or any Restricted Subsidiary or (ii) there is a change in a majority of the directors of the Company other than changes in the ordinary course of business not resulting from (x) any proxy or consent solicitation by a third party, (y) any settlement or compromise of any actual or threatened proxy or consent solicitation by a third party, or (z) any nomination of directors other than a nomination by the Company.
 
Closing” and “Closing Date” shall have the respective meanings specified in Section 4.
 
Colatosi Note” shall have the meaning set forth in the Company’s Annual Report on Form 10-K filed with the Commission on April 16, 2012.
 
Commission” shall mean the Securities and Exchange Commission or any other federal agency from time to time administering the 1993 Act and/or the 1934 Act.
 
Company” shall mean BIO-key International, Inc., a Delaware corporation.
 
Debt” shall mean, with respect to any Person, without duplication, and whether or not included as indebtedness or liabilities in accordance with GAAP, all of the following:  (i) indebtedness of such Person for borrowed money; (ii) the principal of and premium, coupon or interest obligations (if any) in respect of obligations, and all other obligations, of such Person evidenced by bonds, debentures, notes or other similar instruments (whether of a convertible nature or otherwise); (iii) the maximum amount of all direct or contingent obligations of such Person arising under any letter of credit, banker's acceptance, guarantee, surety, performance bond, or similar transaction or instrument; (iv) all Attributable Indebtedness in respect of Capitalized Leases and Synthetic Lease Obligations of such Person and all Synthetic Debt of such Person; (v) all obligations of such Person to pay the deferred purchase price of property or services (other than trade accounts payable in the ordinary course of business and not past due for more than 90 days after the date on which such trade account was created); (vi) indebtedness (excluding prepaid interest thereon) secured by a Lien on property owned or being purchased by such Person (including indebtedness arising under conditional sales or other title retention agreements), whether or not such indebtedness shall have been assumed by such Person or is limited in recourse; (vii) all net obligations of such Person under any swap, hedging or similar agreement or combination thereof designed to protect against fluctuations in interest rates, currency exchange rates or other changes in value; (viii) all Guarantees by such Person of Indebtedness of others; (ix) any amendment, supplement, modification, deferral, renewal, extension, refunding or refinancing or any liability or obligation of the types referred to in clauses (i) through (viii) above; (x) any and all amounts of any prepayment premium, penalties, break fees, expenses and other similar obligations which would arise if any of the Debt referred to in the foregoing clauses (i) through (ix) were prepaid, extinguished, unwound or settled in full as of the date hereof.
 
 
-2-

 
 
Default” shall mean any condition or event which constitutes or, after notice or lapse of time or both, would constitute an Event of Default.
 
Distributions” shall have the meaning specified in Section 12.6.
 
EBITDA” shall mean, at any date of determination, an amount equal to Net Income of the Company and its Restricted Subsidiaries on a consolidated basis for the most recently completed Rolling Period plus (a) the following to the extent deducted in calculating such Net Income:  (i) cash Interest Expense, (ii) the provision for Federal, state, local and foreign income taxes payable in cash, (iii) depreciation and amortization expense and (iv) other non-recurring expenses reducing such Net Income which do not represent a cash item in such period or any future period (in each case of or by the Company and its Restricted Subsidiaries for such Rolling Period) and minus (b) the following to the extent included in calculating such Net Income:  (i) Federal, state, local and foreign income tax credits and (ii) all non-cash items increasing Net Income (in each case of or by the Company and its Restricted Subsidiaries for such Rolling Period).
 
Event of Default” shall have the meaning specified in Section 13.1.
 
Funding Date” shall mean the date on which the Purchase Price is remitted by the Lender to the Company pursuant to Section 4.
 
GAAP” shall mean generally accepted accounting principles as in effect in the United States from time to time, consistently applied.
 
Guarantee” of or by any Person (the “guarantor”) means any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Debt or other obligation of any other Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Debt or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (b) to purchase or lease property, securities or services for the purpose of assuring the owner of such Debt or other obligation of the payment thereof, (c) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Debt or other obligation or (d) as an account party in respect of any letter of credit or letter of guaranty issued to support such Debt or obligation; provided, that the term Guarantee shall not include endorsements for collection or deposit in the ordinary course of business.
 
Intercreditor Agreement” shall mean the Intercreditor Agreement dated as of the date hereof between the Lender and Versant.
 
Interest Expense” shall mean, for any Rolling Period, the sum of (a) all interest, premium payments, debt discount, fees, charges and related expenses in connection with borrowed money (including capitalized interest) or in connection with the deferred purchase price of assets, in each case to the extent treated as interest in accordance with GAAP, (b) all interest paid or payable with respect to discontinued operations and (c) the portion of rent expense under Capitalized Leases that is treated as interest in accordance with GAAP, in each case, of or by the Company and its Restricted Subsidiaries on a consolidated basis for the most recently completed Rolling Period.
 
 
-3-

 
 
Interest Payment Date” shall have the meaning specified in Section 2.
 
Interest Rate” shall have the meaning specified in Section 2.
 
Lender” shall have the meaning set forth in the Note.
 
Leverage Ratio” means, as of any date of determination, the ratio of (a) Debt (excluding Debt evidenced by the Note) as of such date to (b) EBITDA (plus Debt evidenced by the Note) of the Company and its Restricted Subsidiaries on a consolidated basis for the most recently completed Rolling Period.
 
"Loan" shall mean the extension of credit made by the Lender to the Company pursuant to the purchase and sale of the Note hereunder and evidenced by the Note.
 
Loan Documents” shall mean this Agreement, the Note, any Note Guarantee, the Security Agreement, the Intercreditor Agreement and each of the other agreements, documents and instruments executed pursuant hereto or thereto, each as it may from time to time be amended, modified or supplemented.
 
Material Adverse Effect” shall mean any event, circumstance, condition, development or effect that, individually or in the aggregate with other events, circumstances, conditions, developments and effects, has a material adverse effect on the assets, liabilities, properties, results of operations, condition (financial or otherwise), prospects or business of the Company and its Restricted Subsidiaries taken as a whole.
 
Material Debt” shall mean Debt (other than the Note) of the Company or any of its subsidiaries in an aggregate principal amount exceeding $100,000.
 
Maturity Date” shall mean December 31, 2015.
 
Net Income” shall mean, for any period, the consolidated net income (or loss) of the Company and its Restricted Subsidiaries, determined on a consolidated basis in accordance with GAAP.
 
Note” shall have the meaning specified in Section 2.
 
Note Guarantee” shall have the meaning specified in Section 2.
 
Organizational Documents” of any Person shall mean such Person’s charter, certificate of incorporation, code of regulations, by-laws, partnership agreement, operating agreement, limited liability company agreement, trust agreement, as applicable, and/or any other similar agreement, document or instrument.
 
Other Agreements” shall mean (a) that certain R&D Co-operation Agreement dated on or about the date hereof between the Company and the Lender and (b) that certain Exclusive Patent License Agreement dated on or about the date hereof between the Company and the Lender, in each case as amended from time to time.
 
 
-4-

 
 
Person” shall have the meaning set forth in the Securities Purchase Agreement.
 
Premium” when used in conjunction with references to principal of and interest on the Note, shall mean any amount due upon any payment or prepayment of the Note, other than principal and interest.
 
Restricted Subsidiary” shall mean any subsidiary of the Company (a) with assets representing at least 5% of the total assets of the Company and its subsidiaries on a consolidated basis at any date of determination or (b) with revenues equal to or greater than 5% of the total revenues of the Company and its subsidiaries on a consolidated basis during any fiscal quarter.
 
Rolling Period” shall mean, at any date of determination, the most recently completed four fiscal quarters of the Company.
 
Secured Obligations” shall mean and include all loans, advances, debts, liabilities and obligations, howsoever arising, owed by the Company and Restricted Subsidiaries to the Lender of every kind and description, now existing or hereafter arising under or pursuant to the terms of the Loan Documents or the Other Agreements, including without limitation, all interest, fees, charges, expenses, and attorneys’ fees and costs payable by the Company and Restricted Subsidiaries hereunder and thereunder, in each case, whether direct or indirect, absolute or contingent, due or to become due, and whether or not arising after the commencement of a proceeding under Title 11 of the United States Code (11 U. S. C. Section 101 et seq.), as amended from time to time (including without limitation post-petition interest) and whether or not allowed or allowable as a claim in any such proceeding.
 
Securities Purchase Agreement” shall mean that certain Securities Purchase Agreement dated as of the date hereof, by and between you and the Company.
 
Security Agreement” shall have the meaning specified in Section 2.
 
Shares” of any Person shall include any and all shares of capital stock, partnership interests, limited liability company interests, membership interests, or other shares, interests, participations or other equivalents (however designated and of any class) in the capital of, or other ownership interests in, such Person.
 
"Swap Agreement" shall mean any agreement with respect to any swap, forward, future or derivative transaction or option or similar agreement involving, or settled by reference to, one or more rates, currencies, commodities, equity or debt instruments or securities, or economic, financial or pricing indices or measures of economic, financial or pricing risk or value or any similar transaction or any combination of these transactions; provided that no phantom stock or similar plan providing for payments only on account of services provided by current or former directors, officers, employees or consultants of the Company or its subsidiaries shall be a Swap Agreement.
 
 
-5-

 
 
Synthetic Debt” shall mean, with respect to any Person as of any date of determination thereof, all obligations of such Person in respect of transactions entered into by such Person that are intended to function primarily as a borrowing of funds (including any minority interest transactions that function primarily as a borrowing) but are not otherwise included in the definition of “Debt” or as a liability on the consolidated balance sheet of such Person and its Restricted Subsidiaries in accordance with GAAP.
 
Synthetic Lease Obligation” shall mean the monetary obligation of a Person under (a) a so-called synthetic, off-balance sheet or tax retention lease, or (b) an agreement for the use or possession of property (including sale and leaseback transactions), in each case, creating obligations that do not appear on the balance sheet of such Person but which, upon the application of any bankruptcy, insolvency or similar laws to such Person, would be characterized as the indebtedness of such Person (without regard to accounting treatment).
 
this Agreement” (and similar references to any of the other Loan Documents) shall mean, and the words “herein” (and “therein”), “hereof” (and “thereof”), “hereunder” (and “thereunder”) and words of similar import shall refer to, such instruments as they may from time to time be amended, modified or supplemented.
 
Versant” shall mean Versant Funding LLC, a Delaware limited liability company.
 
Versant Facility” shall mean the factoring facility provided under the Versant Factoring Agreement and the other agreements related thereto.
 
Versant Factoring Agreement” shall mean the Factoring Agreement dated as of December 20, 2011 (as amended from time to time) between the Company and Versant.
 
 “Versant Lien” shall mean the security interest granted by the Company in favor of Versant in connection with the Versant Facility, under the Security Agreement dated as of December 20, 2011 (as amended from time to time) between the Company and Versant.
 
2.           Authorization of the Note; etc.
 
(a)        The Company has authorized the issue and sale of a Senior Secured Term Promissory Note (herein, together with any note issued in exchange therefor or replacement thereof, called the “Note”) in the principal amount of $497,306.50.  The Note is to be substantially in the form of Exhibit A attached hereto.  The Note shall be due and payable on the Maturity Date.  The Note shall bear interest at a per annum rate equal to seven percent (7%) (the “Interest Rate”).  Interest on the Note is payable semi-annually in cash in arrears on June 30th and December 31st of each year (each an “Interest Payment Date”), commencing June 30, 2013, and at maturity (whether by acceleration, declaration or otherwise).  In no event shall the amount paid or agreed to be paid as interest on the Note exceed the highest lawful rate permissible under any law applicable thereto.
 
 
-6-

 
 
(b)        The Note shall be guaranteed by all existing and future direct or indirect Restricted Subsidiaries, as applicable from time to time, pursuant to a Note Guarantee in a mutually agreeable form (as amended from time to time, the “Note Guarantee”).  The Note and any Note Guarantee shall be secured by a security agreement substantially in the form of Exhibit B attached hereto (as amended from time to time, the “Security Agreement”).  The Company shall notify the Lender at least 30 days before the formation or acquisition of any Restricted Subsidiary and shall cause such Restricted Subsidiary to join the Security Agreement as a Grantor thereunder, pursuant to documentation in form and substance satisfactory to the Lender, at the time of such formation or acquisition.
 
3.           Issuance of the Note.  Subject to all of the terms and conditions hereof, the Company agrees to issue and sell to you, and you agree to purchase, a senior secured note in the form of Exhibit A hereto (a “Note”) in the principal amount of $497,306.50 (the “Purchase Price”).
 
4.           Closing.  The sale and purchase of the Note hereunder (the “Closing”) shall take place on the date hereof (the “Closing Date”) following the satisfaction (or waiver) of the conditions to Closing set forth in Section 5 through an exchange of consideration and documents using wire transfers, overnight courier service, electronic mail and/or facsimile transmission, or at such other time and place and by such other means as you and the Company mutually agree upon.  At the Closing, upon satisfaction of the conditions precedent in Section 5, the Company will deliver to you one Note registered in your name in the Company’s records and you shall wire the Purchase Price amount to the Company in immediately available funds, within two days after the Closing Date.  The Company hereby irrevocably authorizes and directs you to remit the full Purchase Price within two days after the Closing Date to the account specified on Schedule A hereto.
 
5.           Conditions to Closing.  Your obligation to purchase the Note hereunder is subject to the fulfillment to your satisfaction, prior to or at the Closing and the Funding Date, of the following conditions:
 
(a)        You shall have received this Agreement, the Security Agreement and the Intercreditor Agreement, duly executed and delivered by each party thereto, and the same shall be in full force and effect.  All agreements, documents and instruments required to be executed, delivered, filed and/or recorded in connection therewith, including, without limitation, UCC financing statements, shall have been so executed and delivered and shall be in proper form for filing and/or recording.  Without limiting the foregoing, you shall have received evidence of the filing of the UCC-3 amendment attached as Exhibit A to the Intercreditor Agreement in respect of the Versant Lien with the Delaware Secretary of State.
 
(b)        All proceedings in connection with the transactions contemplated by the Loan Documents and all agreements, documents and instruments incident to such transactions shall be reasonably satisfactory in substance and form to you.
 
(c)        The representations and warranties made by the Company in this Agreement and each other Loan Document shall have been true and correct when made, and shall be true and correct on the Closing Date and Funding Date.
 
 
-7-

 
 
(d)        No Default shall have occurred or shall result from the transactions contemplated by the Loan Documents.
 
(e)        Except for any notices required or permitted to be filed after the Closing Date with certain federal and state securities commissions, the Company shall have obtained all governmental and other third-party approvals required in connection with the lawful sale and issuance of the Note.
 
(f)        At the Closing, the sale and issuance by the Company, and the purchase by you, of the Note shall be legally permitted by all laws and regulations to which you or the Company are subject.
 
(g)        No Material Adverse Effect shall have occurred.
 
(h)        The Company and you shall have received a payoff letter from the holder of the Colatosi Note in a form satisfactory to you indicating that payment of the payoff amount set forth therein, to occur contemporaneously with the payment of the Purchase Price hereunder using the proceeds of the Note, shall constitute repayment in full of all Debt evidenced by the Colatosi Note.
 
6.           Representations and Warranties.  The representations and warranties made by the Company to you in Section 4 of the Securities Purchase Agreement are incorporated by reference herein.
 
7.           Use of Proceeds.  The Company will use the proceeds of the sale of the Note solely to repay the Colatosi Note in full on the Funding Date with the remaining proceeds to be used for other general corporate purposes of the Company.  
 
8.           Purchase for Investment, etc.  The representations and warranties made by you in Section 5 of the Securities Purchase Agreement are incorporated by reference herein as through made with respect to your investment in the Note, and in addition you represent and warrant:  (a) that the execution and delivery of, and performance of your obligations under, the Loan Documents by you do not violate or constitute a default under, or require any consent, approval or authorization of (except for those which have been obtained), or other action by, any other Person under any material agreement or instrument to which you are party, or under any judgment, decree, order, law, statute, rule or regulation applicable to you and (b) that the Company and its Affiliates have not made any representations, warranties or covenants to you other than those incorporated by reference, in this Agreement in connection with your investment in the Note.  The acceptance of the Note by you at the Closing shall constitute your confirmation of the foregoing representations and warranties.  You understand and agree that the Note is being sold to you in a transaction which is exempt from the registration requirements of the 1933 Act, and that the Note will not be registered under the 1993 Act at issuance or in the future.
 
9.           Payments; Interest.
 
9.1.           Interest.
 
 
-8-

 
 
(a)        The Note (and Loan evidenced thereby) shall bear interest, payable by the Company in cash semi-annually in arrears on each Interest Payment Date and on the Maturity Date, at a per annum rate equal to seven percent (7%), until the outstanding principal amount of the Note shall be paid in full in cash.
 
9.2.           Repayment and Prepayments of the Note.
 
(a)        On the Maturity Date, the Company shall pay the then outstanding principal amount of, and all accrued and unpaid interest on, the Note.
 
(b)        At any time and from time to time after December 31, 2014 and prior to the Maturity Date, the Company may, at its option, upon not less than thirty (30) days’ or more than sixty (60) days’ notice, prepay without premium all or any part of the then outstanding principal of the Note, together with all accrued and unpaid interest on the principal amount so prepaid.
 
(c)        Once repaid or prepaid, no amount of the Note may be reborrowed.
 
9.3.           Payments Generally.
 
(a)        The Company and Restricted Subsidiaries will make all payments due under the Note and other Loan Documents in immediately available funds in U.S. dollars on the date such payment is due at the address for such purpose specified below the Lender’s name on Schedule B hereto, or at such other address, or in such other manner, as the Lender or other registered holder of the Note may from time to time direct in writing.
 
10.           Copies of Certain Documents.  The Company will keep at its principal executive office a true copy of each of the Loan Documents as at the time in effect, including all exhibits thereto and all amendments, supplements, waivers and consents in respect thereof, and will furnish copies thereof to, and will cause the same to be available for inspection at such office during normal business hours by, any holder of any Note upon such holder’s reasonable request.
 
11.           Further Assurances.  From time to time hereafter, the Company will execute and deliver, or will cause to be executed and delivered, such additional agreements, documents and instruments and will take all such other actions as any holder or holders of the Note may reasonably request for the purpose of implementing or effectuating the provisions of this Agreement or any of the other Loan Documents.
 
12.           Covenants of the Company and its Restricted Subsidiaries.  From and after the date hereof and thereafter so long as the Note shall remain outstanding, the Company and its Restricted Subsidiaries will duly perform and observe each and all of the covenants and agreements hereinafter set forth in this Section 12:
 
12.1.           Financial Covenants.
 
 
-9-

 
 
(a)        Maintenance of Debt to EBITDA Ratio.  The Company will not permit the Leverage Ratio at any time during any period of four fiscal quarters of the Company set forth below to be greater than the ratio set forth below opposite such period:
 
 
Rolling Period Ending During the
Following Periods:
 
Maximum
Leverage Ratio
 
Closing Date through June 30, 2013
 
n/a
 
July 1, 2013 through September 30, 2013
 
3.00 to 1.00
 
October 1, 2013 and thereafter
 
2.50 to 1.00

 
(b)        Capital Expenditures.  The Company will not, or permit any Restricted Subsidiary to, make or become legally obligated to make Capital Expenditures in excess of $100,000 in the aggregate during any fiscal year, except for Capital Expenditures in the ordinary course of business.
 
12.2.           Limitation on Liens.  The Company will not create, incur, assume or suffer to exist, or permit any Restricted Subsidiary to create, incur, assume or suffer to exist, any mortgage, deed of trust, pledge, lien, security interest or other charge or encumbrance (including the lien or retained security title of a conditional vendor) of any nature, upon or with respect to any of its properties, now owned or hereinafter acquired, or assign or otherwise convey any right to receive income, except that the foregoing restrictions shall not apply to mortgages, deeds of trust, pledges, liens, security interests or other charges or encumbrances:
 
(a)        imposed by law for taxes, assessments or governmental charges or levies on property of the Company or any Restricted Subsidiary if the same (1) shall not yet be due, or (2) (x) are being contested in good faith and by appropriate proceedings and (y) the Company or such Restricted Subsidiary has set aside on its books adequate reserves with respect thereto in accordance with GAAP;
 
(b)        carriers’, warehousemen’s and mechanics’ liens and other similar liens imposed by law, arising in the ordinary course of business and securing obligations that are not overdue by more than 60 days;
 
(c)        arising out of pledges or deposits under workmen’s compensation laws, unemployment insurance, old age pensions, or other social security or retirement benefits, or similar legislation;
 
(d)        securing the performance of bids, tenders, contracts (other than for the repayment of borrowed money), statutory obligations and surety bonds, in each case in the ordinary course of business;
 
(e)        in the nature of zoning restrictions, easements and rights or restrictions of record on the use of real property imposed by law or arising in the ordinary course of business which do not materially detract from the affected property’s value or impair its use or interfere with the ordinary course of conduct of the Company or any of its subsidiaries;
 
 
-10-

 
 
(f)        arising by operation of law in favor of the owner or sublessor of leased premises and confined to the real property rented and not applicable to any Collateral;
 
(g)        that are judgment liens in respect of judgments that do not constitute an Event of Default;
 
(h)        arising out of a purchase money mortgage or purchase money security interest on personal property to secure the purchase price of such property (or to secure Debt incurred solely for the purpose of financing the acquisition of any such property), provided that such purchase money mortgage or purchase money security interest does not extend to any other or different property of the Company or any Restricted Subsidiary, and, further, provided that at the time of such transaction there does not exist an Event of Default or an event which, but for the requirement that notice be given or time elapse or both, would constitute an Event of Default; and
 
(i)        so long as Versant and the Versant Lien remain subject to and bound by the Intercreditor Agreement, and subordinated pursuant to the Intercreditor Agreement, constituting the Versant Lien.
 
12.3.           Limitation on Transactions with Affiliates.  Neither the Company nor any Restricted Subsidiary will enter into any transaction of any kind with any Affiliate of the Company, whether or not in the ordinary course of business, other than on fair and reasonable terms substantially as favorable to the Company or such Restricted Subsidiary as would be obtainable by the Company or such Restricted Subsidiary at the time in a comparable arm’s length transaction with a Person other than an Affiliate.
 
12.4.           Limitation on the Company’s Consolidation, Merger or Sale.  The Company will not merge or consolidate with, or sell, assign, lease or otherwise dispose of or voluntarily part with the control of (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereinafter acquired), to, any Person, or permit any Restricted Subsidiary to do any of the foregoing, except for sales or other dispositions of assets in the ordinary course of business and except that (1) any Restricted Subsidiary may merge into or consolidate with or transfer assets to any other Restricted Subsidiary, and (2) any Restricted Subsidiary may merge into or transfer assets to the Company.
 
12.5.           Limitation on the Disposition of Assets.  Neither the Company nor any Restricted Subsidiary will sell, assign, lease, convey, transfer or otherwise dispose of any assets or enter into any agreement to do any of the foregoing outside of the ordinary course of business.
 
12.6.           Limitation on Dividends and/or Distributions.  The Company will not declare or pay any dividends, purchase, redeem, retire, or otherwise acquire for value any of its capital stock (or rights, options or warrants to purchase such shares) now or hereafter outstanding, return any capital to its stockholders as such, make any distribution of assets to its stockholders as such, or create any restrictions on any of the foregoing actions under its Organizational Documents or otherwise, or permit any Restricted Subsidiary to do any of the foregoing (such transactions being hereinafter referred to as “Distributions”), except that the Restricted Subsidiaries may declare and make payment of cash and stock dividends, return capital and make distributions of assets to the Company; provided, however, that nothing herein contained shall prevent the Company from:
 
 
-11-

 
 
(a)        effecting a stock split or declaring or paying any dividend consisting solely of shares of any class of capital stock to the holders of shares of such class of capital stock;
 
(b)        redeeming any stock of a deceased stockholder out of insurance held by the Company on that stockholder’s life; or
 
(c)        to the extent provided under the Company’s stock option plan approved by its board of directors, redeeming any stock of a departing employee at a redemption price per share that does not exceed the purchase price per share paid to the Company for such stock;
 
if in the case of any such transaction there does not exist at the time of such Distribution an Event of Default or an event which, but for the requirement that notice be given or time elapse or both, would constitute an Event of Default and provided that such Distribution can be made in compliance with the other terms of this Agreement.
 
12.7.           Limitation on Issuances of Preferred Stock.  The Company will not cause or permit the issuance of any preferred stock of subsidiaries of the Company that are not Restricted Subsidiaries under this Agreement.
 
12.8.           Limitation on Making Certain Investments.  The Company will not make or permit any Restricted Subsidiary to make, any loan or advance or guarantee to any person, or purchase, otherwise acquire, or permit any Restricted Subsidiary to purchase or otherwise acquire, the capital stock, assets comprising the business of, obligations of, or any other interest in, any Person, except:
 
(a)        investments by the Company or a Restricted Subsidiary in evidences of indebtedness issued or fully guaranteed by the United States of America and having a maturity of not more than one year from the date of acquisition;
 
(b)        investments by the Company or a Restricted Subsidiary in certificates of deposit, notes, acceptances and repurchase agreements having a maturity of not more than one year from the date of acquisition issued by a bank organized in the United States having capital, surplus and undivided profits of at least $100,000,000 and whose parent holding company has long-term debt rated Aa1 or higher, and whose commercial paper (if rated) is rated Prime 1, by Moody’s Investors Service, Inc.;
 
(c)        investments by the Company or a Restricted Subsidiary in the highest-rated commercial paper having a maturity of not more than one year from the date of acquisition; and
 
 
-12-

 
 
(d)        loans or advances from: (x) a Restricted Subsidiary to the Company, (y) the Company to a Restricted Subsidiary, or (z) in the case of funds that were initially loaned or advanced by the Company, from a Restricted Subsidiary to another Restricted Subsidiary; provided, however, that in the case of (y) and (z) each such Restricted Subsidiary has guaranteed all of the Company’s obligations under the Note, and such guarantee is in form and substance acceptable to you. 
 
12.9.           Swap Agreements. The Company will not, and will not permit any Restricted Subsidiary to, enter into, create, incur, assume or suffer to exist any Swap Agreements or obligations in respect thereof except in the ordinary course of business for non-speculative purposes.
 
12.10.           Lines of Business.  The Company will not, and will not permit any Restricted Subsidiary to, engage in any material line of business substantially different from those lines of business conducted by the Company and its Restricted Subsidiaries on the date hereof or any business substantially related or incidental thereto.
 
12.11.           Fiscal Year.  The Company will not, and will not permit any Restricted Subsidiary to, permit the fiscal year of the Company or any Restricted Subsidiary to end on a day other than December 31 in any calendar year.
 
12.12.           Prepayments, Etc. of Indebtedness.  The Company will not, and will not permit any Restricted Subsidiary to, prepay, redeem, purchase, defease or otherwise satisfy prior to the scheduled maturity thereof in any manner, or make any payment in violation of any subordination terms of, any Debt, except the prepayment of the Note in accordance with the terms of this Agreement and the Note.
 
12.13.           Debt.  The Company will not, and will not permit any Restricted Subsidiary to, create, incur, assume or suffer to exist any Debt, except:
 
(a)        Debt under the Note and other Loan Documents;
 
(b)        Debt of the Company or any of its Restricted Subsidiaries which does not rank senior in right of payment to the Note or Loan; provided that (1) both immediately before and after the incurrence of such Debt, no Default has occurred and is continuing or would result from such incurrence, (2) both immediately before and after the incurrence of such Debt, the Company is in compliance with Sections 12.1(a) and 12.1(b) and (3) at least 5 business days before the incurrence of such Debt, the Lender shall have received evidence satisfactory to it of the Company’s compliance with clauses (1) and (2) of this paragraph, including a certificate of a senior financial officer of the Company with reasonably detailed calculations certifying such compliance, and (4) any and all intercompany Debt shall be unsecured and subordinated to the Note and Loan, on terms and pursuant to documentation satisfactory to the Lender; and
 
 
-13-

 
 
(c)        Debt in respect of Capitalized Leases, Synthetic Lease Obligations and purchase money obligations for fixed or capital assets within the limitations set forth in Section 12.2(h); provided that (1) both immediately before and after the incurrence of such Debt, no Default has occurred and is continuing or would result from such incurrence, (2) both immediately before and after the incurrence of such Debt, the Company is in compliance with Sections 12.1(a) and 12.1(b) and (3) at least 5 business days before the incurrence of such Debt, the Lender shall have received evidence satisfactory to it of the Company’s compliance with clauses (1) and (2) of this paragraph, including a certificate of a senior financial officer of the Company with reasonably detailed calculations certifying such compliance.
 
12.14.           The Company will, and will cause each of its Restricted Subsidiaries to:
 
(a)        do or cause to be done all things necessary to preserve, renew and keep in full force and effect its legal existence and the rights, licenses, permits, privileges and franchises material to the conduct of its business; provided that the foregoing shall not prohibit any merger, consolidation, liquidation or dissolution permitted under Section 12.4;
 
(b)        pay and discharge as the same shall become due and payable, all its obligations and liabilities, including (a) all tax liabilities, assessments and governmental charges or levies upon it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by the Company or such Restricted Subsidiary; (b) all lawful claims which, if unpaid, would by law become a lien upon its property;
 
(c)        keep and maintain all property material to the conduct of its business in good working order and condition, ordinary wear and tear excepted;
 
(d)        keep proper books of record and account in which full, true and correct entries are made of all dealings and transactions in relation to its business and activities; and permit any representatives designated by the Lender, upon reasonable prior notice and at reasonable times, and at Lender’s sole expense, to visit and inspect its properties, to examine and make extracts from its books and records;
 
(e)        comply in all material respects with all laws, rules, regulations and orders of any governmental authority applicable to it or its property;
 
(f)        use the proceeds of the Note and Loan to repay the Debt evidenced by the Colatosi Note in full on the Closing Date and for general corporate purposes not in contravention of any law or of any Loan Document;
 
(g)        furnish the Lender with prompt written notice of any Default or Material Adverse Effect, or of any event or condition which could reasonably be expected to have a Material Adverse Effect;
 
(h)        within 30 days after each fiscal quarter end, deliver to the Lender a certificate of a senior financial officer of the Company (i) certifying as to whether a Default has occurred and is continuing and, if a Default has occurred and is continuing, specifying the details thereof and any action taken or proposed to be taken with respect thereto, and (ii) setting forth reasonably detailed calculations demonstrating compliance with Section 12.1;
 
 
-14-

 
 
(i)        promptly following any request therefor, furnish the Lender with such other information regarding the operations, business affairs and financial condition of the Company or any Restricted Subsidiary, or compliance with the terms of any Loan Document, as the Lender may reasonably request;
 
(j)        by August 1, 2014, terminate the Versant Facility and deliver evidence reasonably satisfactory to the Lender of termination of the Versant Lien; and
 
(k)        promptly and in any event within three business days after a senior officer of the Company obtains knowledge or receives notice thereof, furnish the Lender with notice of the occurrence of any “Default” (as such term is defined under the Versant Facility documents) under the Versant Facility.
 
13.           Remedies.
 
13.1.           Events of Default Defined; Acceleration of Maturity.  If any one or more of the following events (“Events of Default”) shall occur and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment, decree or order of any court or any order, rule or regulation of any administrative or governmental body), that is to say:
 
(a)        if default shall be made in the due and punctual payment of (i) any principal of the Note when and as the same become due and payable or (ii) any interest on the Note or any other amount owing to the Lender under the Loan Documents when and as the same shall become due and payable and such default in the payment of interest or such other amount shall have continued for a period of 5 business days;
 
(b)        (i) if default shall be made in the performance or observance of any covenants, agreements or conditions contained in Section 12 of this Agreement, or Section 5 or 6.2 of the Security Agreement; or (ii) if default shall be made in the performance or observance of any other covenants, agreements or conditions contained in this Agreement or any of the other Loan Documents and such default shall have continued for a period of 30 days after the receipt by the Company of written notice of such default from you;
 
(c)        if the Company or any Restricted Subsidiary shall make a general assignment for the benefit of creditors, or shall not pay its debts as they become due, or shall admit in writing its inability to pay its debts as they become due, or shall file a voluntary petition in bankruptcy, or shall be adjudicated bankrupt or insolvent, or shall file any petition or answer seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, or shall file any answer admitting or not contesting the material allegations of a petition filed against it in any such proceeding, or shall seek or consent to or acquiesce in the appointment of any trustee, custodian, receiver, liquidator or fiscal agent for it or for all or any substantial part of its properties, or shall take any action in contemplation of the foregoing;
 
 
-15-

 
 
(d)        if, within 60 days after the commencement of an action against the Company or any Restricted Subsidiary seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, such action shall not have been dismissed or all orders or proceedings thereunder affecting the operations or the business of the Company or any Restricted Subsidiary stayed, or if the stay of any such order or proceeding shall thereafter be set aside, or if, within 60 days after the appointment without the consent or acquiescence of the Company or any Restricted Subsidiary of any trustee, custodian, receiver, liquidator or fiscal agent for the Company or any Restricted Subsidiary and/or for all or any substantial part of its properties, such appointment shall not have been vacated;
 
(e)        if, under the provisions of any law for the relief or aid of debtors, any court or governmental agency of competent jurisdiction shall assume custody or control of the Company or any Restricted Subsidiary or of all or any substantial part of its properties and such custody or control shall not be terminated or stayed within 60 days from the date of assumption of such custody or control;
 
(f)        if any representation or warranty made by or on behalf of the Company or any Restricted Subsidiary in this Agreement or any other Loan Document shall prove to have been false or incorrect in any material respect on the date as of which made;
 
(g)        if a Change of Control shall occur prior to the Maturity Date and the Company has not previously prepaid the Note in full and in cash in accordance with Section 9.2(b), provided, however, that an Event of Default shall not be deemed to have occurred under this clause (g) if the Company has given the Lender, at least 30 days before such Change of Control, both prior written notice of such Change of Control and the opportunity to sell the Note to the Company at one hundred and three percent (103%) of the then outstanding principal amount plus all accrued and unpaid interest on the Note, and if the Company has consummated such sale to the Lender if the Lender has exercised its sale right under this clause (g);
 
(h)        if a final judgment or order for the payment of money in excess of $100,000 shall be rendered against the Company or any of its subsidiaries and the same shall remain undischarged for a period of 30 days during which execution shall not be effectively stayed, or any judgment, writ, assessment, warrant of attachment, or execution or similar process shall be issued or levied against a substantial part of the property of the Company or any of its subsidiaries, if any and such judgment, writ, or similar process shall not be released, stayed, vacated or otherwise dismissed within 30 days after issue or levy;
 
(i)        if any event or condition occurs that results in Material Debt becoming due prior to its scheduled maturity or that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders of any Material Debt or any trustee or agent on its or their behalf to cause any Material Debt to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; or
 
 
-16-

 
 
(j)        if the Security Agreement shall cease to create a valid and perfected first-priority lien (subject to liens permitted by Section 12.2) on the Collateral purported to be covered thereby;
 
then, in the case of any Event of Default (other than one of the character described in subdivisions (c), (d) or (e) of this Section 13.1) the Lender may, by notice to the Company, declare the then outstanding principal of the Note forthwith due and payable, together with unpaid interest accrued thereon, and thereupon the principal of the Note so declared to be due and payable, together with interest accrued thereon and all other accrued Secured Obligations, shall become due and payable immediately, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Company and each Restricted Subsidiary, and the Company shall forthwith upon any such acceleration pay to you the then outstanding principal of and unpaid interest accrued on the Note and all other outstanding Secured Obligations; provided that, in the case of an Event of Default of the character described in subdivisions (c), (d) or (e) of this Section 13.1, the then outstanding principal of the Note shall forthwith become due and payable, together with unpaid interest accrued thereon and all other accrued Secured Obligations (including without limitation any interest accruing after the commencement of any action or proceeding under any bankruptcy, insolvency or other similar law, and any other interest that would have accrued but for the commencement of such proceeding, whether or not any such interest is allowed as an enforceable claim in such proceeding), without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived by the Company and each Restricted Subsidiary, and the Company shall forthwith upon any such acceleration pay to the holder or holders of the Note the then outstanding principal of and unpaid interest accrued on the Note and all other outstanding Secured Obligations.
 
13.2.           Default Interest Rate.  During the occurrence and continuance of any Event of Default under Section 13.1(a), the Note shall bear interest at a rate equal to the Interest Rate plus two percent (2%) per annum.
 
14.           Transfers; Assignments.  Notwithstanding anything to the contrary contained herein or in any of the other Loan Documents, neither the Company nor any Restricted Subsidiary may assign or otherwise transfer any of its rights or obligations under any Loan Document to any Person without the prior written consent of the Lender.  The Lender may sell or grant participation interests in any of its rights or obligations under any Loan Document to any Person without the consent of the Company.  The Lender may assign or otherwise transfer any of its rights or obligations under any Loan Document to (a) any Affiliate of the Lender without the consent of the Company and (b) any other Person with the prior written consent of the Company (such consent not to be unreasonably withheld or delayed); provided, that no consent of the Company shall be required if a Default has occurred and is continuing.
 
 
-17-

 
 
15.           Replacement of the Note.  Upon receipt by the Company of reasonably satisfactory evidence of the loss, theft, destruction or mutilation of the Note and (in the case of loss, theft or destruction) of reasonably satisfactory indemnity, and (in the case of mutilation) upon surrender of such Note, the Company will execute and deliver in lieu of such Note a new Note of like tenor and dated so as not to result in any loss of interest.
 
16.           Amendment and Waiver.  No term of this Agreement or, unless explicitly provided otherwise therein, of any of the other Loan Documents may be amended, modified, supplemented or waived, except pursuant to an agreement in writing entered into by the Company and the Lender.  Executed or true and correct copies of any amendment, waiver or consent effected pursuant to this Section 16 shall be delivered by the Company to the holder of Note promptly following the effective date thereof.
 
17.           Method of Payment of the Note.  Irrespective of any provision hereof or of the other Loan Documents to the contrary, so long as you shall hold the Note, the Company will make all payments thereon to you by such method and at such address as you may designate in writing, without requiring any presentation or surrender of such Note, provided that if the Note and all other Secured Obligations shall be paid, prepaid and/or repurchased in full in cash, such Note shall be surrendered to the Company promptly following such payment, prepayment or repurchase and cancelled.
 
18.           Notices.  Any notice or other communication hereunder shall be made at the addresses, in the manner, and with the effect provided in Section 9.5 of the Securities Purchase Agreement.
 
19.           Survival of Agreements, Representations and Warranties, etc.  All covenants, agreements, representations and warranties of the Company and Restricted Subsidiaries contained herein and in the other Loan Documents shall survive the Closing Date.
 
20.           Setoff.  If an Event of Default shall have occurred and be continuing, the Lender and its Affiliates are hereby authorized at any time and from time to time, to the fullest extent permitted by applicable law, to set off and apply any and all obligations (in whatever currency) at any time due and owing by the Lender or any such Affiliate to or for the credit or the account of the Company against any and all of the obligations of the Company now or hereafter existing under this Agreement or any other Loan Document, irrespective of whether or not the Lender shall have made any demand under this Agreement or such other Loan Document.  The rights of the Lender and its affiliates under this Section are in addition to other rights and remedies (including other rights of setoff) that the Lender and its affiliates may have.
 
 
-18-

 
 
21.           Expenses, etc.  The Company shall pay all reasonable out-of-pocket expenses incurred by the Lender (including the reasonable fees, charges and disbursements of counsel for the Lender), in connection with the collection, enforcement, workout or restructuring of this Agreement and the other Loan Documents or any amendments, modifications or waivers of the provisions hereof or thereof, or the negotiation and preparation of any such amendments, modifications or waivers (whether or not the transactions contemplated hereby or thereby shall be consummated).   The Company shall indemnify the Lender and the Lender’s Affiliates and the partners, directors, officers, employees, agents, trustees and advisors of the Lender and of the Lender’s affiliates (each such Person being called an “Indemnitee”) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses (including the fees, charges and disbursements of any counsel for any Indemnitee), incurred by any Indemnitee or asserted against any Indemnitee by any third party or by the Company or any Restricted Subsidiary arising out of (i) the breach of any representation or warranty or the execution or delivery by the Company or any Restricted Subsidiary of this Agreement, any other Loan Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby, or the administration of this Agreement and the other Loan Documents, (ii) the use or proposed use of proceeds of the Note or Loan (except to the extent that such losses, claims, damages, liabilities and related expenses arose solely from the Other Agreements and not from any Loan Document; it being understood and agreed by the Company and Lender that nothing herein or in any other Loan Document shall limit or prejudice the expense and indemnification provisions of the Other Agreements), or (iii) any claim, litigation, investigation or proceeding relating to any of the foregoing; provided that the indemnity provided in this Section 21 shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnitee.
 
22.           Successors and Assigns.  This Agreement and, unless explicitly provided otherwise therein, each of the other Loan Documents shall be binding on each of the parties hereto and their respective administrators, executors, heirs, representatives, successors and permitted assigns.
 
23.           Governing Law; Jurisdiction.
 
(a)        This Agreement shall be construed in accordance with and governed by the law of the State of New York.
 
(b)        Each party hereto hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive (except to the extent provided in Section 10.2 of the Security Agreement) jurisdiction of the Supreme Court of the State of New York sitting in New York County, Borough of Manhattan, and of the United States District Court for the Southern District of New York, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement or any other Loan Document, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York State or, to the extent permitted by law, in such Federal court.  Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.  Each party hereto hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to any Loan Document in any court referred to in this paragraph.  Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.  Each party to this Agreement irrevocably consents to service of process in the manner provided for notices in Section 18.  Nothing in any Loan Document will affect the right of any party to any Loan Document to serve process in any other manner permitted by law.
 
 
-19-

 
 
24.           Waiver of Jury Trial.  EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO ANY LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).
 
25.           Miscellaneous.  This Agreement and the other Loan Documents are subject to the confidentiality provisions set forth in the Securities Purchase Agreement.  The headings in this Agreement and in each of the other Loan Documents are for purposes of reference only and shall not limit or otherwise affect the meaning hereof or thereof.  This Agreement (together with the other Loan Documents) embodies the entire agreement and understanding between you and the Company and supersedes all prior agreements and understandings relating to the subject matter hereof.  Each covenant contained herein and in each of the other Loan Documents shall be construed (absent an express provision to the contrary) as being independent of each other covenant contained herein and therein, so that compliance with any one covenant shall not (absent such an express contrary provision) be deemed to excuse compliance with any other covenant.  If any provision in this Agreement or in any of the other Loan Documents refers to any action taken or to be taken by any Person, or which such Person is prohibited from taking, such provision shall be applicable, whether such action is taken directly or indirectly by such Person.  In case any provision in this Agreement or any of the other Loan Documents shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.  This Agreement and, unless explicitly provided otherwise therein, each of the other Loan Documents, may be executed in any number of counterparts and by the parties hereto or thereto, as the case may be, on separate counterparts but all such counterparts shall together constitute but one and the same instrument.  The parties hereto have participated jointly in the negotiation and drafting of this Agreement, and if an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.
 
[The remainder of this page is intentionally left blank.]
 
 
-20-

 
 
If you are in agreement with the foregoing, please sign the form of agreement on the accompanying counterparts of this Agreement, whereupon it shall become a binding agreement under seal between you and the Company.  Please then return one of such counterparts to the Company.
 
 
Very truly yours,
 
       
       
       
  By: /s/ Michael W. DePasquale  
    Mike DePasquale, President and CEO  
 
 
The foregoing Agreement is hereby agreed to
as of the date hereof.

DRNC HOLDINGS, INC.


By: /s/ Daniel Mullarkey                     
Name: Daniel Mullarkey
Title: Treasurer

 
 

 
 
Schedule A

Company Wire Instructions
 
 
PAY TO: SILICON VALLEY BANK
  3003 TASMAN DRIVE, SANTA CLARA, CA 95054
  UNITED STATES OF AMERICA
   
   
ROUTING & TRANSIT #:
121140399
   
SWIFT CODE: SVBKUS6S
   
FOR CREDIT OF: BIO-key International, Inc.
  85 Rangeway Road, BLDG 1
  North Billerica, MA 01862
  UNITED STATES OF AMERICA
   
FINAL CREDIT ACCOUNT: 3300615308
 
 
 

 
 
Schedule B

Lender’s Address


DRNC Holdings, Inc.
200 Bellevue Parkway, Suite 300
Wilmington, DE 19809
 
 
 

 
 
Exhibit A
 
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS.  THIS NOTE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR SAID STATE SECURITIES LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE MAKER THAT SUCH REGISTRATION IS NOT REQUIRED.

 
SENIOR SECURED TERM PROMISSORY NOTE
 
$497,306.50
February 26, 2013
 

 
FOR VALUE RECEIVED, BIO-key International, Inc., a Delaware corporation, having an address at 3349 Highway 138, Building D, Suite A, Wall, New Jersey 07719 (the “Maker”), promises to pay to the order of DRNC HOLDINGS, INC., its successors and assigns, having a place of business at 200 Bellevue Parkway, Suite 300, Wilmington, DE 19809 (the “Lender”), the sum of FOUR HUNDRED NINETY-SEVEN THOUSAND THREE HUNDRED SIX DOLLARS AND FIFTY CENTS ($497,306.50) together with interest thereon, or on the amount from time to time outstanding hereunder, such interest rate to be computed as hereinafter provided.  Capitalized terms used without definition herein shall have the meaning set for in the Note Purchase Agreement (as defined herein).
 
Commencing on June 30, 2013 and continuing through and including the Maturity Date (as defined below), the Maker shall pay the Lender interest, semi-annually on June 30th and December 31st of each year, in arrears and in cash, on the principal amount outstanding hereunder at the rate of seven percent (7%) per annum (the “Interest Rate”).  Interest shall be computed on a three hundred sixty (360) day year and a thirty day month, provided however, that all outstanding principal amounts together with interest thereon shall be due and payable on the first to occur of: (i) December 31, 2015 or (ii) redemption or repurchase by the Maker; unless sooner due and payable after acceleration (“Maturity Date”).
 
During the continuance of any Event of Default under Section 13.1(a) of the Note Purchase Agreement, the Note shall bear interest at a rate equal to the Interest Rate plus two percent (2%) per annum.
 
This Note may be prepaid in whole or in part without penalty pursuant to the terms and conditions set forth in Section 9.2(b) of the Note Purchase Agreement.
 
This Note is secured by a security interest in the tangible and intangible assets owned by the Maker and its Restricted Subsidiaries (as defined in that certain Note Purchase Agreement dated as of the date hereof, by and between the Maker and the Lender (the “Note Purchase Agreement”) which was granted by the Maker and its Restricted Subsidiaries in favor of the Lender in the Security Agreement.
 
This Note shall become immediately due and payable without further notice or demand, and notwithstanding any prior waiver of any breach or default or other indulgence by the holder of this Note, upon the occurrence and continuance of any Event of Default and in accordance with the terms of Section 13 of the Note Purchase Agreement.
 
 
 

 
 
Notwithstanding any provision contained herein, or in any of the other Loan Documents, or contained in any mortgage and security agreement, conditional assignment of rents, or other instrument or agreement now or hereafter executed in connection with this Note, the maximum amount of interest and other charges in the nature thereof contracted for, or payable hereunder or thereunder, shall not exceed the maximum amount which may be lawfully contracted for, charged and received in this loan transaction all as determined by the final judgment of a court of competent jurisdiction, including all appeals therefrom.  This Note and the loan evidenced hereby shall be governed in all respects by the law of the State of New York.
 
All payments due hereunder shall be made at the office of the Lender as set forth in the preamble hereto or such other place as the Lender may designate from time to time in writing.
 
The invalidity or unenforceability of any provision hereof, or any other instrument, agreement or document now or hereafter executed in connection with the loan evidenced hereby shall not impair or vitiate any other provision of any of such instruments, agreements and documents, all of which provisions shall be enforceable to the fullest extent now or hereafter permitted by law.
 
THE MAKER AND THE LENDER HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE (TO THE EXTENT PERMITTED BY APPLICABLE LAW) ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY OF ANY DISPUTE ARISING UNDER THIS NOTE OR ANY OTHER LOAN DOCUMENT.
 
Executed as a sealed instrument.

 
WITNESS:
  BIO-key International, Inc.
       
       
   
By:
 

 
- A-2 -

 
 
Exhibit B
 
SECURITY AGREEMENT
 
This Security Agreement (this “Agreement”) is made as of February 26, 2013 by and between BIO-key International, Inc., a Delaware corporation (the “Grantor”), and DRNC Holdings, Inc., a Delaware corporation (together with its successors and assigns, the “Secured Party”).
 
WHEREAS, the Grantor and the Secured Party have entered into a Note Purchase Agreement dated as of the date hereof (as amended from time to time, the “Note Purchase Agreement”) pursuant to which the Grantor has executed a Term Promissory Note in favor of the Secured Party (as amended from time to time, the “Note”).
 
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor hereby agrees with the Secured Party as follows:
 
1.           Definitions.  Capitalized terms used but not otherwise defined herein shall have the definitions given to such terms in the Note Purchase Agreement.  Unless otherwise defined herein or in the Note Purchase Agreement or the context otherwise requires, terms for which meanings are provided in the Uniform Commercial Code as in effect from time to time in all relevant jurisdictions (the “UCC”) are used in this Agreement with such meanings.
 
2.           Grant of Security.  As collateral security for the prompt payment and performance in full when due (whether at stated maturity, by acceleration or otherwise) of all the Secured Obligations, the Grantor hereby pledges and grants to the Secured Party a lien on and security interest in all of the Grantor’s right, title and interest in, to and under the following property, wherever located, whether now owned by the Grantor or hereafter acquired and whether now existing or hereafter coming into existence (collectively, the “Collateral”):  (i) all Accounts, (ii) all Equipment, Goods, Inventory and Fixtures, (iii) all Documents, Instruments and Chattel Paper, (iv) all Letters of Credit and Letter-of-Credit Rights, (v) all Investment Property, (vi) all intellectual property and intellectual property rights, (vii) the Commercial Tort Claims described on Schedule 2 hereto, (viii) all General Intangibles, (ix) all Deposit Accounts and securities accounts, (x) all Supporting Obligations, (xi) all books and records relating to the Collateral, and (xii) all other personal property of the Grantor, whether tangible or intangible, and all Proceeds and products of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of, each of the foregoing, and any and all Proceeds of any insurance, indemnity, warranty or guaranty payable to the Grantor from time to time with respect to any of the foregoing.
 
3.           Security for Obligations.  This Agreement and the Collateral in which the Secured Party is granted a security interest hereunder secures the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of all the Secured Obligations.
 
 
 

 
 
4.           Grantors Remain Liable.  Anything contained herein to the contrary notwithstanding, (a) the Grantor shall remain liable under any contracts and agreements included in the Collateral, to the extent set forth therein, to perform all of its duties and obligations thereunder to the same extent as if this Agreement had not been executed, (b) the exercise by the Secured Party of any of its rights hereunder shall not release any Grantor from any of its duties or obligations under the contracts and agreements included in the Collateral, and (c) the Secured Party shall not have any obligation or liability under any contracts, licenses, and agreements included in the Collateral by reason of this Agreement, nor shall the Secured Party be obligated to perform any of the obligations or duties of any Grantor thereunder or to take any action to collect or enforce any claim for payment assigned hereunder.
 
5.           General Covenants of Grantor.  The Grantor shall:
 
5.1.           not sell, lease, transfer, or otherwise dispose of the Collateral or any interest therein without the prior written consent of the Secured Party except in the ordinary course of business and if no material adverse change to the business, assets, properties, prospects or financial condition of the Company or its subsidiaries could reasonably be expected to result therefrom;
 
5.2.           not use or permit any Collateral to be used unlawfully or in violation of any provision of this Agreement or any applicable statute, regulation or ordinance or any policy of insurance covering the Collateral;
 
5.3.           give the Secured Party at least 30 days’ prior written notice of (i) any change in the Grantor’s name or (ii) any merger, consolidation, reincorporation, reorganization, conversion or other action that results in a change of the jurisdiction of organization of the Grantor or otherwise affects the perfection and/or priority of the security interest granted hereunder;
 
5.4.           pay as and when due and payable all taxes, levies, license fees, assessments, and other impositions levied on the Collateral or any part hereof or for its use and operation;
 
5.5.           ensure that the security interest in and lien on the Collateral granted to the Secured Party hereunder constitutes and will constitute (a) a legal and valid security interest in all the Collateral securing the payment and performance of the Secured Obligations, and (b) a first-priority, perfected security interest in and lien on the Collateral, subject only to liens expressly permitted by Section 12.2 of the Note Purchase Agreement.
 
6.           Maintenance of Collateral and Insurance.
 
6.1.           The Grantor shall maintain the Collateral in good condition and repair and shall make all necessary repairs, replacements, additions, and improvements thereto.  The Grantor will hold and preserve its records concerning its all of its accounts and, without limiting the generality of the foregoing, for not less than 3 years from the date on which each of Grantor’s accounts arose, the Grantor shall maintain complete records of such account and all documentation relating thereto.
 
 
- B-2 -

 
6.2.           The Grantor will maintain casualty and liability insurance with financially sound and reputable insurance companies in such amounts and coverage as may be reasonably satisfactory to the Secured Party, with losses payable, in the case of casualty policies, to the Grantor and the Secured Party as their respective interests may appear.  All insurance policies shall note and endorse the Secured Party as loss payee and additional insured and shall contain such other terms and conditions as may be customarily required by Secured Party.  All insurance proceeds received by the Secured Party may be applied in its discretion to the satisfaction of the Secured Obligations or to repair or replacement of any property which sustained the casualty, except as otherwise required by applicable law.
 
7.           Further Assurances.  The Grantor agrees that from time to time the Grantor will, at its expense, promptly execute and deliver all further instruments and documents, and take all further action, that may be necessary or desirable, or that the Secured Party may reasonably request, in order to perfect and protect any security interest granted or purported to be granted hereby, and the first priority (subject only to liens expressly permitted by Section 12.2 of the Note Purchase Agreement) of such security interest, or to enable the Secured Party to exercise and enforce its rights and remedies hereunder with respect to any Collateral.
 
8.           Authorization to File Financing Statements.  The Grantor hereby authorizes the Secured Party to file one or more financing or continuation statements, and amendments thereto, relative to all or any part of the Collateral without the signature of any Grantor and ratifies the prior filing of any financing statements by the Secured Party.
 
9.           The Secured Party Appointed Attorney-in-Fact.  The Grantor hereby constitutes and appoints the Secured Party its true and lawful attorney-in-fact, irrevocably, with full power after the occurrence of an Event of Default (in the name of the Grantor or otherwise) to act, require, demand, receive, compound, and give acquittance for any and all monies and claims for monies due or to become due to the Grantor under or arising out of the Collateral, to endorse any checks or other instruments or orders in connection therewith and to file any claims or take any action or institute any proceedings which the Secured Party may deem to be necessary or advisable in the premises, which appointment as attorney is coupled with an interest.
 
10.           Remedies.
 
10.1.           Following the occurrence of a default hereunder or under the Note or Note Purchase Agreement which continues beyond any applicable grace period the Secured Party shall have all of its rights and remedies hereunder and those provided by law or in equity.  The Secured Party shall have all of the rights and remedies of a secured party under the UCC and shall have full power and authority to sell or otherwise dispose of the Collateral or any part thereof.  Any such sale or other disposition, subject to the provisions of applicable law, may be by public or private proceedings and may be made by one or more contracts, as a unit or in parcels, at such time and place, by such method, in such manner and on such terms as the Secured Party may determine.  Except as required by law, such sale or other disposition may be made without advertisement or notice of any kind or to any person.  Where reasonable notification of the time or place of such sale or other disposition is required by law, such requirement shall have been met if such notice is delivered as provided in the Agreement, at least ten (10) days before the time of such sale or other disposition.  Upon notice from the Secured Party, the Grantor shall assemble the Collateral at a time and place specified by the Secured Party.  To the extent permitted by law, the Secured Party or any other holder of the Secured Obligations may buy any or all of the Collateral upon any sale thereof.  To the extent permitted by law, upon any such sale or sales, the Collateral so purchased shall be held by the purchaser absolutely free from any claims or rights of whatsoever kind or nature, including any equity of redemption or any similar rights, all such equity of redemption and any similar rights being hereby expressly waived and released by the Grantor.  In the event any consent, approval or authorization of any governmental agency shall be necessary to effectuate any such sale or sales, the Grantor shall execute, as necessary, all applications or other instruments as may be required.
 
 
- B-3 -

 
 
10.2.           The Secured Party may commence proceedings in any court of competent jurisdiction for the appointment of a receiver (which term shall include a receiver-manager) of the Collateral or of any part thereof.  The Secured Party may, if permitted without the commencement of a proceeding, appoint any person to be a receiver of the Collateral or any part thereof and may remove any receiver so appointed and appoint another in his stead.  Any such receiver appointed by the Secured Party, or a court at the request of the Secured Party, shall have power (i) to take possession of the Collateral or any part thereof; (ii) to carry on the business of the Grantor; (iii) to borrow money on the security of the Collateral for the maintenance, preservation or protection of the Collateral or any part thereof or for the carrying on of the business of the Grantor; and (iv) to sell, lease or otherwise dispose of the whole or any part of the Collateral at public auction, by public tender or by private sale, either for cash or upon credit, at such time and upon such terms and conditions as the receiver may determine; provided that the Secured Party shall not be in any way responsible for any misconduct or negligence of any such receiver.
 
11.           Application of Proceeds.
 
11.1.           Except as expressly provided elsewhere in this Agreement, all proceeds received by the Secured Party in respect of any sale of, collection from, or other realization upon all or any part of the Collateral shall be applied as follows:
 
(a)           first, to the payment of any and all expenses and fees (including reasonable attorneys fees) incurred by the Secured Party in obtaining, taking possession of, removing, insuring, repairing, storing, and disposing of Collateral and any and all amounts incurred by the Secured Party in connection therewith;
 
(b)           second, to the payment of all interest accrued and unpaid on the Note;
 
(c)           third, to the payment of the outstanding principal amount of the Note; and
 
(d)           fourth, to the payment in full in cash of all other outstanding Secured Obligations.
 
11.2.           After payment in full in cash of all Secured Obligations, any surplus then remaining shall be paid to the Grantor or as a court of competent jurisdiction may direct.
 
11.3.           The Grantor shall be liable for any deficiency in payment of the Secured Obligations, including all reasonable costs and expenses of collection, custody, sale or other disposition or delivery and all other charges due against the Collateral, as provided hereunder.
 
12.           Continuing Security Interest; Termination and Reinstatement.
 
 
- B-4 -

 
 
12.1.           This Agreement shall create a continuing security interest in the Collateral and shall (i) remain in full force and effect until the payment in full in cash of the Secured Obligations, (ii) be binding upon the Grantor and its successors and assigns, and (iii) inure, together with the rights and remedies of the Secured Party hereunder, to the benefit of the Secured Party and its successors, transferees and assigns.   No other Persons (including any other creditor of the Grantor) shall have any interest herein or any right or benefit with respect hereto.
 
12.2.           Notwithstanding any provision to the contrary contained herein, this Agreement shall continue to be effective or be reinstated, as the case may be, if at any time any amount received by the Secured Party in respect of the Collateral or the Secured Obligations is rescinded, or must otherwise be restored or returned by the Secured Party upon the insolvency, bankruptcy, dissolution, liquidation or reorganization of the Grantor or any of its affiliates or any guarantor of all or any part of the Secured Obligations, or upon the appointment of any intervenor, receiver or conservator of, or trustee or similar official for, the Grantor or any such affiliate or guarantor, or any substantial part of their respective properties or assets, or otherwise, all as though such payment had not been made.
 
12.3.           Subject to reinstatement as provided in Section 12.2, after all the Secured Obligations have been paid in full in cash, this Agreement and the liens granted hereunder shall terminate, and the Secured Party shall, upon the request and at the sole cost and expense of the Grantor, execute and deliver such UCC-3 termination statements as are necessary to terminate the Secured Party’s lien on the Collateral.
 
13.           Failure or Indulgence Not Waiver; Remedies Cumulative.  No failure or delay on the part of the Secured Party in the exercise of any power, right or privilege hereunder shall impair such power, right or privilege or be construed to be a waiver of any default or acquiescence therein, nor shall any single or partial exercise of any such power, right or privilege preclude any other or further exercise thereof or of any other power, right or privilege.  All rights and remedies existing under this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available.
 
14.           Governing Law.  This Agreement shall be governed by and construed in accordance with the law of the State of New York.
 
15.           Notices.  Any notice or other communication hereunder shall be made at the addresses, in the manner, and with the effect provided in Section 9.5 of the Securities Purchase Agreement.
 
16.           Entire Agreement.  This Agreement supersedes all prior communications, understandings and agreements of or between the parties hereto with respect to the subject matter hereof and contains the entire agreement between the parties hereto with respect to the transactions contemplated herein.
 
17.           Severability.  In case any provision in or obligation under this Agreement shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.
 
 
- B-5 -

 
 
18.           Amendment.  This Agreement may be amended, modified or superseded, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed on behalf of all of the parties hereto or, in the case of a waiver, by the party waiving compliance.
 
19.           Waiver.  The failure of any party at any time or times to require performance of any provision of this Agreement shall in no manner affect the right to enforce that provision or any other provision hereof at any time thereafter.
 
20.           Assignment.  This Agreement shall be binding upon and inure to the benefit of only the parties hereto and no Grantor may assign any of its rights or obligations hereunder.
 
21.           Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which when taken together shall constitute but one agreement.
 

[The remainder of this page is intentionally left blank.]

 
- B-6 -

 
 
IN WITNESS WHEREOF, the Grantor and the Secured Party have caused this Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the date first written above.
 
 
 
BIO-KEY INTERNATIONAL, INC.
   
   
 
By:                                                                                  
  Name: Mike DePasquale
  Title: President and CEO
   
   
 
DRNC HOLDINGS, INC.
   
   
 
By:                                                                    
  Name: Daniel Mullarkey                               
  Title: Treasurer                                               
 
 
 
[Signature Page to Security Agreement]
EX-10.2 3 ex10-2.htm EXHIBIT 10.2 ex10-2.htm
 
Exhibit 10.2

 
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS.  THIS NOTE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR SAID STATE SECURITIES LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE MAKER THAT SUCH REGISTRATION IS NOT REQUIRED.

 
SENIOR SECURED TERM PROMISSORY NOTE
 
$497,306.50
February 26, 2013
 

 
FOR VALUE RECEIVED, BIO-key International, Inc., a Delaware corporation, having an address at 3349 Highway 138, Building D, Suite A, Wall, New Jersey 07719 (the “Maker”), promises to pay to the order of DRNC HOLDINGS, INC., its successors and assigns, having a place of business at 200 Bellevue Parkway, Suite 300, Wilmington, DE 19809 (the “Lender”), the sum of FOUR HUNDRED NINETY-SEVEN THOUSAND THREE HUNDRED SIX DOLLARS AND FIFTY CENTS ($497,306.50) together with interest thereon, or on the amount from time to time outstanding hereunder, such interest rate to be computed as hereinafter provided.  Capitalized terms used without definition herein shall have the meaning set for in the Note Purchase Agreement (as defined herein).
 
Commencing on June 30, 2013 and continuing through and including the Maturity Date (as defined below), the Maker shall pay the Lender interest, semi-annually on June 30th and December 31st of each year, in arrears and in cash, on the principal amount outstanding hereunder at the rate of seven percent (7%) per annum (the “Interest Rate”).  Interest shall be computed on a three hundred sixty (360) day year and a thirty day month, provided however, that all outstanding principal amounts together with interest thereon shall be due and payable on the first to occur of: (i) December 31, 2015 or (ii) redemption or repurchase by the Maker; unless sooner due and payable after acceleration (“Maturity Date”).
 
During the continuance of any Event of Default under Section 13.1(a) of the Note Purchase Agreement, the Note shall bear interest at a rate equal to the Interest Rate plus two percent (2%) per annum.
 
This Note may be prepaid in whole or in part without penalty pursuant to the terms and conditions set forth in Section 9.2(b) of the Note Purchase Agreement.
 
This Note is secured by a security interest in the tangible and intangible assets owned by the Maker and its Restricted Subsidiaries (as defined in that certain Note Purchase Agreement dated as of the date hereof, by and between the Maker and the Lender (the “Note Purchase Agreement”) which was granted by the Maker and its Restricted Subsidiaries in favor of the Lender in the Security Agreement.
 
 
 

 
 
This Note shall become immediately due and payable without further notice or demand, and notwithstanding any prior waiver of any breach or default or other indulgence by the holder of this Note, upon the occurrence and continuance of any Event of Default and in accordance with the terms of Section 13 of the Note Purchase Agreement.
 
Notwithstanding any provision contained herein, or in any of the other Loan Documents, or contained in any mortgage and security agreement, conditional assignment of rents, or other instrument or agreement now or hereafter executed in connection with this Note, the maximum amount of interest and other charges in the nature thereof contracted for, or payable hereunder or thereunder, shall not exceed the maximum amount which may be lawfully contracted for, charged and received in this loan transaction all as determined by the final judgment of a court of competent jurisdiction, including all appeals therefrom.  This Note and the loan evidenced hereby shall be governed in all respects by the law of the State of New York.
 
All payments due hereunder shall be made at the office of the Lender as set forth in the preamble hereto or such other place as the Lender may designate from time to time in writing.
 
The invalidity or unenforceability of any provision hereof, or any other instrument, agreement or document now or hereafter executed in connection with the loan evidenced hereby shall not impair or vitiate any other provision of any of such instruments, agreements and documents, all of which provisions shall be enforceable to the fullest extent now or hereafter permitted by law.
 
THE MAKER AND THE LENDER HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE (TO THE EXTENT PERMITTED BY APPLICABLE LAW) ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY OF ANY DISPUTE ARISING UNDER THIS NOTE OR ANY OTHER LOAN DOCUMENT.
 
Executed as a sealed instrument.
 
 
 
WITNESS:
 
BIO-key International, Inc.
     
     
 /s/ Donna Hoahng  
By: /s/ Michael W. DePasquale
   
Name: Michael DePasquale
   
Title:   Chief Executive Officer
 
EX-10.3 4 ex10-3.htm EXHIBIT 10.3 ex10-3.htm
 
Exhibit 10.3
 
SECURITIES PURCHASE AGREEMENT
 
THIS SECURITIES PURCHASE AGREEMENT (“Agreement”) is made as of this 26th day of February, 2013 by and between BIO-key International, Inc., a Delaware corporation (the “Company”), and DRNC Holdings, Inc., a Delaware corporation (the “Investor”).
 
Recitals:
 
The Company desires to issue and sell to the Investor, and the Investor desires to purchase from the Company, 4,026,935 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company for an aggregate purchase price of $402,693.50 (the “Purchase Price”).
 
NOW, THEREFORE, in consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Investor hereby agree as follows:
 
1.           Definitions.  In addition to those terms defined above and elsewhere in this Agreement, for the purposes of this Agreement, the following terms shall have the meanings set forth in this Section 1:
 
Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the 1933 Act.
 
Action” has the meaning set forth in Section 4.7.
 
Business Day” means a day, other than a Saturday or Sunday, on which banks in New Jersey are open for the general transaction of business.
 
Closing” means the closing of the transactions contemplated by this Agreement.
 
Closing Date” means the date of the Closing.
 
Commission” means the United States Securities and Exchange Commission or any successor thereto.
 
Common Stock” has the meaning set forth in the Recitals.
 
Common Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.
 
 
 

 
 
Debt” means, with respect to any Person, without duplication, (i) indebtedness  of such Person for borrowed money; (ii) the principal of and premium, coupon or interest obligations (if any) in respect of obligations of such Person evidenced by bonds, debentures, notes or other similar instruments (whether of a convertible nature or otherwise); (iii) all obligations for the reimbursement of any obligor on any letter of credit, banker's acceptance, guarantee, surety, performance bond, or similar transaction; (iv) all obligations of such Person under capital or financing leases; (v) guarantees in respect of Indebtedness referred to in clauses (i) through (iv) above and clause (vii) below; (vi) all obligations of any other Person of the type referred to in clauses (i) through (iv) which are secured by any lien or encumbrance on any property or asset of such Person; (vii) all obligations under any swap, hedging or similar agreement or combination thereof designed to protect against fluctuations in interest rates, currency exchange rates or other changes in value; (viii) any amendment, supplement, modification, deferral, renewal, extension, refunding or refinancing or any liability or obligation of the types referred to in clauses (i) through (vii) above; and (ix) any and all amounts of any prepayment premium, penalties, break fees, expenses and other similar obligations which would arise if any of the Debt referred to in the foregoing clauses (i) through (viii) were prepaid, extinguished, unwound or settled in full as of the date hereof.
 
GAAP” has the meaning set forth in Section 4.10.
 
Investor Party” has the meaning set forth in Section 6.1.
 
Loan Documents” means the Note, any Note Guarantee, the Note Purchase Agreement and the Note Security Agreement.
 
Losses” has the meaning set forth in Section 6.1.
 
Material Adverse Effectmeans any event, circumstance, condition, development or effect that, individually or in the aggregate with other events, circumstances, conditions, developments and effects, has a material adverse effect on the assets, liabilities, properties, results of operations, condition (financial or otherwise), prospects or business of the Company and its Subsidiaries taken as a whole.
 
Note” has the meaning set forth in the Note Purchase Agreement.
 
Note Guarantee” has the meaning set forth in the Note Purchase Agreement.
 
Note Purchase Agreement” means that certain Note Purchase Agreement, dated as of the date hereof, by and between the Company and the Investor.
 
Note Security Agreement” has the meaning set forth in the Note Purchase Agreement.
 
Person” means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein.
 
Purchase Price” has the meaning set forth in the Recitals.
 
Registration Statement” has the meaning set forth in Section 6.2.
 
 
- 2 -

 
 
SEC Filings” has the meaning set forth in Section 4.10.
 
Shares” has the meaning set forth in the Recitals.
 
Subsidiary” of any Person means any Person of which securities or other ownership interests representing more than fifty percent of the equity or more than fifty percent of the ordinary voting power or, in the case of a partnership, more than fifty percent of the general partnership ownership interests are, as of such date, owned, controlled or held by, or a majority of such entity's gains or losses is entitled to be allocated to, the applicable Person or one or more subsidiaries of such Person.
 
Trading Day” means a day on which the principal Trading Market is open for trading.
 
Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the AMEX, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or OTC Bulletin Board (or any successors to any of the foregoing).
 
Transaction Documents” means this Agreement and the Loan Documents.
 
Transfer” means to sell, assign, transfer or dispose of.
 
Versant Lien” shall mean the security interest granted by the Company in favor of Versant Funding LLC in connection with the Factoring Agreement dated December 20, 2011, by and between the Company and Versant Funding LLC, under the Security Agreement dated December 20, 2011, by and between the Company and Versant Funding LLC.
 
1933 Act” means the Securities Act of 1933, as amended.
 
1934 Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
 
2.           Purchase and Sale of the Shares.  Subject to the terms and conditions of this Agreement, at the Closing, the Investor shall purchase, and the Company shall sell and issue to the Investor, the Shares in exchange for the Purchase Price.  The Investor shall pay the Purchase Price, in United States dollars, by wire transfer of immediately available funds to the Company’s account set forth on Schedule I attached hereto.
 
3.           Closing.  The Closing shall take place on the date hereof following the satisfaction (or waiver) of the conditions to Closing set forth in Section 7 through an exchange of consideration and documents using wire transfers, overnight courier service, electronic mail and/or facsimile transmission, or at such other time and place and by such other means as the Company and the Investor mutually agree upon.  At the Closing, the Company shall deliver to the Investor a stock certificate, registered in the name of the Investor, representing the Shares.
 
 
- 3 -

 
 
4.           Representations and Warranties of the Company.  The Company hereby represents and warrants to the Investor on and as of date hereof, that, except as disclosed in the SEC Filings other than disclosures in such SEC Filings contained under the heading “Risk Factors,” any disclosures contained in any “forward-looking statements” disclaimer or any other statements that are predictive or forward-looking in nature:
 
4.1           Organization, Good Standing and Qualification.  Each of the Company and its Subsidiaries is a corporation duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business as now conducted and to own its properties.  Neither the Company nor any of its Subsidiaries is in violation or default of any of the provisions of its certificate or articles of incorporation, operating agreement, bylaws or other organizational or charter documents.  Each of the Company and its Subsidiaries is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or its leasing of property makes such qualification or licensing necessary, unless the failure to so qualify would not reasonably be expected to have a Material Adverse Effect.
 
4.2           Authorization.  The Company has full power and authority and has taken all requisite action on the part of the Company for (i) the authorization, execution and delivery of the Transaction Documents, (ii) the authorization of the performance of all obligations of the Company hereunder or thereunder, and (iii) the authorization, issuance (or reservation for issuance) and delivery of the Shares.  The Transaction Documents constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally.
 
4.3           Valid Issuance.  The Shares and the Note have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be validly issued, (in the case of the Shares) fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in this Agreement or imposed by applicable securities laws.
 
4.4           Consents.  The execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the Shares and the Note require no consent of, action by or in respect of, no notice to, or filing with, any Person, governmental body, agency, or official other than filings that have been made pursuant to applicable state securities laws and post-sale filings pursuant to applicable state and federal securities laws which the Company undertakes to file within the applicable time periods.
 
4.5           No Conflict, Breach, Violation or Default.  The execution, delivery and performance of the Transaction Documents by the Company and the issuance and sale of the Shares and the Note will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under (i) the Company’s Certificate of Incorporation or the Company Bylaws, both as in effect on the date hereof, or (ii)(a) any statute, rule, regulation or order of any governmental agency or body, any exchange, or any court, domestic or foreign, having jurisdiction over the Company or any of its Subsidiaries or any of its respective assets or properties, or (b) any agreement or instrument to which the Company is a party or by which the Company or any of its Subsidiaries is bound or to which any of their respective assets or properties is subject.
 
 
- 4 -

 
 
4.6           Certificates, Authorities and Permits.  Each of the Company and its Subsidiaries possesses adequate certificates, authorities or permits issued by appropriate governmental agencies or bodies (including the Federal Communications Commission) necessary to conduct the business now operated by it, and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that, if determined adversely to the Company or any Subsidiary, could reasonably be expected to have a Material Adverse Effect, individually or in the aggregate.
 
4.7           Litigation.  There are no pending or, to the knowledge of the Company, threatened actions, suits or proceedings before a court of competent jurisdiction or a tribunal (collectively, an “Action”) against the Company or any Subsidiary which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the issuance of the Shares or the Note or (ii) could, if there were an unfavorable decision, reasonably be expected to have a Material Adverse Effect.  Neither the Company nor any of its Subsidiaries is nor has any of them been within the last five (5) years the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.  To the knowledge of the Company, there has not been and there is not pending or contemplated any investigation by the Commission targeting the Company or any of its
 
Subsidiaries or any current or former director or officer of the Company or any of its Subsidiaries in respect of any actions by such director or officer with respect to the Company or any of its Subsidiaries.
 
4.8           Brokers and Finders.  No Person will have, as a result of the issuance of the Shares or the Note, any valid right, interest or claim against or upon the Company or the Investor or any of their respective Affiliates for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company or any of its Affiliates.
 
4.9           Private Placement.  Subject to the accuracy of the representations and warranties of the Investor contained in Section 5 hereof, the offer and sale of the Shares to the Investor as contemplated hereby is exempt from the registration requirements of the 1933 Act.
 
4.10           SEC Filings.  The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the 1933 Act and the 1934 Act, including pursuant to Section 13(a) or 15(d) thereof, for the twelve (12) months immediately preceding the date hereof (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein being collectively referred to herein as the “SEC Filings”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Filings prior to the expiration of any such extension.  As of their respective dates, the SEC Filings complied in all material respects with the requirements of the 1933 Act and the 1934 Act, as applicable, and none of the SEC Filings, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The financial statements of the Company included in the SEC Filings comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.  Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
 
 
- 5 -

 
 
4.11           Capitalization.  The capitalization of the Company is as set forth in the Company’s Annual Report on Form 10-K filed on April 4, 2012.  The Company has not issued any capital stock since April 4, 2012, other than pursuant to the exercise of employee and director stock options under the Company’s equity compensation plans, the issuance of employee and director equity compensation under the Company’s equity compensation plans and the issuance of shares of Common Stock to employees and directors pursuant to the Company’s equity compensation plans.  No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.  Except as a result of the purchase and sale of the Shares, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents.  The issuance and sale of the Shares will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Investor) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities.  All of the outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.  Except for agreements filed as exhibits to the SEC Filings, there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.
 
4.12           Material Changes; Undisclosed Events or Liabilities.
 
(a)           Since the date of the latest audited financial statements included within the SEC Filings, (i) there has been no event, circumstance, condition, development or effect that, individually or in the aggregate with other  events, circumstances, conditions, developments and effects, has had or that could reasonably be expected to have a Material Adverse Effect, (ii) the Company has not altered its method of accounting, (iii) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, (iv) the Company and its Subsidiaries have not sold or disposed of any assets or properties that, individually or in the aggregate, are material outside the ordinary course of business or suffered any loss, destruction or damage to any assets or properties that, individually or in the aggregate, are material, and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company and its Subsidiaries do not have any liabilities or obligations (contingent or otherwise) that, individually or in the aggregate, have had or could reasonably be expected to have, a Material Adverse Effect, other than (A) liabilities and obligations reflected in the most recent balance sheet of the Company filed with the Commission, (B) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice since the date of such balance sheet, (C) liabilities arising in the ordinary course of business and not resulting from any violation of law or breach of contract that are not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, and (D) pursuant to or as contemplated by this Agreement.
 
 
- 6 -

 
 
(b)           As of the Closing, the Company and its Subsidiaries will have no outstanding Debt other than the Note.  There is no outstanding mortgage, deed of trust, pledge, lien, security interest or other charge or encumbrance (including the lien or retained security title of a conditional vendor) of any nature, upon or with respect to any of the properties or assets of the Company and its Subsidiaries, except for mortgages, deeds of trust, pledges, liens, security interests or other charges or encumbrances (i) imposed by law for taxes, assessments or governmental charges or levies on property of the Company or any Subsidiary that are (1) not yet be due, or (2) (x) are being contested in good faith and by appropriate proceedings and (y) the Company or such Subsidiary has set aside on its books adequate reserves with respect thereto in accordance with GAAP; (ii) carriers’, warehousemen’s and mechanics’ liens and other similar liens imposed by law, arising in the ordinary course of business and securing obligations that are not overdue by more than 30 days; (iii) arising out of pledges or deposits under workmen’s compensation laws, unemployment insurance, old age pensions, or other social security or retirement benefits, or similar legislation; (iv) securing the performance of bids, tenders, contracts (other than for the repayment of borrowed money), statutory obligations and surety bonds, in each case in the ordinary course of business; (v) in the nature of zoning restrictions, easements and rights or restrictions of record on the use of real property imposed by law or arising in the ordinary course of business which do not materially detract from the affected property’s value or impair its use or interfere with the ordinary course of conduct of the Company or any of its Subsidiaries; (vi) arising by operation of law in favor of the owner or sublessor of leased premises and confined to the real property rented; or (vii) arising out of the Versant Lien.
 
4.13           Compliance.  The Company and its Subsidiaries: (i) are not in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any of its Subsidiaries under), nor has the Company or any of its Subsidiaries received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other material written agreement or written instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) are not in violation of any judgment, decree or order of any court, arbitrator or governmental body in which the Company or any of its Subsidiaries is named as a party, and (iii) since January 1, 2010 have not been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws applicable to its business and all such laws that affect the environment, except in each case as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
 
 
- 7 -

 
 
4.14           Listing and Maintenance Requirements.  The Common Stock is registered pursuant to Section 12(g) of the 1934 Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the 1934 Act nor has the Company received any written notification that the Commission is contemplating terminating such registration.  The Company has not, in the 12 months preceding the date hereof, received written notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is in compliance with all such listing and maintenance requirements in all material respects.
 
4.15           Representations Complete.  None of the representations or warranties made by the Company in this Agreement, and none of the statements made in any exhibit, schedule or certificate furnished by the Company pursuant to this Agreement or any Transaction Document, contains or will contain at the Closing any untrue statement of a material fact, or omits or will omit at the Closing to state any material fact necessary in order to make the statements contained herein or therein, in the light of the circumstances under which made, not misleading.
 
5.           Representations, Warranties and Agreements of the Investor.  The Investor hereby represents and warrants to the Company on and as of the date hereof that:
 
5.1           Authorization.  The execution, delivery and performance by the Investor of the Transaction Documents to which the Investor is a party have been duly authorized and will each constitute the valid and legally binding obligation of the Investor, enforceable against the Investor in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally.
 
5.2           Purchase Entirely for Own Account.  The Shares will be acquired for the Investor’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the 1933 Act; provided, however, by making the representations herein, the Investor does not agree, or make any representation or warranty, to hold any of the Shares for any minimum or other specific term and reserves the right to dispose of the Shares at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act but subject at all times to the transfer restrictions set forth in Section 8.  The Investor is acquiring the Shares hereunder in the ordinary course of its business. The Investor is not a registered broker dealer or an entity engaged in the business of being a broker dealer.
 
5.3           Investment Experience.  The Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Shares and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby.
 
 
- 8 -

 
 
5.4           Disclosure of Information.  The Investor has had an opportunity to receive all additional information related to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Shares.
 
5.5           Restricted Securities.  The Investor understands that the Shares are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain limited circumstances.
 
5.6           Legends.
 
(a)           It is understood that, except as provided below, certificates evidencing the Shares may bear the following or any similar legend:
 
“The securities represented hereby may not be transferred unless (A)(i) such securities have been registered for sale pursuant to the Securities Act of 1933, as amended, or (ii) the Company has received an opinion of counsel satisfactory to it that such transfer may lawfully be made without registration under the Securities Act of 1933 or qualification under applicable state securities laws and (B) such transfer is in compliance with the terms of the Purchase Agreement between the Company and the Investor, including the transfer restrictions set forth in Section 8 thereof.”
 
(b)           If required by the authorities of any state in connection with the issuance of sale of the Shares, the legend required by such state authority.
 
(c)           The Investor acknowledges and agrees that the Shares are subject to the transfer restrictions set forth in Section 8 of this Agreement.
 
5.7           Accredited Investor.  The Investor is an “accredited investor” as defined in Rule 501(a) of Regulation D, as amended, under the 1933 Act.
 
5.8           No General Solicitation.  The Investor did not learn of the investment in the Shares as a result of any “general advertising” or “general solicitation” as those terms are contemplated in Regulation D, as amended, under the 1933 Act.
 
5.9           Brokers and Finders.  No Person will have, as a result of the issuance of the Shares, any valid right, interest or claim against or upon the Company or the Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Investor.
 
 
- 9 -

 
 
5.10           Restriction on Hedging.  For so long as the Investor owns the Shares, the Investor will not engage in, and has not engaged in prior to the Closing Date, directly or indirectly, any hedging or other transaction which is designed to or reasonably expected to reduce the Investor’s risk with respect to, or hedge against losses in respect of, shares of Common Stock. Such prohibited hedging or other transactions would include without limitation any short position or sale or any purchase, sale or grant of any right (including without limitation any put option or put equivalent position or call option or call equivalent position) with respect to any of the shares of Common Stock or with respect to any security that includes, relates to, or derives any significant part of its value from such shares.  For the avoidance of doubt, nothing in this Section 5.10 is intended to preclude the Investor from effecting a Transfer of Shares (or any other shares of Common Stock hereafter acquired or received by the Investor in accordance with the provisions of this Agreement) pursuant to an effective registration statement or otherwise in compliance with applicable securities laws.
 
6.           Other Agreements of the Parties.
 
6.1           Indemnification.
 
(a)           Subject to the provisions of this Section 6.1, each party (an “Indemnifying Party”) will indemnify and hold the other party and such other party’s directors, officers, shareholders, members, partners, employees and agents, each Person who controls the such other party (within the meaning of Section 15 of the 1933 Act and Section 20 of the 1934 Act), and the directors, officers, shareholders, agents, members, partners or employees of such controlling persons (each, an “Indemnified Party”) harmless from any and all losses (including any diminution in value), liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation (“Losses”) that any such Indemnified Party may suffer or incur as a result of or relating to any breach of any of the representations, warranties, covenants or agreements made by the Indemnifying Party in this Agreement or in the other Transaction Documents.  If any action shall be brought against any Indemnified Party in respect of which indemnity may be sought pursuant to this Agreement, the Indemnified Party shall promptly notify the Indemnifying Party in writing, and the Indemnifying Party shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Indemnified Party.  Any Indemnified Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party.  An Indemnifying Party will not be liable to any Indemnified Party under this Agreement (x) for any Losses constituting punitive, exemplary or special damages, except to the extent awarded to a third party; (y) for any settlement by an Indemnified Party effected without the Indemnifying Party’s prior written consent (which shall not be unreasonably withheld); or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to the breach by an Indemnified Party or its Affiliate of any of the representations, warranties, covenants or agreements made by such Indemnified Party or its Affiliate in this Agreement or in the other Transaction Documents, any violations by the Indemnified Party or its Affiliate of state or federal securities laws or any conduct by the Indemnified Party or its Affiliate which constitutes fraud, gross negligence, willful misconduct or malfeasance.
 
 
- 10 -

 
 
(b)           If the Closing occurs, except in the case of fraud, the Company shall not be liable for any Losses for breach of the representations and warranties of the Company contained herein (i) unless and until the aggregate claims therefor exceed $5,000 or (ii) for an aggregate amount in excess of the 150% of the Purchase Price.
 
6.2           Registration.  Within one hundred twenty (120) days after the Closing, the Company agrees to file with the Commission a registration statement (the “Registration Statement”) to register the Shares (and any other shares of Common Stock hereafter acquired or received by the Investor in accordance with the provisions of this Agreement).  The Company will use its best efforts to cause the Registration Statement to be declared effective within sixty (60) days (or 90 days in the event of review by the Commission) following the date of filing. In connection with any such Registration Statement, the Company shall enter into a selling stockholder agreement with the Investor in customary form for a registered secondary offering which shall, among other things, provide for indemnification and contribution in favor of the Investor.
 
6.3           Listing of Common Stock.  The Company hereby agrees to use its commercially reasonable efforts to maintain the listing or quotation of the Common Stock on the OTC Bulletin Board, and the Company shall promptly apply to list or quote all of the Shares. The Company agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares (and any other shares of Common Stock hereafter acquired or received by the Investor in accordance with the provisions of this Agreement), and will take such other action as is necessary to cause all of the Shares (and any other shares of Common Stock hereafter acquired or received by the Investor in accordance with the provisions of this Agreement) to be listed or quoted on such Trading Market as promptly as possible.
 
6.4           Anti-Dilution.   If at any time within nine (9) months from the Closing Date the Company sells or issues any Common Stock or Common Stock Equivalents (other than sales or issuances to directors, officers, employees or independent contractors in the ordinary course of business for compensation purposes and stock splits and stock dividends payable in respect of the Common Stock) having a purchase, exercise or conversion price per share of Common Stock less than the purchase price per Share paid by the Investor under this Agreement (appropriately adjusted to account for any stock split, stock dividend or similar change affecting the Common Stock) (such price per share, as amended by reason of any adjustment or adjustments under this Section 6.4, the “Per Share Price”), then in such event the Per Share  Price shall automatically be reduced to be equal to the lowest price per share of Common Stock paid or payable in any such sale or issuance and the Company shall issue to the Investor a number of additional validly issued, fully paid and non-assessable shares of Common Stock such that the aggregate number of shares of Common Stock issued to the Investor pursuant to this Agreement shall equal the result obtained by dividing the Purchase Price by the Per Share Price.
 
6.5           Changes in Outstanding Common Stock.  The Company shall promptly (and in any event within five (5) Business Days of any such event) notify the Investor of any change in the number of outstanding shares of Common Stock that results in the Investor owning more than five per cent (5%) of the outstanding shares of Common Stock.
 
 
- 11 -

 
 
7.           Conditions to Closing.
 
7.1           Conditions to the Investor’s Obligations. The obligation of the Investor to purchase the Shares at the Closing is subject to the fulfillment, on or prior to the Closing Date, of the following conditions, any of which may be waived by the Investor:
 
(a)           The representations and warranties made by the Company in Section 4 hereof shall be true and correct in all material respects at all times prior to and on the Closing Date.
 
(b)           The Company shall have obtained in a timely fashion any and all consents, approvals and waivers necessary or appropriate for consummation of the purchase and sale of the Shares and the Note, and all of which shall be and remain so long as necessary in full force and effect.
 
(c)           No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, or self-regulatory organization enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction Documents.
 
(d)           The Company shall have delivered to the Investor the Note Purchase Agreement and the Note Security Agreement, duly executed by the Company.
 
(e)           The Company shall have delivered to the Investor the Note, duly executed by the Company.
 
(f)           All agreements, documents and instruments required to be executed, delivered, filed and/or recorded in connection with the Note Purchase Agreement and the Note Security Agreement, including, without limitation, UCC financing statements, shall have been so executed and delivered and shall be in proper form for filing and/or recording.
 
(g)           The Company shall consummate, concurrently with the Closing, the issuance and sale of additional shares of Common Stock having an aggregate purchase price of $500,000 (the “Additional Issuance”) on terms no less favorable to the Company than the terms of this Agreement.  If any term or provision of such Additional Issuance is more favorable to the purchaser of such Common Stock than the terms of this Agreement, the terms and provisions of this Agreement shall be amended, prior to the Closing, to be no less favorable to the Investor than the terms and provisions of such Additional Issuance.
 
7.2           Conditions to Obligations of the Company. The Company’s obligation to sell and issue the Shares to the Investor at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which (other than subsection (b) below) may be waived by the Company:
 
(a)           The representations and warranties made by the Investor in Section 5 hereof shall be true and correct at all times prior to and on the Closing Date.
 
 
- 12 -

 
 
(b)           The Investor shall have delivered the Purchase Price to the Company.
 
(c)           No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, or self-regulatory organization enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction Documents.
 
(d)           The Investor shall have delivered to the Company the Note Purchase Agreement, duly executed by the Investor.
 
8.           Transfer Restrictions.  The Shares may not be Transferred by the Investor prior to the six-month anniversary of the Closing Date.  Following the six-month anniversary of the Closing Date, the Investor may, subject to compliance with applicable securities laws, Transfer Shares.  The Investor acknowledges and agrees that the Company shall issue to its transfer agent such instructions, directions and stop transfer orders as are necessary to implement the provision of this Section 8.
 
9.           Miscellaneous.
 
9.1           Survival.  All representations and warranties contained in this Agreement shall be deemed to be representations and warranties as of the date hereof, and such representations and warranties, together with the right to assert a claim in respect thereof, shall survive the Closing until the expiration of the applicable statute of limitations, with the exception of the representations and warranties contained in Sections 4.6, 4.7, 4.9, 4.10, 4.12, 4.13, 4.14 and 4.15, which shall survive until the eighteen-month anniversary of the date hereof.  The covenants and agreements contained in this Agreement shall survive the Closing Date until the expiration of the applicable statute of limitations.
 
9.2           Successors and Assigns.  The provisions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties.  Neither the Company nor the Investor may assign this Agreement or any of its rights or obligations hereunder without the prior written consent of the other party; provided, however, that the Investor may assign some or all of its rights hereunder to any Affiliate of the Investor without the consent of the Company.  Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement.
 
9.3           Counterparts; Faxes.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  In the event that any signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.
 
 
- 13 -

 
 
9.4           Titles and Subtitles.  The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.
 
9.5           Notices.  Any notices, demands and communications to a party hereunder shall be in writing and shall be deemed to have been duly given and received (a) if delivered personally, as of the date received, (b) if delivered by certified mail, return receipt requested, three business days after being mailed, (c) if delivered by a nationally recognized overnight delivery service, two business days after being entrusted to such delivery service, or (d) if sent via facsimile, electronic mail or similar electronic transmission, as of the date received, to such party at its address set forth below (or such other address as it may from time to time designate in writing to the other parties hereto):
 
If to the Company:
 
BIO-key International, Inc.
3349 Highway 138
Building D, Suite A
Wall, NJ 07719
Attention:  Mike DePasquale, President and CEO
Fax:  (732) 359-1101
 
With a copy to:
 
Choate, Hall & Stewart LLP
Two International Place
Boston, MA  02110
Facsimile:  (617) 248-4000
Attention:  Charles J. Johnson, Esq.
 
If to the Investor:
 
DRNC Holdings, Inc.
200 Bellevue Parkway,
Suite 300
Wilmington, DE 19809-3727
Facsimile: (302) 281-3763
Attention: General Counsel
 
With a copy to:
 
Wilson, Sonsini, Goodrich & Rosati, P.C.
1301 Avenue of the Americas
40th Floor
New York, New York 10019-6022
Facsimile: (212) 999-5899
Attention:  Warren S. de Wied, Esq.
 
 
- 14 -

 
 
9.6           Expenses.  The Company and the Investor shall each bear their own expenses in connection with the negotiation, preparation, execution and delivery of this Agreement.
 
9.7           Amendments and Waivers.  No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by the Company and the Investor, or in the case of a waiver, by the party against whom enforcement of any such waived provision is sought.  No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.  Any amendment or waiver effected in accordance with this Section 9.7 shall be binding upon each holder of the Shares at the time outstanding, each future holder of the Shares, and the Company.
 
9.8           Publicity.  No public release or announcement concerning the transactions contemplated by the Transaction Documents shall be issued by the Company or the Investor without the prior consent of the Company (in the case of a release or announcement by the Investor) or the Investor (in the case of a release or announcement by the Company) (which consents shall not be unreasonably withheld), except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange or securities market on which the Shares are then listed and trading.  Notwithstanding the foregoing, to the extent that any public release or announcement is made by or on behalf of the Company, confidential treatment shall be sought by the Company with respect to any information that the parties mutually agree with the advice of counsel consists of business trade secrets or other confidential commercial or financial information in accordance with the requirements of the Freedom of Information Act and the rules and regulations thereunder.  The parties shall cooperate in connection with the preparation and submission of any such request for confidential treatment and the Company shall promptly notify the Investor of any communication by the Commission with respect to any request for confidential treatment submitted by the Company or any legal proceeding seeking disclosure of any confidential information and shall permit the Investor to participate in any response by the Company to any request by the Commission seeking disclosure of any confidential information. If disclosure of any confidential information is sought by a court or arbitrator in any proceeding by a third party, prior to any such disclosure the Company shall, to the extent permitted by law and reasonably practicable, notify the Investor so that the Investor has a reasonable opportunity to contest, limit or protect against such disclosure; provided, further, that the Company shall seek appropriate confidentiality prior to making such disclosure or use.
 
9.9           Severability.  Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.  To the extent permitted by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect.
 
 
- 15 -

 
 
9.10           Entire Agreement.  This Agreement, including Schedule I and each other exhibit and schedule attached hereto, and the other Transaction Documents constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof.  Prior drafts or versions of this Agreement shall not be used to interpret this Agreement.
 
9.11           Further Assurances.  The parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained.
 
9.12           Governing Law; Consent to Jurisdiction.  This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the choice of law principles thereof.  Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New York, New York and the United States District Court for the Southern District of New York located in New York, New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby.  Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement.  Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court.  Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).
 
[signature page follows]
 
 
- 16 -

 
 
IN WITNESS WHEREOF, the parties have caused their duly authorized officers to execute this Purchase Agreement as of the date first above written.
 
BIO-KEY INTERNATIONAL, INC.
 
 
 
By:   /s/ Michael W. DePasquale                     
Name:  Michael DePasquale
Title:  Chief Executive Officer
 
 
DRNC HOLDINGS, INC.
 
 
 
By:  /s/ Daniel Mullarkey                                   
Name: Daniel Mullarkey
Title: Treasurer
 
 
[Signature Page to Purchase Agreement]
 
 
 

 
 
SCHEDULE I
 
Wire instructions for the Company
 
 
PAY TO: SILICON VALLEY BANK
  3003 TASMAN DRIVE, SANTA CLARA, CA 95054
  UNITED STATES OF AMERICA
   
ROUTING & TRANSIT #: 121140399
   
SWIFT CODE: SVBKUS6S
   
FOR CREDIT OF: BIO-key International, Inc.
  85 Rangeway Road, BLDG 1
  North Billerica, MA 01862
  UNITED STATES OF AMERICA
   
FINAL CREDIT ACCOUNT: 3300615308
 
 
I-1
EX-10.4 5 ex10-4.htm EXHIBIT 10.4 ex10-4.htm
 
Exhibit 10.4
 
SECURITIES PURCHASE AGREEMENT
 
THIS SECURITIES PURCHASE AGREEMENT (“Agreement”) is made as of this 26th day of February, 2013 by and among BIO-key International, Inc., a Delaware corporation (the “Company”), and “________” (each an “Investor” and collectively the “Investors”).
 
Recitals:
 
The Company desires to issue and sell to each Investor and each Investor desires to purchase from the Company, such number of shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company as is set forth opposite such Investor’s name on Schedule I hereto under the column titled “Purchased Shares” at a per share purchase price of $0.10.
 
NOW, THEREFORE, in consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Investors hereby agree as follows:
 
1.           Definitions.  In addition to those terms defined above and elsewhere in this Agreement, for the purposes of this Agreement, the following terms shall have the meanings set forth in this Section 1:
 
Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the 1933 Act.
 
Action” has the meaning set forth in Section 4.7.
 
Business Day” means a day, other than a Saturday or Sunday, on which banks in New Jersey are open for the general transaction of business.
 
Closing” means the closing of the transactions contemplated by this Agreement.
 
Closing Date” means the date of the Closing.
 
Commission” means the United States Securities and Exchange Commission or any successor thereto.
 
Common Stock” has the meaning set forth in the Recitals.
 
Common Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.
 
GAAP” has the meaning set forth in Section 4.10.
 
 
 

 
 
Indemnified Party” has the meaning set forth in Section 6.1.
 
Indemnifying Party” has the meaning set forth in Section 6.1.
 
Losses” has the meaning set forth in Section 6.1.
 
Material Adverse Effect” means a material adverse effect on (i) the assets, liabilities, properties, results of operations, condition (financial or otherwise), prospects or business of the Company, individually or taken as a whole, or (ii) the ability of the Company to issue and sell the Shares contemplated hereby.
 
Per Share Price” has the meaning set forth in Section 6.4.
 
Person” means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein.
 
Purchase Price” has the meaning set forth in the Recitals.
 
Registration Statement” has the meaning set forth in Section 6.2.
 
SEC Filings” has the meaning set forth in Section 4.10.
 
Shares” has the meaning set forth in the Recitals.
 
Trading Day” means a day on which the principal Trading Market is open for trading.
 
Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the AMEX, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or OTC Bulletin Board (or any successors to any of the foregoing).
 
Transfer” means to sell, assign, transfer or dispose of.
 
1933 Act” means the Securities Act of 1933, as amended.
 
1934 Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
 
2.           Purchase and Sale of the Shares.  Subject to the terms and conditions of this Agreement, at the Closing, each Investor shall purchase, and the Company shall sell and issue to each Investor such number of Shares as is set forth opposite such Investor’s name in Schedule I under the column titled “Purchased Shares” in exchange for the aggregate purchase price set forth opposite such Investor’s name in Schedule I under the column titled “Purchase Price”.  Each Investor shall pay the applicable aggregate purchase price as set forth on Schedule I in United States dollars by wire transfer of immediately available funds to the Company’s account set forth on Schedule II attached hereto.
 
 
- 2 -

 
 
3.           Closing.  The Closing shall take place on the date hereof following the satisfaction (or waiver) of the conditions to Closing set forth in Section 7 through an exchange of consideration and documents using wire transfers, overnight courier service, electronic mail and/or facsimile transmission, or at such other time and place and by such other means as the Company and the Investors mutually agree upon.  At the Closing, the Company shall deliver to each Investor a stock certificate, registered in the name of such Investor, representing the Shares that such Investor is purchasing hereunder.
 
4.           Representations and Warranties of the Company.  The Company hereby represents and warrants to the Investors on and as of date hereof, that, except as disclosed in the SEC Filings:
 
4.1           Organization, Good Standing and Qualification.  The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business as now conducted and to own its properties.  The Company is not in violation or default of any of the provisions of its certificate or articles of incorporation, operating agreement, bylaws or other organizational or charter documents.  The Company is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or its leasing of property makes such qualification or licensing necessary, unless the failure to so qualify would not reasonably be expected to have a Material Adverse Effect.
 
4.2           Authorization.  The Company has full power and authority and has taken all requisite action on the part of the Company for (i) the authorization, execution and delivery of this Agreement, (ii) the authorization of the performance of all obligations of the Company hereunder, and (iii) the authorization, issuance (or reservation for issuance) and delivery of the Shares.  This Agreement constitutes the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally.
 
4.3           Valid Issuance.  The Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in this Agreement or imposed by applicable securities laws.
 
4.4           Consents.  The execution, delivery and performance by the Company of this Agreement and the offer, issuance and sale of the Shares require no consent of, action by or in respect of, no notice to, or filing with, any Person, governmental body, agency, or official other than those filings that have been made pursuant to applicable state securities laws and post-sale filings pursuant to applicable state and federal securities laws which the Company undertakes to file within the applicable time periods.
 
 
- 3 -

 
 
4.5           No Conflict, Breach, Violation or Default.  The execution, delivery and performance of this Agreement by the Company and the issuance and sale of the Shares will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under (i) the Company’s Certificate of Incorporation or the Company Bylaws, both as in effect on the date hereof, or (ii)(a) any statute, rule, regulation or order of any governmental agency or body, any exchange, or any court, domestic or foreign, having jurisdiction over the Company or any of its respective assets or properties, or (b) any agreement or instrument to which the Company is a party or by which the Company is bound or to which any of their respective assets or properties is subject, except for such conflicts, breaches, violations or defaults which would not reasonably be expected to have a Material Adverse Effect.
 
4.6           Certificates, Authorities and Permits.  The Company possess adequate certificates, authorities or permits issued by appropriate governmental agencies or bodies (including the Federal Communications Commission) necessary to conduct the business now operated by it, and the Company has not received any notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that, if determined adversely to the Company, could reasonably be expected to have a Material Adverse Effect, individually or in the aggregate.
 
4.7           Litigation.  There are no pending actions, suits or proceedings before a court of competent jurisdiction or a tribunal (collectively, an “Action”) against the Company which (i) adversely affects or challenges the legality, validity or enforceability of this Agreement or the issuance of the Shares or (ii) could, if there were an unfavorable decision, reasonably be expected to have or result in, a Material Adverse Effect.  The Company is not and has not been within the last five (5) years the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.  To the knowledge of the Company, there has not been and there is not pending or contemplated any investigation by the Commission targeting the Company or any current or former director or officer of the Company in respect of any actions by such director or officer with respect to the Company.
 
4.8           Brokers and Finders.  No Person will have, as a result of the issuance of the Shares, any valid right, interest or claim against or upon the Company or any Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company.
 
4.9           Private Placement.  Subject to the accuracy of the representations and warranties of each Investor contained in Section 5 hereof, the offer and sale of the Shares to the Investors as contemplated hereby is exempt from the registration requirements of the 1933 Act.
 
4.10         SEC Filings.  The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the 1933 Act and the 1934 Act, including pursuant to Section 13(a) or 15(d) thereof, for the twelve (12) months immediately preceding the date hereof (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein being collectively referred to herein as the “SEC Filings”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Filings prior to the expiration of any such extension.  As of their respective dates, the SEC Filings complied in all material respects with the requirements of the 1933 Act and the 1934 Act, as applicable, and none of the SEC Filings, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The financial statements of the Company included in the SEC Filings comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.  Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
 
 
- 4 -

 
 
4.11           Capitalization.  The capitalization of the Company is as set forth in the Company’s Annual Report on Form 10-K filed on April 4, 2012.  The Company has not issued any capital stock since April 4, 2012, other than pursuant to the exercise of employee and director stock options under the Company’s equity compensation plans, the issuance of employee and director equity compensation under the Company’s equity compensation plans and the issuance of shares of Common Stock to employees and directors pursuant to the Company’s equity compensation plans.  No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by this Agreement.  Except as a result of the purchase and sale of the Shares, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents.  The issuance and sale of the Shares will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Investor) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities.  All of the outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.  Except for agreements filed as exhibits to the SEC Filings, there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.
 
4.12           Material Changes; Undisclosed Events or Liabilities.  Since the date of the latest audited financial statements included within the SEC Filings, except as disclosed in a subsequent SEC Filing filed prior to the date hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans.
 
 
- 5 -

 
 
4.13           Compliance.  The Company is not: (i) in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company under), nor has the Company received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other material written agreement or written instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) in violation of any judgment, decree or order of any court, arbitrator or governmental body in which the Company is named as a party, or (iii) in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws applicable to its business and all such laws that affect the environment, except in each case as could not reasonably be expected to have or result in a Material Adverse Effect.
 
4.14           Listing and Maintenance Requirements.  The Common Stock is registered pursuant to Section 12(b) or 12(g) of the 1934 Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the 1934 Act nor has the Company received any written notification that the Commission is contemplating terminating such registration.  The Company has not, in the 12 months preceding the date hereof, received written notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is in compliance with all such listing and maintenance requirements in all material respects.
 
5.           Representations, Warranties and Agreements of the Investors.  Each Investor, severally and not jointly with the other Investors, hereby represents and warrants to the Company on and as of the date hereof that:
 
5.1           Authorization.  The execution, delivery and performance by such Investor of this Agreement has been duly authorized and will constitute the valid and legally binding obligation of such Investor, enforceable against such Investor in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally.
 
5.2           Purchase Entirely for Own Account.  The Shares will be acquired for such Investor’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and such Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the 1933 Act; provided, however, by making the representations herein, such Investor does not agree, or make any representation or warranty, to hold any of the Shares for any minimum or other specific term and reserves the right to dispose of the Shares at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act but subject at all times to the transfer restrictions set forth in Section 8.  Such Investor is acquiring the Shares hereunder in the ordinary course of its business. Such Investor is not a registered broker dealer or an entity engaged in the business of being a broker dealer.
 
 
- 6 -

 
 
5.3           Investment Experience.  Such Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Shares and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby.
 
5.4           Disclosure of Information.  Such Investor has had an opportunity to receive all additional information related to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Shares.
 
5.5           Restricted Securities.  Such Investor understands that the Shares are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain limited circumstances.
 
5.6           Legends.
 
(a)           It is understood that, except as provided below, certificates evidencing the Shares may bear the following or any similar legend:
 
“The securities represented hereby may not be transferred unless (A)(i) such securities have been registered for sale pursuant to the Securities Act of 1933, as amended, or (ii) the Company has received an opinion of counsel satisfactory to it that such transfer may lawfully be made without registration under the Securities Act of 1933 or qualification under applicable state securities laws and (B) such transfer is in compliance with the terms of the Purchase Agreement between the Company and the Investor, including the transfer restrictions set forth in Section 8 thereof.”
 
(b)           If required by the authorities of any state in connection with the issuance of sale of the Shares, the legend required by such state authority.
 
(c)           Such Investor acknowledges and agrees that the Shares are subject to the transfer restrictions set forth in Section 8 of this Agreement.
 
5.7           Accredited Investor.  Such Investor is an “accredited investor” as defined in Rule 501(a) of Regulation D, as amended, under the 1933 Act.
 
5.8           No General Solicitation.  Such Investor did not learn of the investment in the Shares as a result of any “general advertising” or “general solicitation” as those terms are contemplated in Regulation D, as amended, under the 1933 Act.
 
 
- 7 -

 
 
5.9           Brokers and Finders.  No Person will have, as a result of the issuance of the Shares, any valid right, interest or claim against or upon the Company or such Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Investor.
 
5.10         Restriction on Hedging.  Such Investor will not engage in, and has not engaged in prior to the Closing Date, any hedging or other transaction which is designed to or reasonably expected to lead to or result in a sale or disposition of shares of Common Stock even if such securities would be disposed of by someone other than such Investor. Such prohibited hedging or other transactions would include without limitation any short position or sale or any purchase, sale or grant of any right (including without limitation any put option or put equivalent position or call option or call equivalent position) with respect to any of the shares of Common Stock or with respect to any security that includes, relates to, or derives any significant part of its value from such shares.
 
6.           Other Agreements of the Parties.
 
6.1           Indemnification.
 
(a)           Subject to the provisions of this Section 6.1, each Investor severally with respect to the Company on the one hand, and the Company with respect to each Investor on the other hand (each an “Indemnifying Party”), will indemnify and hold the Company or such Investor, respectively, and such other party’s directors, officers, shareholders, members, partners, employees and agents, each Person who controls the such other party (within the meaning of Section 15 of the 1933 Act and Section 20 of the 1934 Act), and the directors, officers, shareholders, agents, members, partners or employees of such controlling persons (each, an “Indemnified Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation (“Losses”) that any such Indemnified Party may suffer or incur as a result of or relating to any breach of any of the representations, warranties, covenants or agreements made by the respective Indemnifying Party in this Agreement.  If any action shall be brought against any Indemnified Party in respect of which indemnity may be sought pursuant to this Agreement, such Indemnified Party shall promptly notify the applicable Indemnifying Party in writing, and such Indemnifying Party shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Indemnified Party.  Any Indemnified Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party.  An Indemnifying Party will not be liable to any Indemnified Party under this Agreement (x) for any Losses constituting consequential damages, punitive or exemplary damages, special damages, lost profits, incidental damages, indirect damages or other similar items, except to the extent awarded to a third party; (y) for any settlement by an Indemnified Party effected without such Indemnifying Party’s prior written consent; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to the breach by an Indemnified Party or its Affiliate of any of the representations, warranties, covenants or agreements made by such Indemnified Party or its Affiliate in this Agreement, any violations by the Indemnified Party or its Affiliate of state or federal securities laws or any conduct by the Indemnified Party or its Affiliate which constitutes fraud, gross negligence, willful misconduct or malfeasance.
 
 
- 8 -

 
 
(b)           If the Closing occurs, the Company shall not be liable to any Investor for any Losses for breach of the representations and warranties of the Company contained herein (y) unless and until the aggregate claims therefor exceed $50,000, or (z) for an aggregate amount in excess of such Investor’s aggregate purchase price as set forth on Schedule I under the column titled “Purchase Price”.
 
6.2           Registration.  Upon written request of the Investors holding at least a majority of the shares of Common Stock issued pursuant to this Agreement, the Company agrees to file with the Commission a registration statement (the “Registration Statement”) to register the Common Stock within thirty (30) days from the date of such requesr.  The Company will use its best efforts to cause the Registration Statement to be declared effective within sixty (60) days (or 90 days in the event of review by the Commission) following the date of such request.
 
6.3           Listing of Common Stock.  The Company hereby agrees to use its commercially reasonable efforts to maintain the listing or quotation of the Common Stock on the OTC Bulletin Board, and the Company shall promptly apply to list or quote all of the Shares. The Company agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares to be listed or quoted on such Trading Market as promptly as possible.
 
6.4           Anti-Dilution.  If at any time within six (6) months from the Closing Date the Company sells or issues any Common Stock or Common Stock Equivalents (other than sales or issuances to directors, officers, employees or independent contractors in the ordinary course of business for compensation purposes and stock splits and stock dividends payable in respect of the Common Stock) having a purchase, exercise or conversion price per share of Common Stock less than the purchase price per Share paid by the Investors under this Agreement (appropriately adjusted to account for any stock split, stock dividend or similar change affecting the Common Stock) (such price per share, as amended by reason of any adjustment or adjustments under this Section 6.4, the “Per Share Price”), then in such event the Per Share Price shall automatically be reduced to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula, and the Company shall issue to each Investor concurrently with such Additional Issuance a number of additional validly issued, fully paid and nonassessable shares of Common Stock such that the aggregate number of shares of Common Stock issued to each Investor pursuant to this Agreement shall equal the result obtained by dividing each Investor’s aggregate purchase price as set forth on Schedule I hereto under the column titled “Purchase Price” by the Per Share Price:
 
CP2 = CP1*  (A + B) ÷ (A + C).
 
For purposes of the foregoing formula, the following definitions shall apply:
 
(a)           “CP2” shall mean the Per Share Price in effect immediately after such Additional Issuance;
 
 
- 9 -

 
 
(b)           “CP1” shall mean the Per Share Price in effect immediately prior to such Additional Issuance;
 
(c)           “A” shall mean the number of shares of Common Stock outstanding immediately prior to such Additional Issuance (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of any rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock outstanding immediately prior to such Additional Issuance);
 
(d)           “B” shall mean the number of shares of Common Stock that would have been issued if the Additional Issuance had been made at a price per share equal to CP1 (determined by dividing the aggregate consideration received by the Company in respect of such issue by CP1); and
 
(e)           “C” shall mean the number of such shares of Common Stock issued in the Additional Issuance.
 
7.           Conditions to Closing.
 
7.1           Conditions to an Investor’s Obligations. The obligations of each Investor to purchase its portion of the Shares at the Closing is subject to the fulfillment, on or prior to the Closing Date, of the following conditions, any of which may be waived by an Investor and such waiver shall not be effective against any other Investor unless it consents thereto:
 
(a)           The representations and warranties made by the Company in Section 4 hereof shall be true and correct in all material respects at all times prior to and on the Closing Date.
 
(b)           The Company shall have obtained in a timely fashion any and all consents, approvals and waivers necessary or appropriate for consummation of the purchase and sale of the Shares, and all of which shall be and remain so long as necessary in full force and effect.
 
(c)           No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, or self-regulatory organization enjoining or preventing the consummation of the transactions contemplated hereby.
 
(d)           The Company shall, concurrently with the Closing, close on an equity investment in and loan to the Company by InterDigital in the aggregate amount of $1,000,000 in connection with a strategic partnership involving research and development cooperation and potential licensing of Company patents relating to the mobile market.
 
7.2           Conditions to Obligations of the Company. The Company’s obligation to sell and issue the Shares to the Investors at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which (other than subsection (b) below) may be waived by the Company:
 
 
- 10 -

 
 
(a)           The representations and warranties made by such Investor in Section 5 hereof shall be true and correct at all times prior to and on the Closing Date.
 
(b)           Such Investor shall have delivered its respective aggregate purchase price as set forth on Schedule I under the column titled “Purchase Price” to the Company.
 
(c)           No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, or self-regulatory organization enjoining or preventing the consummation of the transactions contemplated hereby.
 
8.           Transfer Restrictions.  The Shares may not be Transferred by such Investor prior to the six-month anniversary of the Closing Date.  Following the six-month anniversary of the Closing Date, such Investor may, subject to compliance with applicable securities laws, Transfer Shares.  Such Investor acknowledges and agrees that the Company shall issue to its transfer agent such instructions, directions and stop transfer orders as are necessary to implement the provision of this Section 8.
 
9.           Miscellaneous.
 
9.1           Survival.  All representations and warranties contained in this Agreement shall be deemed to be representations and warranties as of the date hereof, and such representations and warranties, together with the right to assert a claim in respect thereof, shall expire on the twelve month anniversary of the Closing Date.  The covenants and agreements contained in this Agreement shall survive the Closing Date until the expiration of the applicable statute of limitations.
 
9.2           Successors and Assigns.  The provisions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties.  Neither the Company nor any Investor may assign this Agreement or any of its rights or obligations hereunder without the prior written consent of the other party; provided, however, that any Investor may assign some or all of its rights hereunder to any Affiliate of such Investor without the consent of the Company.  Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement.
 
9.3           Counterparts; Faxes.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  In the event that any signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.
 
9.4           Titles and Subtitles.  The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.
 
 
- 11 -

 
 
9.5           Notices.  Any notices, demands and communications to a party hereunder shall be in writing and shall be deemed to have been duly given and received (a) if delivered personally, as of the date received, (b) if delivered by certified mail, return receipt requested, three business days after being mailed, (c) if delivered by a nationally recognized overnight delivery service, two business days after being entrusted to such delivery service, or (d) if sent via facsimile, electronic mail or similar electronic transmission, as of the date received, to such party at its address set forth below (or such other address as it may from time to time designate in writing to the other parties hereto):
 
If to the Company:
 
BIO-key International, Inc.
3349 Highway 138
Building D, Suite A
Wall, NJ 07719
Attention:  Mike DePasquale, President and CEO
Fax:  (732) 359-1101
 
With a copy to:
 
Choate, Hall & Stewart LLP
Two International Place
Boston, MA  02110
Telephone:  (617) 248-5000
Facsimile:  (617) 248-4000
Attention:  Charles J. Johnson, Esq.
 
If to an Investor, to such Investors at the address set forth for such Investor on the signature page or Schedule I hereto, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this Section 9.5.
 
9.6           Expenses.  The Company and each Investor shall each bear their own expenses in connection with the negotiation, preparation, execution and delivery of this Agreement.
 
9.7           Amendments and Waivers.  No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by the Company and the Investors who purchase at least a majority of the total Shares issued hereunder, or in the case of a waiver, by the party against whom enforcement of any such waived provision is sought.  No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.  Any amendment or waiver effected in accordance with this Section 9.7 shall be binding upon each holder of the Shares at the time outstanding, each future holder of the Shares, and the Company.
 
 
- 12 -

 
 
9.8           Publicity.  No public release or announcement concerning the transactions contemplated hereby shall be issued by the Company or the Investors without the prior consent of the Company (in the case of a release or announcement by any Investor) or the Investors (in the case of a release or announcement by the Company) (which consents shall not be unreasonably withheld), except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange or securities market on which the Shares are then listed and trading.
 
9.9           Severability.  Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.  To the extent permitted by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect.
 
9.10         Entire Agreement.  This Agreement, including Schedule I and Schedule II and any other exhibits or schedules hereto, constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof.  Prior drafts or versions of this Agreement shall not be used to interpret this Agreement.
 
9.11         Further Assurances.  The parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained.
 
9.12         Governing Law; Consent to Jurisdiction; Waiver of Jury Trial.  This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the choice of law principles thereof.  Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New York, New York and the United States District Court for the Southern District of New York located in New York, New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby.  Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement.  Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court.  Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.  EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).
 
[Signature page follows.]
 
 
- 13 -

 
 
IN WITNESS WHEREOF, the parties have caused their duly authorized officers to execute this Purchase Agreement as of the date first above written.
 
 
BIO-KEY INTERNATIONAL, INC.
 
       
       
       
 
By:
   
  Name: Michael DePasquale  
  Title: Chief Executive Officer  
       
       
       
 
INVESTORS:  “____________”
 
 
EX-31.1 6 ex31-1.htm EXHIBIT 31.1 ex31-1.htm
 
Exhibit 31.1
 
CERTIFICATION
 
I, Michael W. DePasquale, certify that:
 
  1.  
I have reviewed this quarterly report on Form 10-Q of BIO-key International, Inc. (the “Company”);
 
  2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
  3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
 
  4.
The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
 
  (a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
  (b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
  (c)
Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
  (d)
Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting;
 
  5.
The Company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):
 
  (a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
 
  (b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 
Dated: May 15, 2013
 
   
   
 
/s/ Michael W. DePasquale
 
Michael W. DePasquale
 
Chief Executive Officer
 

EX-31.2 7 ex31-2.htm EXHIBIT 31.2 ex31-2.htm
 
Exhibit 31.2
 
CERTIFICATION
 
I, Cecilia C. Welch, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of BIO-key International, Inc. (the “Company”);
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
 
4.
The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
 
  (a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
  (b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
  (c)
Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
  (d)
Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting;
 
5.
The Company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):
 
  (a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
 
  (b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 
Dated: May 15, 2013
 
   
   
 
/s/ CECILIA C. WELCH
 
Cecilia C. Welch
 
Chief Financial Officer
EX-32.1 8 ex32-1.htm EXHIBIT 32.1 ex32-1.htm
 
Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of BIO-key International, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael W. DePasquale, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
 
                (1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
                (2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 
 
BIO-KEY INTERNATIONAL, INC.
   
   
 
By:
/s/ Michael W. DePasquale
   
Michael W. DePasquale
   
Chief Executive Officer
   
   
 
Dated: May 15, 2013
 
EX-32.2 9 ex32-2.htm EXHIBIT 32.2 ex32-2.htm
 
Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of BIO-key International, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Cecilia Welch, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, that to my knowledge:
 
                (1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
                (2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 
 
BIO-KEY INTERNATIONAL, INC.
   
   
 
By:
/s/ CECILIA C. WELCH
   
Cecilia C. Welch
   
Chief Financial Officer
   
 
Dated: May 15, 2013
EX-101.INS 10 bkyi-20130331.xml XBRL INSTANCE 0001019034 2013-03-31 0001019034 2012-12-31 0001019034 2013-01-01 2013-03-31 0001019034 2012-01-01 2012-03-31 0001019034 2011-12-31 0001019034 2012-03-31 0001019034 2013-05-12 0001019034 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2013-01-01 2013-03-31 0001019034 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2012-01-01 2012-03-31 0001019034 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-03-31 0001019034 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-03-31 0001019034 us-gaap:StockOptionsMember bkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember 2013-01-01 2013-03-31 0001019034 bkyi:ExercisePriceLessThanAverageMarketPriceOfCommonSharesMember 2013-01-01 2013-03-31 0001019034 us-gaap:StockOptionsMember bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2013-01-01 2013-03-31 0001019034 us-gaap:StockOptionsMember bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2012-01-01 2012-03-31 0001019034 us-gaap:WarrantMember bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2013-01-01 2013-03-31 0001019034 us-gaap:WarrantMember bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2012-01-01 2012-03-31 0001019034 bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2013-01-01 2013-03-31 0001019034 bkyi:ExercisePriceGreaterThanAverageMarketPriceOfCommonSharesMember 2012-01-01 2012-03-31 0001019034 bkyi:ThomasColatostiMember bkyi:SevenPercentConvertiblePromissoryNoteMember 2009-12-28 0001019034 bkyi:ColatostiNoteMember 2010-12-31 0001019034 bkyi:ColatostiNoteMember 2013-03-31 0001019034 bkyi:ColatostiNoteMember 2012-12-31 0001019034 bkyi:InterDigitalNoteMember 2013-02-26 0001019034 bkyi:InterDigitalNoteMember 2013-03-31 0001019034 bkyi:InterDigitalNoteMember 2013-02-25 2013-02-26 0001019034 bkyi:InterDigitalSPAMember 2013-02-25 2013-02-26 0001019034 bkyi:InterDigitalSPAMember 2013-02-26 0001019034 bkyi:PrivateInvestorSPAMember 2013-02-25 2013-02-26 0001019034 bkyi:PrivateInvestorSPAMember 2013-01-01 2013-03-31 0001019034 us-gaap:GeographicConcentrationRiskMember bkyi:NorthAmericanMember 2013-01-01 2013-03-31 0001019034 us-gaap:GeographicConcentrationRiskMember bkyi:NorthAmericanMember 2012-01-01 2012-03-31 0001019034 us-gaap:SalesRevenueGoodsNetMember bkyi:ThreeCustomersMember 2013-01-01 2013-03-31 0001019034 us-gaap:SalesRevenueGoodsNetMember bkyi:ThreeCustomersMember 2012-01-01 2012-03-31 0001019034 us-gaap:AccountsReceivableMember bkyi:OneCustomerMember 2013-03-31 0001019034 us-gaap:AccountsReceivableMember bkyi:TwoCustomersMember 2012-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Represents less than $0.01 Represents less than $0.01 per share 451748 83989 449110 604784 94380 189904 4351 4186 59303 25088 1058892 907951 18531 24267 55521 8712 8712 193093 195911 275857 228890 1334749 1136841 649308 931276 385623 593599 467108 508520 321428 1502039 2354823 497307 497307 1999346 2354823 8718 7815 51930685 51062624 -52604000 -52288421 -664597 -1217982 1334749 1136841 20526 20526 170000000 170000000 87182348 78155413 87182348 78155413 0.0001 0.0001 276960 395854 527683 1014573 804643 1410427 40715 124017 77098 57413 117813 181430 686830 1228997 732076 604884 262809 254487 994885 859371 -308055 369626 7524 6128 -7524 -6128 -315579 363498 0.00 0.00 0.00 0.00 81465289 78155413 81465289 78156172 5736 7970 2818 2817 1682 12447 20741 -155674 -100290 -95524 165 -1129 34215 8176 -281968 -272814 -207976 18016 -41412 -65905 -607434 167566 902693 321428 497307 46176 57203 975193 367759 167566 43437 211003 51494 BIO KEY INTERNATIONAL INC 10-Q --12-31 87182348 false 0001019034 Yes No Smaller Reporting Company No 2013 Q1 2013-03-31 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>BASIS OF PRESENTATION</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 36pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International,&#160;Inc. and its wholly-owned subsidiary (collectively, the &#8220;Company&#8221;) and are stated in conformity with accounting principles generally accepted in the United States of America, pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;).&#160; The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. Pursuant to such rules&#160;and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Significant intercompany accounts and transactions have been eliminated in consolidation.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 36pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company&#8217;s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at December&#160;31, 2012 was derived from the audited financial statements, but does not include all of the disclosures required by accounting principles generally accepted in the United States of America. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2012 (the &#8220;Form&#160;10-K&#8221;), filed on April 1, 2013.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 36pt" align="left"> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Recently Issued Accounting Pronouncements</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 36pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.</font> </div><br/> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 36pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>GOING CONCERN</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 36pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has incurred significant losses to date and at March&#160;31, 2013,&#160;&#160;had an accumulated deficit of approximately $53 million. In addition, broad commercial acceptance of the Company&#8217;s technology is critical to the Company&#8217;s success and ability to generate future revenues. At March 31, 2013, the Company&#8217;s total cash and cash equivalents were approximately $452,000, as compared to approximately $84,000 at December&#160;31, 2012.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 36pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has financed itself in the past through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. The Company currently requires approximately $390,000 per month to conduct&#160;&#160;operations, a monthly amount that we have been unable to achieve through revenue generation.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 36pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the three months ended March 31, 2013, the Company raised proceeds of $1,297,000 net of fees through the issuance of a senior secured promissory note and shares of common stock . See Notes 5 and 6.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 36pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the Company is unable to generate sufficient revenue to meet our goals, it will need to obtain additional third-party financing to (i) conduct the sales, marketing and technical support necessary to execute its plan to substantially grow operations, increase revenue and serve a significant customer base; and (ii) provide working capital. No assurance can be given that any form of additional financing will be available on terms acceptable to the Company, that adequate financing will be obtained by the Company, in order to meet its needs, or that such financing would not be dilutive to existing shareholders.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 36pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The matters described in the preceding paragraphs raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company&#8217;s ability to meet its financing requirements on a continuing basis, and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.</font> </div><br/> 390000 1297000 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> SHARE BASED COMPENSATION</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table presents share-based compensation expenses for continuing operations included in the Company&#8217;s unaudited condensed consolidated statements of operations:</font> </div><br/><table cellpadding="0" cellspacing="0" width="95%" style="LINE-HEIGHT: 1.25; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="LINE-HEIGHT: 1.25;"> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="6" valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;Ended&#160;March&#160;31,</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Selling, general and administrative</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,121</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,223</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research, development and engineering</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,326</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,518</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,447</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,741</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/> <table cellpadding="0" cellspacing="0" width="95%" style="LINE-HEIGHT: 1.25; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="LINE-HEIGHT: 1.25;"> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="6" valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;Ended&#160;March&#160;31,</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Selling, general and administrative</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,121</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,223</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research, development and engineering</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,326</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,518</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,447</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,741</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table> 11121 2223 1326 18518 12447 20741 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>EARNINGS PER SHARE (&#8220;EPS&#8221;)</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s basic EPS is calculated using net income available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of convertible notes and preferred stock.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The reconciliation of the numerator of the basic and diluted EPS calculations was as follows for the three month periods ended March&#160;31, 2013 and 2012:</font> </div><br/><table cellpadding="0" cellspacing="0" width="95%" style="LINE-HEIGHT: 1.25; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="LINE-HEIGHT: 1.25;"> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="6" valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;ended</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basic Numerator:</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net (loss) income</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(315,579</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">363,498</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basic Denominator:</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">81,465,289</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">78,155,413</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Per Share Amount</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.00</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.00</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes the potential weighted average shares of common stock that were included in the diluted per share calculation for the three months ended March&#160;31, 2013 and 2012.</font> </div><br/><table cellpadding="0" cellspacing="0" width="95%" style="LINE-HEIGHT: 1.25; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="LINE-HEIGHT: 1.25;"> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="6" valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;Ended</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock Options</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">759</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/><table cellpadding="0" cellspacing="0" width="95%" style="LINE-HEIGHT: 1.25; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="LINE-HEIGHT: 1.25;"> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="6" valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;ended</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dilutive Numerator:</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net (loss) income</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(315,579</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">363,498</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dilutive Denominator:</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">81,465,289</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">78,156,172</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Per Share Amount</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.00*</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> &#160; </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.00*</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> &#160; </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* Represents less than $0.01 per share</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth the options and warrants which were excluded from the diluted per share calculation even though the exercise prices were&#160;&#160;less than the average market price of the common shares because the effect of including these potential shares was antidilutive due to the net losses for the three months ended March 31, 2013 and 2012:</font> </div><br/><table cellpadding="0" cellspacing="0" width="95%" style="LINE-HEIGHT: 1.25; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="LINE-HEIGHT: 1.25;"> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="6" valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;Ended</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="13%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="13%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock options</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">647,660</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td valign="bottom" width="70%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">647,660</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth options and warrants which were excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:</font> </div><br/><table cellpadding="0" cellspacing="0" width="95%" style="LINE-HEIGHT: 1.25; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="LINE-HEIGHT: 1.25;"> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="6" valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;Ended</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="13%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="13%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock options</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,025,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,588,560</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,250,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,250,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td valign="bottom" width="70%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,275,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,838,560</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/> <table cellpadding="0" cellspacing="0" width="95%" style="LINE-HEIGHT: 1.25; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="LINE-HEIGHT: 1.25;"> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="6" valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;ended</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basic Numerator:</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net (loss) income</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(315,579</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">363,498</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basic Denominator:</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">81,465,289</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">78,155,413</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Per Share Amount</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.00</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.00</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><table cellpadding="0" cellspacing="0" width="95%" style="LINE-HEIGHT: 1.25; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="LINE-HEIGHT: 1.25;"> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="6" valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;Ended</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock Options</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">759</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><table cellpadding="0" cellspacing="0" width="95%" style="LINE-HEIGHT: 1.25; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="LINE-HEIGHT: 1.25;"> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="6" valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;ended</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 1.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dilutive Numerator:</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="14%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net (loss) income</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(315,579</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">363,498</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dilutive Denominator:</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">81,465,289</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">78,156,172</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="68%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.8pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Per Share Amount</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.00*</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> &#160; </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.00*</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> &#160; </td> </tr> </table> 759 <table cellpadding="0" cellspacing="0" width="95%" style="LINE-HEIGHT: 1.25; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="LINE-HEIGHT: 1.25;"> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="6" valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;Ended</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="13%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="13%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock options</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">647,660</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td valign="bottom" width="70%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">647,660</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><table cellpadding="0" cellspacing="0" width="95%" style="LINE-HEIGHT: 1.25; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="LINE-HEIGHT: 1.25;"> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="6" valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three&#160;Months&#160;Ended</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March&#160;31,</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="13%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" colspan="2" valign="bottom" width="13%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%" style="LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock options</font> </div> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,025,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,588,560</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0.75pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,250,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,250,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td valign="bottom" width="70%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,275,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,838,560</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; LINE-HEIGHT: 1.25"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table> 647660 647660 3025000 4588560 8250000 8250000 11275000 12838560 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>NOTES PAYABLE</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">The 2010 Exchange Agreement</font></font> </div><br/><div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective as of December 31, 2010, the Company entered into a Securities Exchange Agreement (the &#8220;2010 Exchange Agreement&#8221;) with Thomas Colatosti (&#8220;Colatosti&#8221;), the Company&#8217;s Chairman of the Board. Pursuant to the 2010 Exchange Agreement, Mr. Colatosti agreed to exchange all of his outstanding shares of Series D Convertible Preferred Stock, including all accrued and unpaid dividends thereon, and the 7% Convertible Promissory Note dated as of December 28, 2009 issued by the Company to Mr. Colatosti in the original principal amount of $64,878 for a new non-convertible 7% Secured Promissory Note in the original principal amount of $350,804 (the &#8220;Colatosti Note&#8221;).</font> </div><br/><div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The principal and interest under the Colatosti Note was scheduled to be repaid by the Company in cash on December 31, 2012. Pursuant to a Note Amendment and Extension Agreement effective as of December 31, 2012, the maturity date of the Colatosti Note was extended to March 31, 2013. In February 2013, the principal balance and accrued interest owing under the Colatosti Note was repaid from the proceeds of the new financing (see Note 2).&#160;&#160;At March 31, 2013 and December 31, 2012, the amount payable under the Colatosti Note&#160;&#160;was $0 and $321,428, respectively.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">2013 Note Purchase Agreement</font></font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to a Note Purchase Agreement dated February 26, 2013 by and between the Company and DRNC (the &#8220;InterDigital NPA&#8221;). Pursuant to the InterDigital NPA, the InterDigital Note was issued in a principal amount of $497,307 and bears interest at a rate of 7% per annum, with a default rate of 9% per annum while a nonpayment default is continuing. The InterDigital Note matures on December 31, 2015, is secured by a security interest in all of the tangible and intangible assets of the Company and is subject to acceleration upon an event of default. Under the InterDigital NPA, commencing July 1, 2013, the Company is required to comply with certain financial covenants, including a leverage ratio covenant and an annual limit on capital expenditures other than in the ordinary course of business.. A portion of the proceeds from the sale of the InterDigital Note were used to repay the Colatosti Note in full, with the remaining proceeds to be used for other general corporate purposes.&#160;&#160;At March 31, 2013, the amount payable under the InterDigital Note was $497,307.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the InterDigital NPA and InterDigital Note, the Company incurred costs totaling $57,203.&#160;&#160;Such costs were capitalized and are being amortized over the term of the InterDigital Note on the effective interest method.</font> </div><br/> 0.07 64878 0.07 350804 0 321428 497307 0.07 0.09 497307 57203 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>STOCKHOLDERS&#8217; DEFICIENCY</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 36pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Issuances of Common Stock</font></font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to a Securities Purchase Agreement dated February 26, 2013 by and between the Company and DRNC (the &#8220;InterDigital SPA&#8221;), the Company issued 4,026,935 shares of its common stock at a purchase price $0.10 per share, for an aggregate purchase price of $402,693. DRNC has anti-dilution rights under the InterDigital SPA that would require the Company to issue additional shares to DRNC on a full-ratchet basis if the Company, within the nine months following February 26, 2013, sells or issues any common stock or common stock equivalents (other than sales or issuances to directors, officers, employees or independent contractors in the ordinary course of business for compensation purposes and stock splits and stock dividends payable in respect of the Company&#8217;s common stock) having a purchase, exercise or conversion price per share of less than $0.10.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Concurrently with the closing of the transactions described above, the Company closed an equity financing with a number of private investors pursuant to a Securities Purchase Agreement dated February 26, 2013 by and between the Company and such private and institutional investors (the &#8220;Private Investor SPA&#8221;). Pursuant to the Private Investor SPA, the Company issued 5,000,000 shares of its common stock at a purchase price $0.10 per share, for an aggregate purchase price of $500,000.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the share issuances described above, the Company incurred costs of $46,176 which were offset against additional paid-in capital.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Issuances of Stock Options</font></font> </div><br/><div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"> For the three months ended March 31, 2013 and 2012, 2,300,000 and 1,125,000 stock options were granted, respectively. Terms of the options&#160;issued in 2013 include the following: term - 7 years, excercise price - $0.17, vesting - 3 years. </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Derivative Liabilities</font><!--EFPlaceholder--><!--EFPlaceholder--> <!--EFPlaceholder--><!--EFPlaceholder--></font> </div><br/><div style="LINE-HEIGHT: 1.25; MARGIN-LEFT: 36pt"> In connection with the issuances of equity instruments or debt, the Company may issue options or warrants to purchase common stock. In certain circumstances, these options or warrants may be classified as liabilities, rather than as equity. In addition, the equity instrument or debt may contain embedded derivative instruments, such as conversion options or listing requirements, which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative liability instrument. The Company accounts for derivative liability instruments under the provisions of FASB ASC 815, &#8220;Derivatives and Hedging.&#8221; </div><br/><div style="LINE-HEIGHT: 1.25; MARGIN-LEFT: 36pt"> As discussed above, the Company issued shares to DRNC that contain anti-dilution rights.&#160;&#160;The Company determined that the anti-dilution rights are embedded derivatives that must be bifurcated and recorded as derivative liabilities. In addition, the Company would be required to revalue the derivative liabilities at the end of each reporting period with the change in value reported on the statement of operations. The Company did not account for these derivative liabilities in its financial statements as it was determined to not be material. </div><br/> 4026935 0.10 402693 0.10 5000000 0.10 500000 46176 2300000 1125000 P7Y 0.17 P3Y <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>SEGMENT INFORMATION</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 40.5pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has determined that its continuing operations are one discrete segment consisting of Biometric products. Geographically, North American sales accounted for approximately 98% and 97% of the Company&#8217;s total sales for the three months ended March&#160;31, 2013 and 2012, respectively.</font> </div><br/> 0.98 0.97 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>FAIR VALUES OF FINANCIAL INSTRUMENTS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 40.5pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash and cash equivalents, accounts and notes receivable, accounts payable, accrued liabilities, and notes payable, are carried at, or approximate, fair value because of their short-term nature.</font> </div><br/> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9.&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLES</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 45pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the three months ended March 31, 2013 and 2012, three customers accounted for 61% and 76% of revenue, respectively.&#160;&#160;At March 31, 2013, one customer accounted for 56% of accounts receivable.&#160;&#160;At December 31, 2012, two customers accounted for 88% of accounts receivable.</font> </div><br/> 0.61 0.76 0.56 0.88 EX-101.SCH 11 bkyi-20130331.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Disclosure - Note 1 - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Note 2 - Going Concern link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Note 3 - Share Based Compensation link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Note 4 - Earnings Per Share ("EPS") link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Note 5 - Notes Payable link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Note 6 - Stockholders' Deficiency link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Note 7 - Segment Information link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Note 8 - Fair Values of Financial Instruments link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Note 9 - Major Customers and Accounts Receivable link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Note 3 - Share Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Note 4 - Earnings Per Share ("EPS") (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Note 2 - Going Concern (Detail) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Note 3 - Share Based Compensation (Detail) - Share-based Compensation Expenses link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Note 4 - Earnings Per Share ("EPS") (Detail) - Reconciliation of Numerator of Basic and Diluted EPS Calculations link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Note 4 - Earnings Per Share ("EPS") (Detail) - Anti-dilutive Securities link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Note 5 - Notes Payable (Detail) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Note 6 - Stockholders' Deficiency (Detail) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Note 7 - Segment Information (Detail) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Note 9 - Major Customers and Accounts Receivable (Detail) link:presentationLink link:definitionLink link:calculationLink 000 - Disclosure - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 12 bkyi-20130331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION EX-101.DEF 13 bkyi-20130331_def.xml XBRL TAXONOMY EXTENSION DEFINITION EX-101.LAB 14 bkyi-20130331_lab.xml XBRL TAXONOMY EXTENSION LABELS EX-101.PRE 15 bkyi-20130331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 17 0001437749-13-006114-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-13-006114-xbrl.zip M4$L#!!0````(``^"KT*UO8.-AT8``.7Z!``1`!P`8FMY:2TR,#$S,#,S,2YX M;6Q55`D``QWMDU$=[9-1=7@+``$$)0X```0Y`0``[%U9<]M(DG[?B/T/6,U$ M1T^$*.+D(=F,H'5XN"U+&DF>[MX7!P042;1!%!N'),ZOW\P"0!0N$B`@6W+3 MT0>-(X\OC\HZ\>Y_.AWA(W&(J_O$%!Y6@G7ZL[_XA]`13NEB>6=8PL3QX:[A M6X\$KCF/Q(6_P_VY[R^/N]VGIZAT1@+^^>__>H=, M3EV"+(Z%3]01/NDK05($63Y6>L?B0/A\?RK((EQA+\$;SP^N+3PO;,=[?\`Q MPLM'U)UU95%4NI;C^;ICD(/PR6.\:]5XW@)E/'_]`GO8(\;1C#YVPWOPGB1W M1*FC2/%+)K&*WX`;!8_C(V;FC4B@7C>\&3\:>)V9KB_7STYU[X$]&]THH&Y; MSM<-"N/M!]U+`+(W//S;)3S-R>*OEL0K%(;=*9#&\J@J2_U-%@B?B%^(_&;] M0I$?Q<\^?%TE#SY8M/.5K/`^RJ&("H=X#I0GA4D@#8?#+KN[?M0K>@XDE;J_ M?;J\,^9DH7?67C-BSBP([Y#$L(RCO#SQKL;01;W9M[I+I^P.4 MO!-+>?3LF0?=44C(H!!;S[Y@F>\/#/'+V+N>*M(GW<6'&3OV&#Q('-_R5Z/U M!;ADF7AQ:D$L,E%(2I78*4\GOQR,1%!(E(:BHK[K)J_Q]+L)@_C2DK@6-=,L M&1+^",7KB`I8_ETWOK:FE+P7ZMB-E%RCEU):BI0^(P;ZT^M66N[`/RTH+7^Y M<.E"^E_=023OZ6NV.2CJ^F>0N2.K2_#/NVYR51#XIXEC) M+!Z(>\`'XDNCA6F!S!8DT9I="TN_8_*\M"W#\D/!!-."!SV+.N\/HJ+O&*L0 M,[#)]?0<2@NZ(N2.N(^60>[FNDL^0'5G8J4.KX&FU!G;-C78K^OI+3'HS+'^ M0\P;!O,I]7SOP^J6+*GK0[5'QL^6=S!:-.6!S1AZ)39>H8`3,WKFUNM/W2%"25%YM^=3X>KU$4*-$_>7\F;B&Y9$;%RQQ23SO?JX[XT?( M\3,"KWTE/KMS/07;+*C#;)5J*-^&\XV!I&G9`395=\0(7,NWB'?^;-B!24S$ M"WTO\".'.]==!QH[#]PM],Y5,8%,$YF#M]3-.,5JQ5!AJ(1&&0?^G+H8))\= M$^1.A+FQ=0?")67J6]V916&#XUS'#?R@BI)O.#N7COHTCYTW$CQ[K_OV7J?L MG,0_L@D;MYXOO@U'W&?Q.O%4VQ'*]?P!`DHM'QW8!]0^H-YT0'V7;H96VD+] MJKNN[OC[6&H_EE+0[L/H!VB7>J7MTCZ,]F'T%L/HN[1&Y5.,S0/GC43.7]WO MODOZ+I]TW/O=7\3OODN^&[)U)/*`K1@2AU_NYW2A>Z?4UGWJ^594--R11^)` MTVB`5M$:8.O!!CSIPO(\ZJZNJ/_6YI'&AD$#Q_=0=.^2@A>-'?/"M1!27"N2S+3[7.F#CI(@"NBEV"CU?UJR?M9(7AMEP5GY,&?.)[O!J@[ MQ[V&D3;(U-BGDW4_XA!7>,F#Y@LFQ=2Z-O'+&N*4WW%RO7+?*[5A@6(O.D#- M+=(2VUK=*J47,N^-]0+&:FO]M2RG%V#OC?4"QFIMW;@2-M:]"_+`(HMMS3FS M9I:OVQE[O7%K%6OV@I58.K:@U>HU-Y>:281[<[V0N=I)A>%`M*Q%T75/*P7: MWG0-^]H0:UK5OG88EPW[/'*OFJ'O;L9O+D+7_9<2"Z]U^G;K(+^]??L;FLF4 M4?X;K,PIM;?T M&QG"5L122W\D=.;JR[EEG%('AZ=<-K1[:WE?HP'&*^KZ\_$"&!JZ\_:JJYQ: M'[BAP?BAK2AL\H^=Q+KSP9ZH5<):MSE'+4#]!]X?H4BE?C%'* MEXC?Z3;Q;G&`/R`?*36]*Q(OZ+B?NX28+W3W:V;] M7RD&%:8SZHCT2?^#NFM$4_,[>:@KQ<0;3IJEYR_L?7+OD]\I3V8'5N.IW&32 M-O+#:V<-S0_LA&7J;VTJ6W'`',9O:]A7T3(S8*7.=/]$BU+:WIW:S6%'@FGV$61/<"EXRB8\^./]^=O>O&%X6$'K[/_7U-SF.KD))1 MK_A5=M#=<7B7([B9&,AV`YC&)&.:IO4(_I8"!5^Y"A9X)B#EP[:*1HE%LE32 M],^(0Q>6$]\KXE&B99Y+EM;:<(EN6[!9`N54,*=EP-MY-7/DV)EO4TI]A_H$ M3]-+'0T'#@/M'C'CP^%<:J?S0?JH/+S-#O#C;,7>LZF1HLNVMU,W)FOK#\1^ M?_`EMZ!9]RRC4W[VV)>4?Z0.L/M;0V+=44J!&*&4%O&9?W70B0EE5)_ZCO]% M9&?\P25G!M`[G<]W!Z-;L@0VD!<\`:HV3_#GNB/\73S"\B4E&>\)J1MC-XV] M[AHQ<_BY1>;HB>Y4-_Q.5O8I`-F6U7R:@$!=D[CO#R0T0IM^5-XMV,&/*A(K M\:/O991Z$+RH4YH]SK0[/NYP($T\0M&DA"U/58XW+EGJEAF= M/@9QU*;!M:$B*HDD%7B-6I5N,TRR)@X&3:1K"25)U`:#H[U M=Q/HC$P)8!?M]2+L$,`KZA@AH(U@TC1-YF#:RBDOVI)Z%C2*S,3)H[M+-.A+ M,B]0,?V<%^TBR)9B8#=!)HX/13;N8XL>)7ZXAQ_/D*74?+)LNX%;0]X;*GP* MWLZMJ#%H)N.6]G"H0:725,;V/$KN:P.MGTU':1/NSGM+U,N0@,7ZO!MXB**H M?76895E4IF[EM,7.DM(;J+D\OZ$@OM%76!0V;M=Z*H3!(%]WINEGV]3:0FQI MY11)[O?J"^$&Q+RT]`?+9N=S-`9#&6@]64G)4G+DB;*HL(Y4*'G-!)@2[Y6-'7`1U,E`:@SNR?N M@D>Q@>L.^XK(-5=%U+/APTG91HN9$Z&(_$9#-*EPAD-%[14R+VA:*O+H% M/*,3-_!(CX9C8E!C\B-B&;I9*]?ANUGA_D#2JO,=FZ:%BS!T^P:ZL1/G5%_B M-IX&O0XL8WL#3H02%D6U1'UAMF1I2>S)/5G=19A;XNN60\QX%!?:NV`1L/P) MR1Z7?NP.4D>3>Z(JBEP#LIU=+CLWDW`SZ2;0#O922;>%[0&"^L%61% M+:X7>#Z;*Y8:$FW#":L(39645B2Z#GQL7=E:@*RR;-!#NW;9 MAB23E6WQ%'(J;W`SQ55!5`]&XA$N[RT4LHQK>=YH).<&0%N1D]\/$7V6Q]LR MHE[^-=3LN&-OV.-R2`FK?$%47Z3R;XYF^OU#;:"I]46ZA!OXD;/HT3;0T0"> M0:K+E6*1+T,J2U`5#$F45*V_481L+$+YY#V3DPK:ZQ* MHBKWB[EFX]?SKZ>Q3[2AL2KVTYU.GD$3`2IK+ZNBU-\H0:'/L5FP-A#H]\7A M(.=NC'P#[E75U_JI=F<+]Q"<%N-=DJ#M4[+HEX5:9?:5C3^05$6LROZC2SWO MQJ73S=WCJKKW!I#J..8<^;SC5^1=W>OEP9#O$F>99QJ?2E^[;"4:%%GDYT^J M<^)&^5NJ.GCP0AWR2W\"P<%!K1P&K`BEKJCKH M[R[@]1+WZ`#T\;=7VT!M.`3K! M14<1!Z)6!$;"IYDDE0M6**'YH8Q"08K6-Q#H2K095'V-'R'.,&@F0N7\(_%3 M=MM%N*(.39P*_JLPU6`V\2A2YH= M!PS==O/(8R5KA..CDMK39'ZC0RTY\J[8IAJ5("\92GT9-2+SU1T)?@%[E$F2 MR^CM:E+/)#VI+[>GR1GN43,L=@9$*Z..?86K)GGJ>7^HRKMJJ]P?]L6JO,<+ MZOK6?Z)O?657T+;22QSP2T\V\RM:AK&S@)5[B0-^L*ZA@.M3+UL;S)-Z_"S_ M)F[9&8?"KP:U(I*LJOS:AT)&16,^M26J;$.QST_P5Y8(JE67P'-G)/S_Q,G/ M5[=2J4,3TNNG.G;;&;^`O)5[.)(HROQZ\M;D95N2HB4`[269SE#+])NW\RW: MKI!]*]YYMF757_58UC;)R''+3DOM+%IUBTORL+IP6\6+]J+%2Y$+]Z2U`:FB MRM)&4*L(\BT4JCPT)_5[;>A3,6]46$9<.0BA)1WV!E621K*\N$U!*_NZW`=1 M*V7C>H)F]B"T`ZH(]=Q&C\@SKMIRU)"W^OR7*.T@[199,SL:6@%6E51^X]U6 MINV*67VL41N*&Q/<-C%Q:[SNS6]KO)G=W6:Q!B>L@6EZ7A@LCUUS-QQ5`KLTBB MW!NF-J9O85HP/;C45SC_Y>'T]'HKS@J_A]-*PYS9^K.)7]%>[;4Z57>[5%X? MDMET4L:K((G>K#5@F,9`M];74WNIQG\3N]QF\O6S[(-&;4NF]>74.0CEW(HF MB(I#*?E"1*L9:-C';1];`[F`>Z5#8&[8F9?9--Q*Q/3Z?6WKL3#%_(M6UK0D M_JX)]$7$KW$$CYI:T2GESC11E?XV8;DAE;J^+X5_J"5.4Y^C"Y%GXY_UV87-V? MWUZ-[R?75^-+^-OINVX9[5'"^HP:['MN^"V'RBPEL?.OD#K_^BBE4S2$<&%Y MAF[_3G3W/#RRNS*33GR:[B9JHRR(#9:*]YB'2?(G?54\+;!>QEZ-71J/,49YAADHA)W;K%+QL M1MWJ@-Z!R\![PEH7`<=6=6?%LT^1'A7P_I78]B\.?7+N(.U3!QIBW+CA[JAM M";6"/)!$V`5=$C*42GF%#5T];O^2BGAQE%(.&S\5WJ^;A_"_\4GQ MI=1RA3E.:4(VB89'T`NJ\OO)]D],ZU'P_)5-WO_T9T#]D\O)U7GGG^>3C_^\ M/Q:D(UD[$>[/?[OO3*[.SJ_@DKCT3X2SR=W-Y?CW8^'!AG1T(GP:WWZ<7'4N MSR_B)Z(KMR$=N!12%W3;FCD1*YM,H\L_S>#?OSV;)TPS_(.B34&-E&QKMI9C M6PXY$2ZNK^X[%^-/DTNX>&\MH%J](D_"+5WH3G3W;O)_YZ#(6@)D)1W]I"^6 M)W^3>N))#49%I#A"/\HO`*2+B*!Z'\9WD[O0,L+:-M<7PLWM^1VX`RL!4B_$ MS\9/LYO@8^P>_'YPN_'/]CU/Z>5=#Z^])M^[GY,LGCI$+DO;8>&@!Z;%UKI@ M%64`$3ULB@C\GC`\.H`IT M*D`IU_E*5FLJ,1%6.CIZN`7^,/$*Z!T<"5!L"!:\_S2GMKWJ0)('H;S@P;-, M"]JWB%A,ZF<#GB+8DR/VZI!)$-(;R+)X$K54ZRO2R3\8?=P6!Y^7T+XV4]\(5&1P^CN_)3'A\M:`KB1L%[A"/R]P`;#`#:QVV2=+/PN MA,?P=:@O.,0@GJ>[%J!D01%IL(7K*'U,S)_KOK#05\)#SF/)\Q(,"]@A0["B M0'&B8^VQ(2\![N%]1&,:V+:P@@;Z*`W<#0>T%QCS`J1Y<`\%@[AXRD!6H,3W M+>8@X2PVOKT^8MF$AMNF^%$$#P!PL73*>FP4+.@MH=1%$377`:8'0APN,*F; M5HN"AP(\1\(=9!QKBA^$\T-THDA/8A%EQ-Z2IQM,Q32AA!FQ+?;9B%"Z)!/` M.T>%&7B??POS[\3)&-UGD60YZ##@_?"V/F.F/EPGS?+DG/5#/D,7NP_69N#` M`(:]CL&L'^KF'X'GL^EB'C34^`ONF3;'7I`%C+O1SIF3),^%;YT/@9&-;X`AC,+4M M2-E8Q$Y7<:[^X;)UF'[O?[^$_(OG)UD&)TS##(ZKFQQ_W7@GI6MXK@77#[YQ MJ0._C=`QBY#_P6!O"^)/ZT8P'VWKG/@`)0EY)&&=F!2!;F0>P6+V"!,I/K\B M?B8@R'0:]@\.^3S)!C5U%S+"5(C.F\-$:5*6)Y\P3^5R"JN3=&B\,0U"M(>4 M,19S;7A!)VI3#ZHH8#=Z33(,GQN8B0:FV*?C/E*V1A2//Q>G+U,6N;T^NKT_/;PD&;?3*L.F(3%2F0=M@("R8I M4_"XOAX4AEY8;6.>"0X$>G M^12M+Y%;U%U9E/C+E#;3K#E"\8..B!!9=/\X*5D8"N/_:$0IS8&K058A>6R3X. M'V#?)I?UW>@(DR-A[(=X"FL8R\6E>&0DWRE)]Y;PCD"2F5SA"0K5+*2J)A^* MH@CM%O;H@(F;%+IK96GVK8&*+X$G;.BX_$4*Q&\4G&&+3MBP);&G<2=CJ7L^ M_'!I,&-CB.P36%3X__:^O;EM8\GW_UMUO\.LKU-EGPO))/B4X[B*EFA'.;&D M%64GV:VM%`@,2<0@P&``RNQ4"I7,<=K0(IJ][>2@5^?T*L\78\\QPFS/K1UB)#YA;:ME%\1`7 M=6<949C(28&87/B,4[(A<(]=R"ZVB@3>\0H<1:YF MDAR/?A&4ZS$M\;*IJ&<]SD4V9NH)33!W]\5.LM',H#:-1[`RDF*;U'$/98N. MS*+E+"G.@[A,UD1%!7LX+BTH%5D>T77QTD'4X4]U(4JZ291TDMJ7.!>8)":J M2QU-_`FS2%AD,117^O$<9[P^QW?1U-$LBA+4?N'WC=B4>]BWG;&(C2Z;,-/W MFJYQLF!5J04Q?PJ`],E7YNL0FOA<">MNIP2PS;[#HU+,4F'&29*2Q%^PP%(4 MCF4#XN^4!>FR6$!S85'CBVZG MQDU%/;A`/+V\,7WX1_[4*Y,N;B%J):G_ZW[C;JQ03*>4R:D10GR72Q0=<9FN M"0>:4@?;CKQTEA[ADA<1.:(DWXTQG>*]9EILB].S8AXU=N#)685O$ELN@J6)42@?\-L,0R[B.\$8A:3C:CS01U_)$TBQM?"( MIHA4((.=.F8)+KZU(IZ>7AL'EJ#K,*#%#G/::_)H"W9\RHTG?`^<[GV8F91S M>.QEOK#"BAW3]KDPI[DMX0DQ!T"C#$RH1S>.XO/LY#KF)8YTS[2IJRVHY<#M@K0F MC\`2&:SS-/7L'-\K],LBOR]K'@9$Q#G4/D6W6'=8BX'@>9X6FVM_I7.RO$1. M$%=D)W0&+X:@=&"E\CS(@YU(QN2S=#(W93)"+9C]Q%IW+YSXXRCCF10L.T*Y M",,"NUUL9(85M25W\1D1DPC>&V/6\(>IC(DI()HNB`\<]Z.S7"B\A\)H:29M MEI,WHUN=3)@Q$8G2F2(I%.CL.(TBESZQF9R7@VMH]*5P)/>."`60TGKAAN:/ M$)<74>?`>E5$E0[+7-72)`@29''1'^.8';1DT5C52JQ>@FH<3/EE*[?EW9OB MB'%8G!KOIY\]&V#W`99R#OG7-A%U\M]OK8_"^>,1ZB?B4_H27 M1P6I?)`K[.4?FQJ,N&,P$G[!S=(M8"8^J[[?[5&N)G5AHI7M8%+IVZ:6N6-^ M(&S9#B$XA,4/[40-$\*3/1*G"![&(FE!DF!E:B`-X*.?![=#]&$P&EZ@ M\^O/-\.KT8K:3DG,X`V8#AV([W(LX8G#KN#@*D\+8GXD*+F@`G["W#QNKT7- M5W#0\#.GQ--QXRH_5FA3HHPB/;&H>B2_PC2NU2.3,VLUO-TT0\I^%+30L64M MF"-J3X.-:`0[RCXA"TW/?O)@&MXL^-M9YX?@KVNX+;&='M].FVZGF[N=17\H M>'X5LPD:>.Z:^15Y;EL)U+H=R$7?%5`43>2-9^3HFA@=RQ&LN5-Z[9]@ MP1]^"^8Q=BRC-`TW)J'N,-$,:=C=B!-;C3S*?KB^O1C>+@D[MC1JY%#R(@Y& MVS+E02R?]FD_5PVQ(ACL%M=(/!#%.X MGRL$I?C,=AY<;1&01/RR$:_E"C'?\<&OEY^NWB*&HS\B>6'P$%(M/G-7JZ^5 MD`O*"933L[-Q@7)2-P.,=LV44[-BRHE%+4#!U$O!`+@!N`&X"7!3`=SJ!6ZR M6L\E-J#*=G*<,B[+W#V=LX^48KO7*&L)664R'@A4CY0907Q!?$%\9:7B3FR= M/1LUE23L+CQD*2SN/9+F&8"NTO0"I`.!!(&4B%X@D/LV/1(K&&OZMZGK^+9Q M0CG5<=^B_W?>^$C_R=3:Y$Q#HIC,II'4DV9_;2Q5?"552W?:ZVQ53G<0/@JN M6T\UZ0G_"YE-H;R1JK:,19TA)PO+1 M.YM-I:DV=T4K4+`0F@,8`Q@[.(RIBJJ6J%H!$)/"2P##OTJ&_RTFF)4@IX_\ MA_\8^!Y;SH(=4N'F/[:G]'68-SM9#UY@_(/6K`VI*JH]FTI+[8+VE(C?`,P` MS)Z;5%4%L[[2:?8AHB$!Q]4B99`NKFU+4UQ;+?USE'1\`KUR3P50HO%&3A8. M7,]-4>3X@E<;T;&T2CND0E.5=KM7,85VE-(.J`FH":@I!VJJ#:77KEIB\YBD M?:5S(#[DS6_9YU;.S2Y/[-^6Z@8WTF?8\"TZUG"^L)Q'C$?8O3=U'`T1?\G` MHF/PGZXGK/?EU#;_H2_A=ZCQ-V_7)Z[>'9E6>G[0D*F:"A>.A5O0D`D:,L&1 M\D/!X#$?*9=W5T`Y2SPH4F'E5,&>)="0J68*!L`-P`W`;0H-F>H(;K): MS_4LLH":L9U3##JZ;$1&J)$"\96)8B"^(+Y29#'+VCK0D&D_'K(4%O<>20/] M7S:C%R`=""0(I$3T`H$\]M,5<"X;&C*!3XMVH5PE/\8H15ES!8XO0D,FZ802 M8`Q@#&`,&C)5421KE8P%PY^]%AHRU4M$CT!K0@\3:,A4:7X#,`,P>VY2517, MH"&3+!Q7BY3!,1V2WZ?^.4HZ0FN19P]>5;ZU"#1DJHJT`VH":@)JRH&:T)!) MQ$;^N,/O[$>,?-L4G99\8KQ(ME[J%;5> M^C,HI/DD*F8&MC%(U,L$8Y//>#[&[@MD8-V<:Q;YZ47CQ?MFLZDV(W*4F^;[ M@+`[7%T_OCHU6IWZI-6IJMK:8G$[7MM9X;S\V]"JV@/TD+0H'IKJ^F^^X^3$_3? MOWW^VOZ?__Y=7_C?_[`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`&X`;@!N4^@@7$=PD]5ZKN>I M`#CDM'.*00O2C<@(AWI`?&6B&(@OB*\49;=5.9,G>3>/?(^F(/W_W`[-!Y;> MSZW/1^@JK`58E7)/GOPC],IR"'D=G@/+92B[XO\_1U?M9H=I=,[RZ,6*-(R%,P]8@SH!>@%Z+5W,K6Z+:5]EM>>%K!+ M.B>@*G:]]-0&C0$:0QI2551S0!!)2BH"H@&B/3>I`-$`T2`LOC5T'F]8?.O" MT`ML.W/3+BX-A>)023`1M.VN2551;=MO*NUN1U'[N9%ST+;@/U2$8H!H@&C\ MG;V^TNQTE':9;B.`:%+X#^`25-HEN,%ND8&/$&^HC@9SZA!ZX!-(**%'H$$A M"UV*3(W31B.74J`RP0FH!,4`P@#"`,*>7R!76OWBP_`6-_:;W#](>6? M=!&#N"F!7P'"[R@@_GRNN>8_P<4>T64>X34CJ.B:D?!RD4GB:@\ZBN;1AZEY M'MP88M`?^-CAE0Z+I66?&"I^L4/>10[!#0XY5S9DN2%QAT/^]1W!=Q..09)K MX!('N,2A:@8']#VUX!*'M&)2*];W=,TE#L/J7>)0M1V`2QR@#2UE*BC`A*<*L87I:\?@T.L6Q$KI-=E?N!0@5[6&+Q!"2K.Y+U.M"3\]EY;:5G M(#XLJ,>M=V4E%%9*QJB0BX3"RKWD(ML5RT6N*:S$U2NLK-H.0&$EI(:AL!+T MO>QL#+5'>=JF63%M`X65]5,P`&X`;@!N4RBLK".XR6H]US.`"YDHJ,R"RJSZ M,B.(+X@OB*^L5"QEZT!AY?%T/+U@_9',>YSOI+!_KOPY=HLO0H!Z2RE0$90+ M*!=IJ`CB"^(+XELU*D(<3"K1![`$L`2PE)Z*(+X@OB"^5:,BQ,&.+PX6O?4* M>WGRC]`KRR'D-6LB[LQQ#H=!L$L*Z*OOD3RX'*,4F5ZUFAVETX/S>%M3\/6N M&`W0"]`+T&LC,K6Z+:5]UE]C7P!V2>$$5,6NEY[:H#%`8TA#JHIJ#@@B24E% M0#1`M.&SN,-BS^Q//0"V\[!$5H1@@&B`:?V>OKS0[7:79*W$X'Q!-"B\"'(-*.P8W MV"WV"48SS<5H,*=NH0<^@802>@0:%'+1I>G*\I/MVOXZ5_)$JE;O'`Q MP;9'Z.81@KR99J.7E.F::(%=1)@)6EAAE;`WGT;>]6WOQ`8\@;R'H>_=#*>9 M>.)8EO-@VE,D+D\@F%)[XKC>C)(;(T=9J8^RW#&`Z8. M`?ZN6[Z!#32AV,%',%AZ@?YAN6-(URS=MS0V,,+WV,Z,Y,TC[]C5S<) M1@O7U.DJV4MB$KG\*>(/+UQC.)IVCUUMBM%<<[]A3PR$G`D?7G?F2J;I4Z;-%LCI-<-L7HY'&=34K'"0!XU1RS.-(*V"#)^. MZ"3GQ-Y@T\FPLPB8TYO_R6-]U!&=D3?&.&FAL\JW"36;5B36;7 MW)@QK-Z-&57;`;@Q`WK^[CE%`?H>]+TD3>5S`TP5UO=%J319M0W(+XBLC&4%\C^=(Y`X- MH\-5/OTJW MVUB3.@65^NSV'6`98!E@V4IRG92P.0#)I'`.JEU&`%X`>^UO07GS`3,9>U". M\F8MGE\/;),FW`KFCH&8N4IU$VJ65;J@<2N8HJR61W&4=`30!-`$T*RWL!]O M9D/ZK8$(&43(I"%512-DD$:7DHJ`:(!HSTTJ0#1`-#EB_T\Q?==[+^U<[R7O M%$+X9/;8@?C+V8H6)IM5$95@CXV/292=W6%S!G>.IUEKB@VJE"W(YZ::0>*N M`U^4:,AP_+&%MXU\'0,YRX>^BNA96F-#O=&3%4C-1!Z@$Z"SNN2L)W16/6]0 M9X%?Z?B(#W?4NO(`O17C\Y:DM6)Q6T71X3!#\TW[*L9:&2;-D61#1=ZM<.IB MS4))AH`4AM""46?E"UXYB$D(+P@HWP(,6 MA,^]`]""$)JH5/WL`.C[H]7WT*6K4MH&6A#63\$`N`&X`;A-H05A'<%-5NNY MGK5.4+VYV[NL"X']:#Y"'LMM""LJ.#" M$1XXPI,D5TMIJ!VET<@K"@:U*IF-!W@&>`9XMI)<;:73[RN=W$,.@&<2N@G5 M+B@`?X"]%IH15DTT]W9&!OIJ'6=?K;ZB=AJ5\R..4N0!.@$ZJTI,@$Z`3DD= MF5KF.Z3?&HB90JUQZO:#D![/&CPL>=J=M#WH.\E MZ2#5KIF^;U9,VT![O/HI&``W`#<`MRFTQZLCN,EJ/=>SX@9J"'=.L=UK%)G. MH$#!G)14!/$%\07QK1H52]DZ\AP7VZ%A=+AV&/D>S9H[]?;(12MMZ`\:,?7< MHA"$EDGY53?2)3A+RA+8>DHRJ!50*_)1$<07Q!?$MVI4A`B85*(/8`E@"6`I M/15!?$%\07RK1D6(@!U?!"QZZQ7V\N0?H5>60\AK.KSNS'$.AT&P2PKHJV\; ME9?Y%-H;B7+O59*_?=0"15J&@J]WQ6B`7H!>@%X;D:G5;2GM ML_X:^P*P2PHGH"IVO?34!HT!&D,:4E54@0:%++0IEE MU3;0@;]^"@;`#<`-P&T*'?CK"&ZR6L_U#-I"WFGG%(,&1AN1$7(N(+XR40S$ M%\17BI1I;NX0#EIM6E79ZVQ25GD(ER9Z[OF+)J.P#%E)`.AF)*T/>RLS'4&^5I MFV;%M`T44]9/P0"X`;@!N$VAF+*.X":K]5S/H"UDGZ`:"ZJQZLN,(+X@OB"^ MLE*QE*T#Q93'TZ+RPK1\S[S'Q<6=5_XW&90BTZM6LZ-T>G`&;VL*OMX5HP%Z`7H!>FU$ MIE:WI;3/^FOL"\`N*9R`JMCUTE,;-`9H#&E(55'-`4$D*:D(B`:(]MRD`D0# M1(.P^-;0>;QA\2>6AUY@VYF;=G&!*)2(2H*,H'-W3:J*ZMQ^4VEW.XK:SXV? M@\X%+Z(B%`-$`T3C[^SUE6:GJS1[)0[G`Z))X46`8U!IQ^`&N\4^P6BFN1@- MYM0M],`GD%!"CT"#0BZZ%)D:IXW&O^JN-".IR?D+$_H#VPC%HZ]M(>::YOV ME%!CC9MD=VS(._S=^\",TO?+=[X+7W!IZRZ>8]O3K'-G/G=L_A@9>)YKCGT^ MHSN'OML*[EVB+_Q-S'%\C`NCG7+/+3B\NKCR_>]SIGT8J?,*'WJ;5%Q!O8GFD$ M@>T1UGW7]$Q,AM]URS>PP>9)W[6@HPOR9J@8$C"Y0C6^PE:TPM:+]YR+:WS[ MP,H,T>$O'^CEMGR7M\F=G%H8^G5:3[Y\0,V-0U2X7Z=:L7Z=:RX?&%;O\H&J M[0!DO[X!,QE[4([R9BV>7P]LDR;< M"N:.@9BY2G43:I95NJ!Q*YBBK)9'<91T!-`$T`30K+>P'V]F0_JM@0@91,BD M(55%(V201I>2BH!H@&C/32I`-$`T.6+_3S%]UWLO[5SO)>\40OAD]MB!^,M9 M3L!^D1.67Y\_*,$>&Q^3*#N[P^8,[AQ/L]84&U0I6Y#/336#Q%T'OBC1D.'X M8PMO&_DZ!G*6#WT5T;.TQH9ZHR?>`6@B!VTPJE[]#?K^ M:/4]]%FJE+:!)G+U4S``;@!N`&Y3:")71W"3U7JN9[4*U-_MG&+0A6HC,D*Q M&8BO3!0#\07QE2)EFIL[K,M1*V@?P5X+3>0J*KAP"`,.823)U5(::D=I-/+* M.D&M2F;C`9X!G@&>K2176^GT^THGMTP=\$Q"-Z':!07@#[#70CNYJHGFWDXY M0&>DX^R,U%?43J-R?L11BCQ`)T!G58D)T`G0*:DC4\M\A_1;`S$SB)E)0ZJ* MQLP@N2XE%0'1`-&>FU2`:(!HQLKO MKR=#S;5->TINL#N::2Z^P]^]#\PC>!^^]EWXCB>./)@[/B6];YO>+9[\](*P M/Y(72*>$HB_E?].;S3_90,U?-)NU=KAS6LW/FLM^_).?)K@6IP8^X_D8NW\. MOV-7-PF^<4T=_XH)N9MI]N`>N]H4T\>^88]_G%Y=7'%^^[[5ZWVX@HNI/5OD?/0T6UD(H5(-GAR=7:FND^N5CSL/L$(K8: M:H<:M/M@O,,3LATGI!H14CT`(=N=?K^S'PD^/"$[A1P9%%'NAX9]SHLUH6&W MD!F!AF5IV"NG2)Y.M6:3>O;[(-OA:=8OY+M=TTREQOP^("]!LPL\]BY,HEL. M\6/V87+1A0;'B_?;U+]OU]ZG?.5[W)S>T"&XXP[!%74(;MBG/X_=-^&/F_);J[MGAD,' MXKER@_.U7PS/KV\'=Y?7U,OV;0.[[+-8LF6&$17@1DIB*)90P)IB-)BZ&,\Q MW9?$!A5E9S;8K'TDM,0&E\EH'6:?AI,)UAE*9\(#&D'.!%U@G6,^:C45O@T* M\NB&,/36[$?$&Y9A@\["C*R1T0I;F.<0SL_1[%7M']+780(DEA1\T>S_246>:Z5(" M4DJDV(\]\<'17.,4W?@N\:D5AR@)O(!9<]:KH,_N:6J4Y720QKYFL"%P^*1F M66P'9B;="-\CGF:S]OU(Z/IH1C%JNXS2%W14F^IQSV2-_V]NS5S0GS1A'F4V[66WK?1[?31Q7*3Q6)KMV"=ZC%QT49QI MZ5Q2"T@-5>+EZ&6KTU#ZC3;G].2B\EA2O";&EZ&NG!*/.-,7(Q%PK!I4O&I*R@:V2&'#N#ENII M5BYB:*&)-P\H/!@<$ME,A]\];!-J%L=0+ST(#E&[`*55`6ESS6/X^\B%CWTO M1[@R-,#L_8;`(MY#/1RT=8HN;?01CUU?&`SQ#MY#!99@\C:4].@BWT98-3[&5+;2IM!I*4 M7@NQX];CCF`!3-&-35'>Y#F%#)R?J%!3I4WV:8SN&;/EV:X0(',@6"NB=F!= MA-B$U&X@OQ2J,R(\QMX#QG8"PYFT7=Q>G6>,TDL&5A=4R;.*KXP(WPP2^CIC M"L:?9M]6L@B<_$J(=($]1%6+ML*NB4WE9?NLI[0:/;Z2,=9<$N&L1O]%;J`" MJ(6SH-BDV;8_5X0)G;';#3S1?,M;/G,6>P8]S$R*H'WS=)=F(L M.F/:/L7?4W27(0E;+]=2S*)-ZL\,M>F&=JC]2K5T8*&QS16_,!VW7"XCFC"= MO<@JB/$1-:ZYK1>8!4I7$&8.]TA__1?$WK:8QT+^@OZ' M>@OX'@L+,"#,*?H2*H0TJ;,GMJU&:1+H0?H:W:'S8_T/LC2.>0?45A310,17MWQ*Z'*;$5G>H].`X=R\EUB<4 M40@Y/44#M'!<3NQ@HY8VP-(J()J%T[N_0MHHTR"?"+HQ`^,QS_HP<]8W\2TK MD"#VA(OGE,R,=,LI":N1#\Y<#K[VI/1/L4UIS+;$I>MBXK;PZ4\$DW(&2@Z@ M%)HBN4B3YL<01_*-#%!;A6KKTDZ!`P4^FYELE%67/)*6=BY+F7U1DAN:]#4H MVC$AUREO,@:CSS"6>]GI*6JCE$R&X!S?R"HYC_,06?"3?\VQAP$ MYDS8V-^I\`LNHG.=IU8:2&*6OQPAX9&W$F)T:H`Y]F:.D MIU)5[&N7-O%_VBU45SS,G^[&#KU`9?7:O)5]=L_+EEL M*75;G4:_T=Z8O&P\EV;J=$JRM>"C%V;F, M0YB+JN-S;@"LFI&H_5$[`2'OG`T9O-.C)DF*5>(OSYD@3U+,'(O:K&1(_1F/ MJY&Z9?T/99-V(?%?,O$_NKL^__?/U[]>#&]'L0Q@*O8[_'AY?CF\.O\CWSF2 MQ3MB?RO)BA4+P(;PD7%;J0LBZI1$FG-=]%6:K9(0-%;&7V,9_8VBL.G!1)3R MB7'89>([&89-1\IX)+6M-.ATSEJ=*'^.3(\DI4`7+$08"XFHZ2)>2*JY9QT M%($?WB%%41RZ,PXA=E*M)+(PN+\BH7#O&'J"PC#/-1T@Q7$WB@[4G;BT49"C7"BN^:81?/&SCU6:9URXT8@D*K^$:*YJ-U6;[T\^P)9:4,AEJ)'R%G_TMJ MI:PBRA2WE-)+.8HHPP>18NJ(J1RHO*`VTEHJ\"^`,=)`JT0TPRO)F#^W(;I* ML]=EJ5@J`3R&3[46P911IAKC^E1&*%+UK'[FA!!')\@HS:A2".U%47J6K<(*:JU4I250*@_OFTI3W`T4&HR" MA$)`INR@%392I53H#KOSO$W@5ERP!#2SM5RD7ZC$A28 MD^8RDDZ6/D1L)`./O:3#/M<"\V@IOQ0G'H(;.YC)E31E\GQW7J@:UKWHIJO[ MW9/DF-H\Q,[0U0LR)*8K7K8@9%%87L_0RM6Q!CB``GTNH M@<5*,Y1A*V2$8._,>%E\$2R\;C!D-):,&J>L(FQAC<3`@IK<5*6$:6DHYO\&S.'5VHM*1`4 M"+-\5U`M0_!"8Q4QUB-;EY8:*D:'<$_B%!6U9DMG00S,?>\<#EPY4CSVLG"= M>Y,(.D[0Q\'H0YI[!J-SU&=E:C'W(L(6X<+_C(TI*X>+.17/),8#:HB:1/<) M21BB:2\E%1]B`:?\.C_&J8E@5A"^RBU+B6U09F^9SJ3X;(C@%B^PSAF6%ZJ$ MDI&=D1&C.Q]G[E.>2S(JVP\7ZXYK(-*?HY(AQ03<;AQ5HO$9<7% M]YKE"[LA_PTH6#6UAK*G6+!&!=7%O`Z.59O1$1PC%AD0IX?H5HBWB&^R$IZ< M&C;NF[!$[3RH6'0603$C28J08;(>.UXH2C%)B@U%"M=#9\/\VJ@&W"YZ1K/$8?#P!'8B M,4S_N/LU\:1[LQ$DWB37?40>),-XM7ECA#O56%$.4V)8GSC&]6[N1I'[Q MK@6AN#`25RQ,O#5&O,M#66':ER@]<5%;2U,:[/)Y.)@"=T:XJE@E54]<2B/< MG76"E9Y47I,KXR^J]+F>N7,&RSC8C68:E_:Y"(+%B%6^-N:LL!])R26VN\U> M-]8PXPD3S4@9V]H/5&J-\UB>:<#\FBDGU(?'Z"LWHI9I0/T>(X@Y?>(.T*4M MF.:3ZY"U(EE8?Y.6.[65EKO=3S9;A'5XBK2*>J_D-9SI/!-%QNF7"+0;^-[, M<5G9-S^V$NN8147-)HGF,;=L4L%?6"(RF,-OF%GHV`@:RMR&9R/.@\RIKUDL M\J:6+N.ZZ?V1HM#S3SZ4.Y%9>BLDGNU&,$[B7>6T0!DY$E#?>_>FU'MW!@[\ M/U]%C%*P5K/\[K72N[>C&>0P-IZR!VY#_ZA^M8,'":WVH'2P;.G@\--GNO-9 MWYJB^_7M9QYSEK?\H=TXW>2BYH/P7DXSAS`,,4L%!EA81R3,E[7A402#QX<< M.S,8BWFY=!!$!%:PITD0%'4FZ(/IS+%'L9/%^PQ?]TBZ;6%4>):&8Z$+J@0W\WYR*\>=;_@0>BSGH_I(Z?)FIU^&$O M,7@R8#)9DTB+&#>;44N7FSVMST`,Y-?#$+9CJ6;=^M2;Y%IP>:*VO^ M6XU"QTR.K9IG6MMNOJ%G8O&]'*^IMMZ*/FNE^ M98'%:$=)333K0<"M#XJUI&+].+B\3<'3U\&O7X8C=/T1?;R\&ER=7PY^3753 MN!K=W7YA^G@DP6K@)_@)?H*?5N,<^`/KZJ$U,LMXO\R"Y6W78G7_2I3I9Q_; M[#`D2^]B^H6QA:./,^6THHI>6?8H2]1Y1&-%W^-M$US77":>E_/R%%9D$;/P M%32A-E.0C1UC7?-)V)_$9`6[U%@[B755B$W+YIUQGM(78:6UMLP,%MJ!]0N> M'(9CS\#(*PE^GP>_7-]FO/TOH[OKS\/;$1I<7:#!^?GU%VK0H=OA^?#R*^O% M/)*Z.TV[/((>A!L_9JO<-JV[Y=_-*?KQB>=0/S,5[4#=IHAH]+H\HN&R7B$^ MSK:;2H8;U-U[HDY=,2[EQHAT@,%;\HN+Z_9XX-3N.I^_X?< MWFRY4]CB!/$*A[U<(WQ83IG=S2RR%9^I7?$]=O8YTOXA!P&6W2R8+YGYM+V=>,/%. M-Z@;6#6;&#\]<>:=5`.7PIG?/3CK:-[OEYKZ__T_[]Y\'[N6,'G^%U!+`P04 M````"``/@J]"$M>L^P<)``#F80``%0`<`&)K>6DM,C`Q,S`S,S%?8V%L+GAM M;%54"0`#'>V341WMDU%U>`L``00E#@``!#D!``#E76M3XS@6_;Y5^Q^\S)>= MVDJ')$`(U5"53B"3AD":``,]-36EV$HBD!]8/=Q?_U,J21VH01-0J$C#A81:_Z7JKU)):NFJ,9"1U-4H^U2F:`K9 M,VT*3?8W^WQ"J7%2+L]FLR\R*TID9$*B6Z8,"7\@E4IG$O_W[W]]Y2`M$W*( M$ZFG:U(/+*1*3:I63VI')_O'TOU=2ZKNLR?VE]@W,-)>AH!`::YBC9SNK8#- MAR;^HIOC>\K.:7;K2:#3*]J?+H@2%%6355LJ/O:N! M/($J*"&-4*#)'("@$V(_O-)E0)&N)6B7%%F"_U5RBY7XHU*E6JI5OLR)LG?V MSIPD?35U#&_A2+*;?D(7!CS=(T@U,&^1_6QBPM'IWO!E@4JQV_\"=_ M,<6(CI'"N?\&,._)8`(AW9-XQ?>WW64?AD@OO<`%UZ[,/RM'?K5\)J!Q78T! MPP%EOZM0V[1]_F^7A1#8`F1R@?79AHU;?JWLC@C6+!E@V<*V&5VQ1GB:!^<4 M:@I4W`;R&K?0:N?PD'6.%EXZ9R[E7VI!E$XPGEO[*^;6==LJQ;#.06 MRI`!#C&\AE2DL<7A>6VOD!+%\^4H4_4ILYTT-W0"3>&C/P3E`\@0QHU#?BT3 M\KLLN-+8QXMK*(1V3_V%=TQ>-ARB#[+P/WT3&@`IYW,#:@0RY[<;JT\"6SXK M^BA(1)ZCUJ%_6*0*1ZYU318=D:Q@;&]=NL%RI$6?16*4\<-G58,'I8)&=2Q> M4=QJ4#NO3<51%A%Z;&U-;3B"K"G*!=)XK-S2R6K[!*FT'O1C2)6`O*B`9'N] M#)T@%I/NP`M$8JU,ZL65)HJGB"AERR"%`FV,6!#JX$!Z/I>QI;!**E(R^B*BG533I[A)LQ"TAR9.H5%)S$12Q.:'#.2@:]W*+JX0 M&"*,*((BP]X0E#2S@9L,]\&"9\([6#;P(>6=.$6K%K9FX*0LR7Z/O` MM!N&`2%HA*`B4)]-X/.?"9/)MA&E48%4VOE2;!82#K2M#5[IVO@.FNHJ<4): M'893).<<'YF'TQ05,Z8U(,%FDW-('M)1#]710#,?Q!N>Y]E)\5"XM1EW6EFN0'`D#@U#:`Y13(D@O;NHJ#R MG^7\*GG,-(J@C%,:F9\#<('$N$8O1.Y.(X[U`!\9K^WQ#=>;D4"VO0!+$[?/ M^_AX,\_'F7#FC]IAPWEK3X=/RVT^[8UZ]3-1OVR^GQ_MR"X/I7?]O%W M>GS?NNHK3S]Q[5!['-ZTVMU%Y^[U\JU7[T^>#QX;LE*O5%]K;PW24-6.BCO/ MU3$NVK7.@"SXT;[Q<+]L2K_KI]7:ZU6XXC>4_7\ MB(Z)\MO%`1U7'RKM=I."WWH/#S^:-W6Y>OZS]8JT`?IQ7'Z=EJM*NW=^=(>Z M!T;ML/;4[52LWF%8K+]KH\>FV]_#J\_[RAM+==>-F+"EHUY[I@Z(7U3'XE)9U:KSS?/#^FH-U]Q9X=B+FFM M:;[/@H(64MK>1&X,?L^()7'.Z4$AXS$(DF+I#6+,#V;8%Z0PRQ":BHHT1"A' MF$('04C,F0PY?W.*U-03BR;D,L]8KYA3$NH-5F"*(D6PYZMB>/QT_,`H<"]"["YJ2MG2D*YU M3?>V1>`8CP9+D=/9-VPA$>F;_!"YY]!K5?,=FO02%!P.I12NZ!I2L4[("Y#_ MG!W:X=!1NUIL75I6R)[$V%G\RLQNEVV75X13K(CR2X&L&C9E3!%KQ+?%/>'K MP4LMF_P.O[##!QN@I_#U_X#*SO$$\F``3?@.L,HB_ZVO"VB95L0@;3 MAN\_NYKO6H285&L=Z$QB[D=(/^OG&9(!61\AC86/2]Y*:W3K7%=Q/-R8#Q#I2-H)+J)F- M2ONU'L[I?'&Y1"+B\<,=UYZ$OWMF-J(E:\LG43L:^:P8A>UJ9KN4N<]I.U-=<6?I$W0\=$G&!0.@YE:_+_W_`+O4W M4$L#!!0````(``^"KT(+,[7STAL``(GM`0`5`!P`8FMY:2TR,#$S,#,S,5]D M968N>&UL550)``,=[9-1'>V3475X"P`!!"4.```$.0$``.U=6W/;.+)^/U7G M/VBS+VQ(XOXFE\W@.X&T'CWMX.#SA5R$#5<9'4>EQW<^S]W]H_.0:='9O-[ M$W<&CLO_:KIX@?AGS@)1_F_^]ZGKSM\>'CX]/?UB\J\R$U/$B$=-Q,0'G8.# M7SOBO__]GW<"I$>1@'C;N2%.Y\98=HY/.R9[;#WK_8`'M^I/8OA$X.3XZ.3@^C+[X(OOGV67P0^_[3J?_M MX_/S\T/_KZNO,ISU1=[L\>$?-]?WYA3-C`/L,-=P3`'`\%OF?WA-3,/%Q)&0 MJY/[#?&O@^AK!^*C@^.3@]/C7YZ9M1*1?\=R5S";#;PZ#/[XPB>LTWE'B8U& M:-SQW_&MNYRC]R\8GLUM(;K_V92B\?L7CS^6^$"0?70:@/U=?/*-JY81&UM" M21\,6[SR_10A]T5'-/QI-%A)\8C)P0^T%$H^%'\[S'WT\-<.K'#?A@9%CCM% M+C8-FVTA:[(E$-$'#I<#W;O\]QD'JRAN\FE?1.4R]@PVO;3)4T7A5H\=1KU^ M>[%NB8LDQ/"_IDQ?HK4C2=0CU6][)(T<0*O#E0<^4FAX88L5P'UTE=!5L(\4 MFUEE?`"#JRZ#+45/J^U'?>0: MV):TX?#+BOM1T*IL/XJ^K7)("]NL*(+J(2UJMJH82F?85:.5I5`SU_:)Z0EG MN>M8%[P3N,N!,R9TYG=2"8D*'X]H,J@I*V!.,!C%T0' M*^1J`F1**$9R-E)^,R8DIF,7ER23P2A%J+O7_!)*;#@ MM]S-<[F)7=C^MW@O0),@0Q/]W2;["UKZN/>1(Y!,>D^8U@[B@&% MK_K23I`2.?)%^YT&*^''QIX<7ALUE8UVW9U"ZQ,[D MLV%[(`Z`'/#AKV##6[FNL@US4T^2[('-0EW3)!Y''"$3<70^-]XBM^=1&K@@ MZCM2$5[<#%NHK6*VX/K8G3M%-!`/4#<9**W72!8SH1Y.U.MAX"PX`J'+6P2B M@5C[+1^YXER$G)\J'Z"&%,T-;(6)?#Y4[J8OR,!"NLXJ-"1%7:BXEXI=9W`% MM6J6/AHC;@;6)79$RK!'F,MNB6,&M@&DJG+0UNM+@K=0::\AE#8G#',!?3'7 ML#"ZRL%J,A:5T4\>1:%:SM2.=@/'-9P)YIYYB(C2UT18CWA=3I7 MK>X/T=N'_)ZKMOAK;#QBV]\.`YFYS()I?_HRDQRXN#[*ZPR-I4CJ["#_E4!J M--8OL,2LY%>2),C<)&_!VA`/5C$Y8,V&^?+*R>.J/"VY5<0R0@OD>)!])@=I M'_I,'DDR0UDMK8B-;%$/'2%;[$(9&M2W!]M@S%^2`U15%?B&8TM)#58B5"8+ MNK6W`*B^W-&O,2W5L.<6V&@'60Z/L2_:%33(D$LN5&`\.UKC$_#$E-F^:<4<$ MFQ@YYC([V,P[FU/<1+.#3G$H*46!Q(1=;U,,F02)K&WI9:&1N+0C8.L M"X,ZV)DP'L=Z,\_W\P*)069L"=0F/RBU3'S_2QX\DHDS;)D]BXKTDM$^\1W?LV>F3`I!KEY4$:'/2 MIB:EI;K=-HGC5Y=A7<^=$HI_KGTSH'Q."J[1M4XYE16R)1%^JE'1@#%O1^H) MH1I>(*NIG(@GL',;*<0[SQ7E+,4&MYVH9Q-O/W448ZP\XMQ>43QDO*.^L):? MEATBZDL"K*]:2);D"SJ67.6U/D!G1_0^0&=']#Y`9T?T/F! M+#V%FS]!M_FG,!K<`",W\Z19`=JH?&_8B(5H]X@NL(D8T('*/*B&XX\\`XSU MC3R6@`:O:PX@*O.&D#!KDG&(AL.)8C.,KS\FN('9'1.9!>1XU+3I5V!]38?, M5%!].YY_-CFJ#1`5IJZT&Z^XA?:>ZI)Y_?(,8`L" MJDI7&^I%8LBV17T#_](WF_?5KC7CQ`A0<3]$*`9(8":'W+"S6FJ[L8!-DDRH MV($A_F:B=F6?CZ`V\8LD`6JP&+!)W[>2UDIX`TJ!I$3Y@:SM'1<:4%C>(6FO1:2ZQMM:I1PH'B MON!#?D%X,N6R=!=\#IJ@U%[12AJ0;JS-$W-%6J+>H-Z)2LAPZXDWNANG9`&; M1*H)T(Q.:QGQYC!7D66X`JDY@H1CQ4ZVO5<5H;GU,0"-YQ,MET?;]8YK<7FQ3;D'OMM:[K?5N:[W;6N^VUKNM]6[K1&P4S;"77.35DD+7=/&BH-!Z MWFX[R;;:N[A2C1*@M<>_1O*RCO65IS.5Y@VZUG>/N<)8V`,9(>YJF-B_P%!` M!N`/1+S")XYT2>B0D@7F?NZ'Y;8]"0:YP>BUAJ(A50"S=[`O4ELF-MP-/TKQ MC4;K]IN+2T&[1>(JI`T^07KXC%`7__01JG70K`<;[%_@.BF@"V@:W`2[&R>O M_X'H7R6(3:JWP$YC56!*.`.\^BB&'%PNQXT*;`][(5Z3+DT]524)@ZH>&RT[ M(JM'9F()'FRRRD'Z"TQ;>1PKWB\?^%53WL/1P`EOYW*LTDNR\F(WF8::JI== MUWN48P?H'`,W*8JX%?11\).+D:K'!='QI'`;TV0%>XUOZY(A$RB1E0;WMZ.% MQ=3@_!$IW/W79!:90#YE&CRZE!WHAHUBP.:./BI37HP_N/L&T\#A#>+1?6&9 M-XGO1J-2DOP7J%J.<;@;O?+G`,"KH\I!&\V?*I].*]PQI5*-B:L8=Z;)).[^ MSZ999)8?T%&DR<3MC;M18Q+TOZ-#IJB4.=M3=[U)!%CK>%<$P-PM2P=:0(M1 MLNB-GHZ3-O;$(I4TM:JK2:0BYU6.2<'R;E%;>[2\6T@)4%Z`&X.)D,4$OB@J M+(IVWXTWJJ)"]+)RT+8L`TM8Z68/DV`3*"LPXM[PTD\GBIH8JXM6EWWT"%2P MK@!O3[57S"%0$F#39*!OGLW%:BX>5-/7,B^D55ZM?KBR#K\O1QT<;%6I$&]/ M^U@QAT!%9=:@HBOO4&]IN`8+7*E06@9_,+5F5+*19%`B$5HO+A<7!E\26CD&3S[7WCZ3_ZI@&E=^T9&N=*`](^T9:<](>T;: M,]*>D*BMY6M:[@S?R=T>+3' MHST>[?%HCT=[/-KCT1Z/NEQ0'S/1ED>#39&KT\CA9CM_W\+ZO'*TN2''/5)4 MQ61+D?:BV/K6O+?/41.>FO;2M)>FO33MI6DO37MIVDM3YJ4E[TX`];_RP=I\ M8X$$55)%_7;H+_FI+>TQ:8])>TS:8](>D_:8M,>D+J^%'MUUC@4V7Y4#M1]Y MJ#R>6IA?"M<"M<>D/2;M,6F/J84>T[N_'1QT_OWEYO/+__S[#W/N/7]U7IU; M/\\6DZ]+YU/?>[HZH^=G'T^^?WI8,OML8?X\LG]WWWSJ70^MK_^R3U\Y?SS> M]?J#Y=7#GQ]_WIP-I]]?_G%N6F?')W^>_CQGY[/9U/^O/N[?4:& MDV[/&%^_^OQ],!MX+XVG-^?]'YX]G,S,+^3BY+37.W_M?G)G%Z_=";-^NWSI M3DX^'_?[7=?X[>;SYW]V[\[,DXM_]?[$SCW^YYO#/Q>')U;_YN+U`QZ\G)^^ M.OTZN#KV#J]NEHN3XQ_.^(^OHYO/WWL?/WZ9W/6N/YU]^AU_OQZ??WUI_O;] MU=GD_?O_='KWHX,#[4-J'W+/?4B_',*4V+Q])@Z`NDOAB.S(JY0';^T^LQH\ MMN>6P97/J7?<:Z]3>YW:ZVROUZE]+.UC[:V/%0R9(S07MYTXDUUY5Q*P^[#: M*45?Z]8]C_2N?NU5::]*>U7:J])>E?:JU'M5EP:F?G6RM3\`NV>_&+"]!<@D M"9/6U(Z]*+WE7KM0VH72+I1VH;0+I5THM>5S16D$QZ7!J3S,?NPH,R6%V_HE M/SGVVK7:YX_B3*_V::=*.U7:J=).E7:JM%.E>K7/G"++L]'=^&(VM\D2H7M$ M%]A$ZU('F\40NK;?'/]-W/YDDHF#?R(KN$K!KY``NT8()FS[\V&`BFI=+BWP M^_2*I/;\M.>G/3_M^6G/3WM^@)Y?S[!-SPZ=A5MO)FXZ)K3K6'WDD!EVQ+\& M3JJ,@Q@3=N3N*9%P+TY_JM:*[*'1+] M/G&3HG!,/3=\E9U63@&0<@\N38#0C>1]L;L($7S1'I,1S\6S^!6QP%?1.6,= M.309.2B.UC\L@PW%XMW!@A!HF?=-D\Y.I: M/.#"S-\]L4"1IWD3<]35'H:J(D"SQZ)@YYWXT:I*:@&;:4>((4[0U(_%%\@F M<^%3A/!P1B$#^U1;D'6Q?!^(X.WRDKHE(1.2>C%S)8&_WHQ4R]FZL7, M?5K,]"].]&?>]0K9HP@(3#>NGYQ[(G,>;?$:3^$;PZT6WR)WX'`W"%T3!C)K MQ`$:WQ5$5KNZ%#]ZKK^EB?1X&'XW]Y,I7W*0S;3K3UG"F+3.?'78SSYT2*E8\/G%#IWXAYJ"C#6W#81^6 M%\^(FIBA(<4F&AG.!&Z_#X"8D&ZDRDP?A(9*P[]=&U-:4,#T(H"8H#&)7&82 MKBVN/L&=9MMSF_F&9W0#4S`LI[AZLLX%J M"V[31R;HK3$#G%5+,7>RG;!@@MQ!QRNWG$T=@"W6ED'#3&)R!M#LI-0R&Y"; M:>I?/Q2F10`W?Z91&L[.RPY]J2N&$EQ![2L/\U-P*HD#[*$V$@Q)3)+5E^%C MKM\U8NQA:CAAEO_&H#^0Z__E;KR9=LS26<:28 M%NB*(NX34DA[J`[1[`+UKFVBA@I:&ZYU9\1SW-VY6U4%:_\:D"(%M*YP5!^Y M!K;UX6^]_J-W6K+P%%D/I$<&^SA3>REV M["6UO6Q%6OI6XNO)N19Q-3(0L)F*K`6.>X8BPNWN/'$RH'X(A MBW]GAADCU+^-75A:$)6[J>)H.9I4@=/B?JB.R])-Q8TFAGWAN-A=BOPA?PK1N4'= MY0/'`=LYH5*^/0B4U>H#++[>P!9H<7RX2%L&MO&8&Z)+;9J(%/=`0;L$-DSX M+JGY1K=%-*]WV$Q`'SVZ`X?Q=L00!C7B9Z#LR2;S+'Y@ZI7%D6"WI.5B[6)O M;,$PFV^-^3JIN'%,J6Y@QL5"[32[36P[!:DO]N='DP]3WCKK$9M_@;FXPNZ# M["<;/-A9P0=;!=,YKZ_V)(N/=(\6R!GRH95KM4> MKU4V.J^T48DCB$T[*T.HJ(RLYYI,#THSGOG"()OC!J(K]O$$NX9=D=V<1QM- MU$DSG/?>I4ER!9.MCXV8.^*>FN^N66'G,B8@J:8*Z"W.LM;A4G67R9;ATC`! M]W[E8K5WH:.<)HFUJ+H%H418.S264'G;6/M[T%WB?$@4I*D^A\35W`^<;=$A MOTRQC;JWQ)D;RXT_#;AGQ_U!QTN5A,J9:;8":'/M&07T22P9U1_BPD4LO_PQ MV-@6`]F#'I7!3'G]F296[8YTM1&]9-?8DMTJI0R5@8T#[$GR-<$*3&V.%0A< MNC4)T?AR5J:Y93(/?B0W@0234U&*599%Y6H,,N4YZ(8=G':,#JK)+27(-M;Z M"%>>%JA*QME;,W/WL:KI5^6@>]&E)+A37NL;<=T[7PS]X1G$K>=H\D:HAO+1. MLL+:BUU1VF7BO]&'Y?HKPR"9W7TRJ!76X;GRJS@/G,`MN*)`5WE`B+D7HP2( M?D)3.E,?"`E1'A75(`D_$>FX\&42=?Y'2)#,?5*QJ"(N5/$,^P'1V0F8!;;@ MU?9AH&L+5Y&AOU$S9F(_I?`MR"P($D)Y8C+GVQY#YB\3LC@,F@DL+_@]:7-R M0&VV!$FJ0OV]9JM M?]92K]KJ5=MF5FWY]"=VSP6'T$>8_?@`>FZR"`YN*XC"]=Q"ON`NWDO!"E"X MU=XBN*9+/4M8;*'"-IEK1&$PZ\.E*FOVU(TZK4D>)MQN=KI"9$*-^12;A@U> M-2T%!NBD0Q1/2Y,%II]@#MP$!*R?E@O6^.:74CN-Z2F?-*"K@O(`@4JH%>FI M%274MM*2[.'I6JI:PZ5&7+@JYN6@#6=9);RM3=5)D*CZ5&]0@HA0=]J=\0C7 M-)P*.W2RGFOT<$G9J+XNNI3UQF#[^E+:7!\U`DGO%.+MQ<)#,6.RH]C.4S!! MO2N=A-%)F&:2,#?&=T)['G,)']K`;OO*0-F33?19_,"XKN($\=TXA@<78.2# M-1Y@Y%MD[*QA/EM@DW(N)DQP4:BC)H.++34$>#M51JKG`W+,ZZ5B4!D/-KOEH]2CVB@"E?76ZCN+#W;GK*`J\)M^JM'SZ_+< M9KPNQ&F\AR=2RVS3CS6<[JA@M1FO#'6J11R@82-1G.FO))`UO_T"G>9E*\5>L!YF*> M2$TPA0VTFG:)]Y+G'J?F$%-5<>Z\.M_#IPQH3-?ZK_&+D<+X6_!JX_0 M!#-7G*,0KD2^R-'^;OYD("W_)2ED;JOMK0B73X3B>J$"*+([L4J[/=.QUEJ[ M23K]WLJ'7@'1\RCE")>8F8;]%1GTPK'Z7*[M:7(MK$&:\N\S1[BT([B-F4NP?O%+(\V:K M[?9:LHDH/4==>VCW_7I[P+WLYX]HJ6PT3S3;YF-_!61(G#FNRWLPB8_0G%!Q M3DR(Z!6$%A7ISVZ]Y0--,3.EQV*WB)8^$]OCX2Q=7F(;465J2#:['[T@18;$ M@=>:O/L(/2[6A%!E8T^\T3UQ'1-,2)P6K4GY%V3;'QWRY-PC@Q$GJ-A1E!BN M1GY>\WNBAEQV(H6H6J[:C)^#,\+*(MOL9ML^]N20$?%>6+F_-O/K&/J2?Z)@ MW,]KN.4S;RX?$?T*@]8X5J!N$/8WFVZWSU]`2:2`LGK[>?GU=X<"290U\1GX M?U!+`P04````"``/@J]"P@M\D$TV``!`H0(`%0`<`&)K>6DM,C`Q,S`S,S%? M;&%B+GAM;%54"0`#'>V341WMDU%U>`L``00E#@``!#D!``#M?6MSW#:RZ/=; M=?\#3O;__J(! M/H<`"+X`.C=;M;$M`=T-=+/1Z&YT__6_#@[0!?9Q:,780?<[Y)X^B==/T0$Z M#=:;6]M%BMD*H!S^X)`252,5?8NP[V$F)!1`23E,, M5*XRP``ZL$M`/1"9($QA4LQ_^^;^T\[]#_FH'.Q'V"%_B0+/=8#6-Y8'4G?[ M@'$<3>^C&#[!\O;!Y`/X:HZ>,ZGY2U-P="M2@H&B$LGIY]QD'^*"*'59Z7^\ M>X]^IV2^OR(\\0_>W7[S4P8`%2&@!`1B,/YZ2''^5%K9-"SSPPKME$+RUYJE M)2,.[8!@V<0'7G&!RS!8M^9D'+3;FL-4M_;(.Z\?MAVUY1OZ-07S[XR%Z`_, MQ"/@8B-UL8T.5I:U^<\TBH1:(5D_7?O2BN[I!B03R48W9W6U!6/2*BYP=(!62U>CZ@L4D\#Y4MJ/< M+_%KV=GVG]6I%3U,?0?^./MMZSY:'O8)[/C4"L.=ZZ_>6]Z6;\)T_-K4$/=_ M6LOD18DFT3%-)B'+=Y`-?\'Y=+/2U(B_12%3WXO6&MVV@RV!>8-M3.#?>_@* MQZ?;,"2(!M'O,GS:59.$&)'F3Z:@,)LS03Z.4;!$EN<%GZE=L0Q"Y`3;^WBY M]9"53B%#_OOD:/+]R0_(BLE5-+0?T//C";N`@M3.",SU/;GD)C\],62.-!&. MDDZLV\^2)FDDI]?Q`PZ9SAU0.CE8=,MDE02!),ZV1,X(N]"2G#]!:%A4Q/PI M"HA@<>W%8NX_$B!!N"."-H1`E.#K/0>+J`4BD`TQ>L:6-4[-7K27L1E>8B*KSKGKPR7B-(CBZ(JL@`GP0()6CU2WM-52 M)+*'DWEHR28B&V8:]]$I<[4H96I[T$74-D'DQA%3D3GD821,@*MWWZY_J3SCE9/D/#NEDY-).O;O[P\.3[YT<-1!"ZC[7KKT5B5M0[" MV/V=QOU-2U\3QI>O@(K[=-@\E%TV]X;593P=9L)8K]5?S%[W`_]`:+.;M-KE M>DNBKSI(QG#R8$H*1+R_OIM>HDJ(TARWQ3SNRME+U[IW/3=V\:!!:1X:_9%I M#A4"";B<3]_,+^=W\S/S,6H)BXKR(%J<[MN'@`Y>R+JPRZ.)6W?;[0Z)(4GD M9V'M(.RC(8"XATFO;YY/1%W(<,-&F];)4E;QPGF<57:0DW"+G8+\#2LJ`F2: MW?5"0L02`^.1ET\P;?G7,FY/<"3K;>V,3[TB-_@1^]LAE8P`D\:T53DE=2ZP MD(TVK&GD_.+YNSBK;*MIKH(8IYKK!M.K],(*J2QZY"[D+EWL#"A!3=#KMG$: MT"80-("0'F>(.BZ.?R1"QQP6&P)K9]8,:L'\HC@VW:#VCE@]!Z'P!-1\;54^ M`,OA1OXQ:-B\EHB/Y-QK*26!O[K#X;HHEX/("0^/9EN)1X-,"RWVC6HCHP*`VK4OD[E#QDOOQG`TL+49E1.HB MY;O)#,M"C02TY3M])G0;!_8GR,,@MPYB79_^_/?KR]G9S2VU7E_\B&9GY_/3^=G5Z2^O33X"4V-1]O!+8?DZXJ&* MM/"\J#6\X+_-^R,PYJC]H7\:K->!3U$,]S1H'X?.N/H^3Y]^]I`\UGI$YQW"718]`@>#%QHN7D^/OOY]\1_XI>[QAYM610$I*#XQX M&]TEU.HX+B0J6-["M*_EW)DMO?+$:];E0[IK4AND)G64F+6 M%65(L.1>_+13W]$C/[4X!PA'-;A:UK'SM/G MQ>=!.$L>%U=?W`X93V]$@.X8>Q/BFCSNKGO5_828<+/`\ZPP>FK-M[.,6>TOO9M/LYC;PA;:"3G.%"S$E"A?=27*3+5QTJ0PR4.9%4(&M@ALH M=S-:UU39ASNG]WXMDI6@TGT3%=#11*82YPA7GD8A3&4N2@6IL/KVAE\%ZG7N M,](B2T5\Q@6J0$P3J2KXV48L6AS.2N5K?S-Z$;*%%5Z'MS'<=JE#;H%#BFU@ M61.BU6S%*9"D)'BYW[9@GJ$-#IE(/C5:[*`!NP4"*-V;Q@:9N(0@14$?:U\O MY[X=K/$[W]HZ+OE5]]*@*L![CQTW+Q.J0&:SHJ$Y0`@T,)#H20;TJD5-U*/>9X9SH;%!RMX_EHPIRC$("C+B&H)(=XT`=A%1S:])2(`H$*2H>9 M=J:)F%)V_'.6I-G^X-'`^\S3<;SO]FO:WZ-N<13+PU$"]A:'CZZ-HX'JE(A0 MZ;X2">@0)1HE(XS*1@V72G$3R>JZ!$]L6FLL`3Q,K*2,0G?2]VZ-6E6-6KX-S`^ M&XR_T1^"'=WL-P!_O4P/^F%5=J%]1(4):VD)BI8SB<%0Z%#O=7#-H+)O@DMC*@\I&`4W_'FEEXDLV@2EP*!5-#?H2>75"Z2='1X'9.\HJ'SZY[.F)(?*4N+ MD`Y!E'V@,]?;QL.\*Q6ATNU=%=`A*D+.?MM=N,8@6WO^N^C9T?' MIH1#G3=9XE;]TG7FT=52P[NIRCAA^MG#$!QI=X&EL#]@=_4`;Y@>B1V[PI7G MP8T^865@VFNMJE(F^+33Z2B9GSP#1P4(1DNO-N5B)EJ-]D5;.=8F5/&^?Q5V MC2$TKX]W'2JV[J&YVD*ET.ME!=U@UY-F!&CVH#8B3GZC&4MUB58,+YJ7S?>D M;^%,#%HM94^:DJ`WC[@A=747(XZ,CDA$Z]BN(*32C6D:ZE5[37YJ10_G7O`Y M&JA`A02^]J=)K4GM4J<"H"(*5E"K8HS%"NJE0KU>0IWP0T&ZEP/$P0`FB&Y M"X#![\AA6H,*H:9HAJ.5]I\FH,M@:<6!Y:W ML9Q[7[GP=7#*SB`D9+L6M+(9PJE5@J_78U5$+6P6G@\Q'7;G<:+<'WQO.:V< M2--U$,;N[Q1*L\.:-U'_6E M!B'UJ^Y)HLY=WR)6@K\:K#2-%)_V/H(28H1'^!*'(;$Q;1@T)DGB\TXL1YSE M=G@>GR1[@O]V#:GD@UEX`DQZ;3T^$:+'[C#XX!Y&$ZG)AYNM4"IE6.D]NWBM M[>**#V1S\-QGVFOJ.\4.7HV<[2J`-%>S5R!)Y&6G4\GM-CFDZ.-T+Y_^VIRU MTX1CN8]6=2MT5IY7I(GK5Z_C#]^Y\,=B5J:O$NLITN]:QXB3'+,OUI49W'Y*:/B5O0J?O0)7])7;[@;E!+>48A? ME2Z1$;S%"!B/ED0O!.'HA$[,6+G0"3:@5Z&;^X\$>A"ZPY14D2/L+^^@+&=W M==41I&0)[^ULQ,[X\S7T^0U;UK%6*=N4Z)D M1&*H0J]`/I.I>66)D=2P[28>!\>X:$M M9FZMT/&VH5>S,-6H`U8$KT;M9?X4R4XLGD=H6="FP3B[.R=.S&^R!=VEAA?%NAN\':F\LP=>K?*E'"&0T M">NL)U-`Q/P@QJG_`7W[EY$T7ZJ[+\3D=D)J)4#::Z M<;"$/BD^0XI+1I.TDV@<4-'"8SH=%?A9$JRZM7=04AEHT'@:):N*KD=W01NQ MJA`DD*K,&&;IHN`BX.LKLY(E9"=?L/BK;]M/0N!3X-PC-+JH>-C'XZ+B4%?G MHBKZI9:95'+]4B-R2TF$0,$M)=JFUCT["8ZI[\`?9[]MW4?+@^]A@4,W.9+K1=E`H^;(0@`W MZ(*56C?WLK`AIS+UH+@'';*M*AB&4!A5)`/X"^IRJ2I$2"HW4ZG)1Z)?8=\1 MW7AC4>A:CA5U"W^QK13,14#?01.Z0K^=;I%#T*Q6I,3(-,H)T2AT,DIFFWS) MJ,243(W4K[EMQ3HNY/9"T7MBKQ/8VW6J^I47(+(LE@@R^3$B^L%"T?8>"DG' MKN4A)]C>Q\BZ#[;0.!L1A&Z\^];:!-&/9"C-C-W1JEP!?(Q;*+9!(*P"YOVF MR*G_VT+@U`A\&A5F-U?01+&[QNA)T@_>VY%A.VR%+-Q'*$+WED`C""&8+/!)_CPG:P1QF02AE':.4^`C&A&]'R80`5 MWO)&41JP%BT71@ZQW@EZ$+VW/8(8^FZT\V`,2'XO^GK M;62MV>L(,I:*0?[/ZM1"4OLSLY=:J2:2:\*!GMJW.(=$U]O2N2.T1KZZ36]? M*77&E-LV9(E-6>F-)/6$1M[RXAQI>*Z=^=(7+KWE-GJB6F81/2<6$>N>1V&@ M4],%7(80C4R*^]S0]GD&':D8XG;7E20C+VLZ$BWLJ9)"I?T)"G!1`AA1R!-4 M+'R40A(?SQ:W["^&VZHH,R]3U6J;TKHNH!#\$-I5C$QGQ==::@1BQI$N MKI(SH>)JV2AKKUM52RV,6'P?YTJQI7%:`T.ST2FG1J:+OB>ZB";[HD7U5;X! M*U*--[EUJ+#R#E8?'_H@UIP`E1DKC4^,\-7S?8P*)MAH-$T-^\JEQ<4K;FG\ MT%SGA\!SR&Y#!D>\@^^LJ^)I#E6SH[\Q@3+M]`-<=0L`F>L.S?#2M5WLVSNC M;Q-;#IOU258Y,R\];K8H M3POF%MMJ-]NL#M==%5Q#*#PEO-HON2I4"6L1%*8BF*MPIS7RWJH!QTO/K53W MIHOSQ7[`SM;#U\NS]<8+=AC?XO#1M3&_G\W4H^!H9R3HE;GRW=^QP]YCTJCM ML'>2P8C5?]X/MA;1[2?!!Z9IBA$E*$LI"$6L$Y3CA8DY9L10LQP&\K'1M,U1 MN9&&%NS2[6M09G:QJW/*3BW/WGH)UBMR'0EAVM1W9M@/UN2R0OXU]RO!36"L MIH^Z%PJ-!*?Z78/"%UQ``__,$%'3K(`*&C%Q`^_"[]7LM]JGD/(_T-X8U*$+ M8$;,U(]=Q_6VD-5]B^UM2-.GS[Y`]C=VH.@5J(UMG)"K-=MD`"H-//7J?Q4* M7V<1%ZY10$=/1H5F99$92! M"(\280I].TMIKNE\HQ&>1MS+@SOJ&Z*E&F1#HGCO1FK9)*BN_`?DV5&'L[L? M^YZ%:2Y='\^"M>4.T@%X($K[]A#QQ'W8)8CR4WN^%$^20","S.A7AMNT*VI8 M\2UER0['NP[NK@0A=J3:8HC/41&S]M[N2F0U;-F=]GHS[@1JQNY2$WCU?6F9 MBPGR[MNNY^[?1:^74++!ABLI6+[8.=M$A5MK,YNS.Q:=21[]D"PLNEZ$6W:; MD']0V,Q_PJ"CL\5MT=$2&2P@U9NP9.92/[NLPQKHCUR>7=Q9*L;2E62D(G+4 M,N6(8LC]I=1I=;V,HR`,%8ZA\R"6_ M$.AX;7K[&RV+QYX6^V(@"K'OEY9R*??_3VF]G>+W`I614`2_?#JJ![-"_DA6 MWKGW-:WFY27-K"C#IW$-<;9I'XS@%MX'*V(!WY?T]?,CU:%__:^#`_3KA[?O MO_OWK_^T-]LOO_C?OW)^?_&X^F7GOYMM/U^\"%^]^/GDX[N[7>2]>+1_/_+^ M)W[Y[O1RX?SR+^_Y]_X_[Z]/9_/=Q=UO/__^]L7BX>-W_WQE.R^.3WY[_ONK MZ-5Z?;'V+CZ>K/!RMIG^C_GKWZ(W\7KLQ_B5>3\_?R[>'7R_G@VF\;6W]^^?_^/Z?4+^^3L7Z>_ MN?ZM^X^7A[\]'IXXL[=G/]RY\^\VS[]__LO\XGA[>/%V]WAR_,E?_O.7F[?O M/Y[^_#-VHU=;>_?V\,/O;W:+5_=7X4=\<67CZ]F_(MLZ=?^-3F]O#@Y:/POE MQB42$V4;/P0AA-+>^0Y1H6"B,2-E`?5%S[[@T'8CO`A=&]\0N1PP"CT$F;IC M9`.LH6$N35(D+D(Y.K0%?*AH?B.*2/\1+8K:SW@MU>+4V_#CCIR).8*YZB<()C)RZLP%&I69'`IR*RR(VW;\'5, MG60W"7UBV90PK6Z37DA6D>^H:HV/2)I;"D^]R+?922/NE1L MKK>T:"DK`"6),[.9>9[WD\+DI'Q4;#P>4K]`'E=5MT7_\U+5CG4G');13F(0 M^J=_*WWLZWC\`K'BS"P,78B.*#2GM[7R^DM]MT@I.<8=LB8 MM1M%04AKCL%7Q:(&L6H?G#[PZ$YRZ8%F24_N%#1[,)4"!_FW$(./$@0HQ\#* MVU&]39&P.[))?UJ/`I1]!WUM_!!F5&VKI?8?,=>;FFG%)=6*84$KVHE6#$I: MT4+K1"_>`^!G!EW?IK5B)0ZO1P)Z$E^>.(#BV)04AUM2'!%3'%&B.#:YXO!3 MQ6$SQ1$!FF=_:@[!UK?U3%SBE>6=T49A=V0XM(#80@/4C17&N^'<82IH-?4T M;D"2X'2D,Q&;BF`NZS*2SQZ)P[E/ MIA*1HBIX,"-)K#)[EM;Q3RQ2>XONHO1H8Y:D+\L0@E.";T!Q%?%+ZF*:[TTC M8TCI`\0A4LNKSGD[/=NA'+@!E\P]2$BI29*G3:XTR&97(EI M"8+!3L<2$E,F6I$(J6"F+A08:5SG"9E4.0(KZ]/>5KZK)'/3\X$E;D%7.(DN M"$%7?$YTA9_K"B?7%78&_=F?RH*7XM^L;CVK\N^OAG,?[*/0[*/:0R\J19^. M&DNE&P%C2J7F.2MKWZ8%_**@;K`SVX8$**MBPW(.K_!G^JM!#A-%S&8*HRK1 M)GU:QF8C-CVIL)3FPTX0@<%&&`MNMQ.`2M,JM4WJTO>/@\'R6)YKFEZE9*DK M`]-NE:M2UD;>"(PDG[K0'7E,SZQ:,;K<]4]UZ[2GF#%>$T._XZ)!;4(V$;I,T7Y>..J(X(&O!Q*9;J ME:XX]-=-[4BQ0`VE4`L/.:#[2@:YHH8RZ#*YYBHH[?JI)SG*U%8?'&AM\O&_ M.8+VD5P]%IYET]?C0YA\BIB-F'QJM(ED7ZBO$P`H@S"J,C+-1*%><7.WJ\/K M(^?C-HII![J[8.HX+C@K+&]AN<[EUR)=M[W]=9Y?KQ;*>ZSH%_EF MEP]9,._2]+,5.DDQD`M:!V3N,S/Z(BQ4EQK^>6TW,LTX"OI?2--Z]05DZ'Y7 M*O^<($04XR2M=C-!#"M\J^D]D6(>XQO;7D2W_HUM=XYUZ*L"Z.Y[>O6;_`2B MI@G!>[5C;C`X#S%U18P9 M0&G6YJ$TB?!P&TA1L\5ET3&'1<W!Y/HP;RYLE!59*N[_O;4#;!-=;O`+]H.&,\U<9JF5@R7Z1K;^TBKPAH_DQI$.->BL^(TUI&D;*2FO#> ML(U$0W$X*E51^^MO?^[!,\WKY5OK8Q">;HE9L<;A<%I*C$RSEA(2(GJ)!&]R MB?E%9Z!T2E5-&7F75,?!TB,EZ<+[4U%OL&\_K*WPDT83:A^G83MJCQQU8RJ; M.%Z+2L!>J<[B[4>K)W(2;;@7$Q(DP$D!Z,]NDY'3ZG1#)P8SSU2XDUWZ:I?> M^[6?W"CO@P[,X%WIU;EAXJ+>*T.&Z.I4ZXFI(XK7#>V?-D/*,+A(T") M"%R,OOUM&\0_WJ?:C?T3/2'XG;RG"_1DHZ,Q@R0&S".8-V3K6(X2 M&54F;Y/+DH-#0H_#TO9@I.,^NN`B,>P%[%7(CKOD)D`A!Y"F6P+1"MU@^F6_ MS&5?KX%XB'1V;>=2(+IF)T/0KS#(K,$J95'YO8YH@1TZDW M`Y#Y%?5S$*U!(-[\3@QE43?F0AI.X'IJQ2#=[/:J./>#513^6PS]P(;X;NJ1 MZOX*:BD2R'0^#W$NB;^RN68UN3*'BX*JMA\]6`!%/^S@5D`%F6Z_NXB06ND" M=WM%4QJU"T2,X]H&W/6V3T>W/!S=X$?L;_%%$#C1%8Z'4U82;%H-22$9(FL2 M)J!DQ@31.?!$/*ZJ)6/"5,O(DC3)=Z"#N5ERM49#J2$.%MW'7)4$@?"4?>C1 M6,PT,:.*@B)89?O3*JN-,91HE!'HEHH2]OJ2)J,XA[@LX=8SZ8'_M]@C/UY= M8!^'Y`#SG:FS=GTWHE;1(S[[`J8\C@8\@QH1H#V;H`%QP@P#"@,R#"@46GB\ M#`>E@'CGEYFT@Q9244Y%:+IQ/<;^:"GIH?29#)WIB%]&2=/,J3V]-XX87X6- M\O!>>?%MLZ9N<(0)U=`L:4;L,2_8@)&?R.MP6E`%K6;=IT"20,S2F533%>:F M:FX8#WOK*"'1;9"7L`@%*QG!OL,,$?OCHVECP5LBCX"B9-]@.5CY$/=C+$EJMXLWN!F^",+YT_>%B M=T/3K-4Y./!BA`%KAA:R+E/$*,&,1*_K)BA'#Q-S`I+WWC$J$)`Q MAB]>EYR7+HDZ6-OIVV=A_W=^M,&VNW2Q,^`+"B$RW3X/$2$UJ1T35)@QHA<4 M=4PL2Z1L[=UJ!B,Y0F/$4JYA7[IU$.0)Q4\VB+H,K#\:.H[610I%T=B014:,I:; M,0[I4^^5/JU.@QX)5VD`NM?[]_T0(L;3G;WM=(=[`2?VD#TNTAAV*N,T M'GLJD=/JM=D(Q%B5M36AJ.I>M'II1CM$SMP5E#\%P>=9A8(W9H*I>J1$0H&P M:A<9C)+1"(:;#1(I;'_VG$2R4/V/^<3$\%Z.%4?_87:]>UV4>MKJ<4 MXMWG(,M7;/!5<:;INFP*\`L^*S*PF$QJU"E1L^$9EP6+T]>R64(%[W.JV^.O M:)/;U`ACX!Z"M15EWV>33XD[4\]#'1L2A7GZ/@M6SGAR,P+SM03(RX>VZ MO]JU2T>">0JHF40$]1+Q_[5(=%!YM_#\,ZE$PTH/Q^X]U*(.UFX4!>&NH5^J M"3RM5^L&A`F?5!$(:8DK5("!IKSA;FF^Q#!7OR?/UG( M<;8UUR#7/DX]#@WT1'66QB!1!;G@BR?C"F5/1R$1PMW.^,Y?G/Z8$)<.WIF1)R>`[L&MV M^BO;ZG*KH98>LXL06V2+AW2:-4>AT:SL1JF:[RP!V\U]9MA9TEI.^/Z2=CNM MWR#N3K2")ZU>/E2<:7\*2%M[_BH(XX[J"<(C$3I MT''(CF3/,X$0K5"[,UU`"._35MCKKVJS.[BI9TFU_*GOL!S[N;\,PC5[H7L? MT<;'2M^9$B!MEV@5:D1OC9*IM-Q-\E"C,!O]FLXW+"]-.)<)D/*^:+3NX'W4 MC#53V(;X#G^)WQ"!_50DA_<1UTPSS!PY<56^J.R!SLMQ3@P]Q[-7^S?0TP*S M!_J5YKF1.O/Z`6^8R?TLHBH,?>Z]3J$A]+C1]3)YW.7Z*V5YJ)]ISM523UN% M@ZH;H350VT-+7%YKG(Y@_^PZO+_%&H_>I,4HJ[-"Q+3%,=P`A%%6-Z"3$_%M MN$TZ?6-[U;.4&5<[T:S;HHZZJF=";2-T?ET-6M+S-*OJ?)/^1U4:J]]4H\W1 MY[$YM]SPO>5M!?Z&V<7)K^81.8F)[MX221-];UU@FOP&N]#-O8EVVUB=KV7WGNJWL%^: MP#!W!VE"986ES;=)Z[UD2KMA7B_/M[X3W>#?MFZ(G;N`4.UL[?AZ@QGAT;7_ MEDC:@[>CMRO11]P.FCG.MJ.WPN,NFZB5VQ0!N\\_5`?34.W==FZZSN5W'*2X,1D,Z3 M#T6_@HPC*N3FZTY65E)D4,URM=:%O72M>]>CU?M/MV%(SE_1GA=&3E`RUG2? MD"KUO'T6K5%SG>_$Q/=7:3,NX:N0=ILQHI?H*W;P]%BQ.JRS?X,3Q$4&] M>AJ)74`92G"8B/8ZG\/Z!]!9B$Y#,,]PQR3Q@GA,J-\`S2)/757)T4.#XK)4 M$92.I$T;C&Y\A6[>;@L6I[>L=Q1AJ-'JVW+ES<9-4#[2^!&Y3SIOB_G+TUYD MO^>V&25W`_?J,F`O%&(GT6KN/&OIC]`'A>OQT<3)IFG3#L[S_1C4,]^9$;6= MCJL6-(ZP_6P5/!Z2J:R6,?G+?@EC,5A-ZE](0%U"9R*H9]#&D`PW(IBU3`&! MDJ]0YYTI:6(N/%G3WYLM\YQ2P;=:BBO0;*&0>_*I%3V0>_"CZV#GS>X=T0%S M/S-GIW;L/M*K@S!5'<<(0*`4!C2;>@)@D.L_1;DQGX,R?6U27S2/7TVW3*M! M)%#DT"URA>%K?;.K)&9./UNA0__S'D=QENAP+#R>!2.>_CVSAK=AB#?HY949%MXEDV7(:X\QV8CV/;\LD-,M;0F M70;"K+)66R:/Q4TV2'>7M;;2E_2=NH!^L]'<9P)X$0:1\$3H03\D2">(H24G M2:(DX"<$M>EV]?UO9J\:HXYGNF6O/CNU)GD797-1/EG@\C8B$/4KY#)8=6,T M-ULAY@W$0L@?$$Q[M#SPJ3$IFOMVB(F\S3#[4YBU!"8A/%"C?RF`F:2WG!02 M>I+">FKXLVZR;AX[F^^;SIO2/@5S?X:7.`RQD]Q`Q/5D*HP"A9S.1LETP\RK M71Z/8XI[HEE?,K=?33PJ=6F.)!15HEGLRS09@-IC;2H#'MI'7N(`' M_IEAHB=2`1?HL10;G$O,)I7YB`T[B?O80+EGN#\6F;CAW.];RZRXQW0;/P0A M>*_?^0XA.6^H2VYE?E2J&7(#UG7R$UA58DQ_P.[J(<9.4D?D!D.;9I8[1C.* MMI9WA\/U2=-;T20MQI+3B+9`)"KV+$:4S@G:J_E":U8#*2 M48%F!$0;ENYQ,$YX`S-/6MLJK>"FGY(;A@.WC'//RM)PV@=6RN#TW$LJ>`5Q ME&P,@D&&SFGAGJ=QD^I*S`5TIW[L.JZWC=U'3%/BJ-_Z[(OM;1WL@!L+Y'X; M)\>!\`6CRIE>#-R<'UY6>\ZWXL\,%JC+=S M"1`55F0UDY+!B(Y&9+BQ>+N4*>FY(5ZA3B]2^?4E+=>+(_K\\C:F"7?9*Q9Y MKEL&8H)2(`B@$',X9CF(&2"SUJGZ@H5)<@VVR[`N7H1X8[E.ZCE(DEG)Y>\Z M?L`A<^$TU,X)R#27E][`*33$P!D_O-OM@IKV5M]/G=^P((,AZV[?.>DC@S3^ MI`_.HALD?0BW3.MW7%8RYY:-V6-;90T,4Q";8]R[R5]*O6[=7W:;9,3DB,W? M`+&;_O4VCF*BMPKO6#I;2C(Y&]:5!^3K`HO.FH/BTPKHHE*^)FU=1M@%9V`%Y(AY:&3&$02T+?#XV: M"6P7:>9&KJN+TNR]%]]\"?N[.`62Z:.+3N\MKYDWH+0GNE.&@QC7,86.J6R] M$;.O0"W7L*NLIG$[C/S@.'<]')Z2>]TJ"'MSJI2!ZK<-2OCEQ@`=BM*QAMTI M7&:4#_KJTEHQ/WT)<>Y&MN7]@JWPG/PDZBX`(L#ZPBX""NH>LK#A",8C.L'8 M+5^!/_L/6GAK[>9N76SO/=<^]P(K[DLK%$'J\!UP,CXQE[8Q_P_K9@ZREP2&2\%CL>63SLJ#_N7\`%-VI]*RBGQHL`]F4R:I MWR[)I&KE#F6NSP3">%V@U76J&:BB_>FF/]\''K%ZK9`=V#TP3( MU6DVF)E99H]4*5_*FI6W2-T1JP8O#JB_9)2/#`0+$;E&Y8\)-&:;J-;F4JED M]JVU":(?$8/#^G77\_;"QZ M`J--/_/@+(#'!N$Z=2JO0NVFJ>]4)4.A6A5K$T5'&S4 MAJ?!@BO\F?Y*_#Z2YO6RZ8C-SUXW,A`31("P$>:-0[7%"A69XC89>6(C?UMC M6$V)S>[^#.O$4L\>($)22A^.*RET?=XK&1DU8OV4J3Z5^E3Q6J>].-ZOG`_:\G_W@LW^+K2CPL4-O,&%?YH\(O/Z8 MOX`2N4T$DPX^P2R43F-WV-"X>53#N+*=)%N\?C>#DKM'["*=QG'HWF]C^F8N M#J"T,S9=8$O-[R/S]!A-3(,HI4_4A"0_7A#\*\PTK6JERU*+]57V0:=C=.I\ MW+)0<7073!W'!=5O>0O+=>;^J;5Q8\LK^)^4TF8+,.%3R:$B``L,3`!/4-&' M-Q&FUQIQ&W78&*ZSJ?-&=WRW/L.1';HT'Z#[0^Y:],-9<%HV, M&Y6'[?NK*VOLQFEU=V1<=\Z7H.G*F"HBKVOI((2LTSTB(D)PN*=AQ&(^?*6[@WYKKHY)Z;]CG MQ7)C!GDX5`2M[:XK)$'Q[5!2);KR>LCLXR$.E_C/A_87K-EK>6ZYX7O+VQ;2 M1NOCMS`)T5F%`)$X+FODZY4NC/?Y*NR$WBF,]IY#"G':RJ+:A-MK8"[='T\)W^5'(L]2$&.17LUS@H)]0(!0Q$= M:UXCBQG%E8[R*C,-D2R#_/93NA3R(_(O2!*BW^;_`U!+`P04````"``/@J]" M10*I(@X=``!4[`$`%0`<`&)K>6DM,C`Q,S`S,S%?<')E+GAM;%54"0`#'>V3 M41WMDU%U>`L``00E#@``!#D!``#M75MSVSBR?C]5YS]XLR_GU"G'MUS&JX&NO'KWW9W=\Z`!WPK`,[.W6H'#O\GF/_OSN[.$,T7-S;<&7L!^:L=P"4@ MO_.6P"?_)G^?!<'BW=[>P\/#2YM\%-O0!QB%O@TP_<7.[NYO._1___U?OU(B M0Q]0$N]V+I"W;?_R\['V^'.X3[Y#?L2^88+O6]W%@8[ MCW/7P^]?I(@]WOGN2^1/]P[W]X_VD@^^B#[Y[I'^(O/YAR/VZ8/CX^,]]M>G MCV)8]$$R[,'>'Q?G-_8,S*U=Z.'`\FQ*`,-WF/WR'-E6`)''P==.Z2?HOW:3 MC^W27^T>'.X>';Q\Q,Z+WR+D=G9^]9$+KL']#F/]7;!:@/1"AV+_P7+I3&YF``0O=NC`'Z_'3W.X M@VCW&UA1V>W1O^V5?G7O-\W,?9E8/O""&0B@;;FX!J_YD;2P/O8('^`F(#_/ M"3%!=O/?WM,B^Z&%9ZA!D[NEK>\EBKL_6)0H`!QOL8\KD14?;YZ2ZKWJV M^]R4(]+JZ/(3WE>H>/&(`L09=96D16CO*U8S8?H:%$ZY< MP+-_I#ZL6!31J+PX))]6)8J;&=G_J(/A4'<.>)CY+2>/]$>`&34.SGA&40C; M-;"19T,7,C+H_C*<4_\4^>C^@X7)1NXY(^B&9'LZF=P,+=<.7?9)[OG4)*!. M1P=>`!U*B3C7-\`.?1A`?K%4?5OM.AJ!P((NIP[''U:\CJ)1>==1\FF5)BT> M4Y`%U28M&5:4#:4[[-.@PERHV6M'R`ZILSSPG!.R"(+5V+M'_IPM4@Z.*K^> MP+0@X2SY#/OE.6$FPR9X#(#G`"=AE`XK$4FMEP@AZ"([0\.E42;R$Q*N=0?< M]R_(6`XUNT[9H'APAP,:L//&"+S#/0F.F]<0[TXM:_'E*;B)+5N:KQ@S%AO? M6_B.!*X689]')0B^'>SS@1P\O M@`WO(7!&:&Y!3POVI<0RFF-2!$7JEY%$.5ZQ-/9?[J>-4;OU*67S8O8/7^[7 M,/L#C$NW(S4ZE*/0$J0W]HXTVGE04HJR0YB^![X/G/,(R%*F&$ M\#2]1YP@^I^3[R%<6BYA'P^"H>7[*^A-/UENJ&6_YB.<5CT#`BW6W[0P.?&3 ME[&;B%=Z+QW8-@H)4R3F!81!8@,N03`,?9]EJC4LR2IZQKP[78Q M>7G)^)THL-PGOU-V/:(%\(/5Q+6B-!SQGA;4=]9D-ROI&9NF M=[M13.H4>C1=-$0XP)?(LR,=TR3*[40[($\.Y&*AOFE>J`N$(6&?36+-E!Y9 MEM`R&\GSR*\,I%AL;^OL@Y*N9V!Y4T@"EI@I$)P\VF[HD#CT#"'G`;JN'I>4 M@Z[1E"J/H\J#72S:7^HYL#5\'+V+L6@1FA.:B#IONCD%*[*VIU-#;B)M:))N`8R MECE*AK,K%0I;E*[,PV0XY>R'A-IZ!GJE5T+,=&*%7X)E:"G(-DN*,(E/KL$2 M>*'.U5="J1NKKPPF^?1SUG)*+T%ZYRJQ"=?`I7 M>+3.*6LA2!7DNNNZ.1K%6VIL#4I10N-+'"#U*5)IIQ5YTUO@S]-STR+/(CH= MV3Z+,3)W&I%B6V^X7DS(:#A8I:\EBTU'H*XB2-0L,<-RXEQ::3CDSQCJ!?`W M`;*_S9!+J&/B;D$;`L]>"=UQWC*$:4-7':%OF[]"5U/N"AF:SY''N-1W6RQ/ MP\CJX=/$S/6P#6Q4A.5R,;GC0(J1Y4XLZ(R]H;6`9%EJB!D<5,WD-\6%R@.@@GMCT@). MSXB>[P)6FH;R9^(2W8Z>?"R7ER^KZ]O+ M%_8E):(-%/SEVY'T]7]]_5]?_]?7__7U?WW]GWE].E==_^>ZZ(':D5/DCU!X M%]R'[F9YC0)\QJQFH9:2[<;NR06@BL-C(ZF&?"M18<^M M,!A\&@]?W4<4/GI6Z$#RI_JI!I[!I<.9/NW0K;2#@*:))"'Z'$2?@^AS$&V8 M3/,YB/AFKM:BCPT:[5B\E8[0)BZJ&A')VEO+!3CFZ@;X2V@#K*F"N(R4\?"D M3%DS*Z4,)R45'Y('H#9K!!QSI>>\,TO"N'FNUM;L`6<.'6,IN42]=-I`\XM( M0#1K0&J4NM6[>LHJ_Y,>'DE';<&PJFJ$EFS\A7O1EKFK*C^4SK7@X.H^T2`] M:94,!3.BXE+`;`HEBXN:2L,Z&P^;@L9=)QK?T"F"L'RRH*@X.:BQ?#2Z!%D" M!A,94NLG[PW(W-\NN-TD+*8S'V$\\=&]GNNCZ>$[$!5ET#`LF:L%?9,">M-J MKT"-G,J)&?>TN017`5:-ZZ%9-T(NK`6N2SN6L"?V7&(G!LX<>I`R1Y_MB-G5 M$N7R43;NKV_5\TSTRPFGP1@+`S)WVA5X1$R\BUB7-HUBKB9HUOT7$NT6Y,SU M0MB812,&N!NW5@JP47==NZ:XHA.D<[*C:Q58BDR;@^U*>%05=\KWMF[$R2G+ MD+1>9I4)$HD.D4H2).QA8(!U;FYY$J:=4>X@;P,;"8?D.)*5!Z;T;+RF'WJ) M/)1=^1K%5D[,M`#YUEL%6/+M/56T3;X$@=Y=+4O`>&S`*:XL*O)M.A6UD4@* M3),;9>Q-21W2*B9D=$,KU-"TL$K`,7=ZF6;Q3%SV\$%3(K7?$DX&Q MIH*$BO'K7_7OBQ+*J+2W*&&[PO'7)?15"7U50E^5T(;)-%>5D-B/4\+(TT', MP`[@LN)EBK+=BW.LEH!<&!YQXV&X..%GR;L*ZN?V)&R#^;R!\S7$`=NH;]$U ML)%G0_9X+V4H8NT6T0E^)!O\*?(G/EI"XL]^6-5=B7HHF[+U$CJ@"7IE%\`E MG\`@-&W((->QY#/C&PI@M:Z9W'MY*3`-&(QQTS4A:0)FS M=_EXD%1XP4^=R-E]Q;@7I#YWB8MNQT5>A*3$'JQ?Y&-O25A$OJ8WC*H)&BIA M5B;E#'@2!CPKWEL]=GSB@X4%G>3MR?AJ:E*"VN0RY^*DZSK!![=$E6$CRI)[ M'[C9'3_[E&"GM6`#QQIE3FJ>>"WD,?>2<&/BSM/M^&Y?A&2-&BD]2SOW^'`S MLLX3?09+>P-'=755\L>--"Q=)Q!H1H'XH)OAJ::S2%[JAFM4N==$[J"2&UR% M+Y)*WQ-XROPIN"=0-597[@E4XF'XJ((HE0V`@RF?M/L[?:?AZC[5=%K'>MU. MM!7W"3CT.+U,.:`T5S-T34*"57PG,/78^&H$[C1U&*V@UT7I5@/8@L1*6OUT M/[]>2LM0Z*QFT18^R%[S#0PY43YI&K,;B3'1=NQ82:^+B[4:P-J9#P6+]8E! M:C\:%/`F.5-=`E5(MP`\B2Q'N7!5QD(%DVPP%BJB;C@6XE@#'%%0(:SJHB"Y M3I*$3Q+?T__0)V&7EDOG.0$^1$X^`M2A`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`T&@36/RX^??K7 MX.JM?7CRU_`[]&[@OW[9^[[<.W1&%R=O;N'XU>+H]=&?X[.#<._L8K4\//CF MW?_QY_7%IZ_#WW_?"\/5*0*C__OX?338GWQ]\QV'?PW>O__/SO#F>G>W+?Y' M[P(:%T'O`M:,Y#@-KAYCQTN\'1%?I8LH@*3:UZR:=1F%;W#?@"G%[AHLZ'L& MWK2VIR@P7G^.]TS=1'&=ZD_TVK*%]2Y1[Q*UVB7:;ERT*!8'V=:H6+4GQ`-@ M=\_[]B4NF)]:T&<=-]982%X?YQM)P=%.[_:TSNT1TB(AAZ?W=WI_I_=WVC"9 MYOV=2JNB0Z6J";9$#I4>SA;(5/DV)EP;B5O9K';0"_SHYCK$W^JF>(0&[,\! MGZ&G(Z-2/\$1H'&KV'L[QD70>SNUO!T>RZ)#L[CHMF.15[H^?/AU](2+J2,6 M/>'JNP?T3E,;G*:^>T#O4?4>5>]1-7U>9L^`$[K$Z)S,%RY:`7`#_"6TP=K6 MI*W1P&7#D9_HTT\VFGKP![%&K)D^M[T/0>V&]%]9[8:WSPH:6:X=NO&U?AG/ZKC'R!YXS`AZ:0X_^:^QM MF"#*<4.NEQ(..U(YJ%HNJ@L.:RC:P`N@`]TP@$OB1]JAS]Z+.WFTW9!X8?0I M0NI,AD$\Y48[96C@LA.]XG5(1]VCVLUY]VP.=_F`YN21_@AP9)Y%"QD*8Z1D M2+$:!KZA>O?_>;K_8IK41`R@."_P815=_J58:PLG=//<]LA$N\Q4!#G`);^> MG@&/>#LN\74&#O%T(&;GATN0J/P%F-\!7XN6"#%@/!AJ:!UF;^L+B:@XUA+3 MBFL"+`%EQGS?)7#1@FIZ3$F?+O"0_1DU@$L>DBFM)Z0O7Z*)4[-; MB@'5TB7QDI1).S=J72F?&#?@5/J3.I8')^6.I&AX<53Q+FR3,3!=2YX-7<@& M0^N<$[JG3\K9%K'W-$$`G)/)32H[]10>"^IEEEXJQW45T1NLZ2UPFIY0[%R? MBHJ2ISZJ;EU4K4S]!`+N_L2M/W'K3]S:,)GFW"]F3-;G-Z*OI1=\M2TN;*&7 M5#9=E1=^A)?R)0C&'G%TP#G"6DQGEH"Q/:U:U])JGD/$J'0^`SB=D7UVL"1\ M3P'A_PZ073C>?9F7C:_"``?$`]7TU+,H"ZU>@M*X*CZY$T_XY`X58TZU9&Q* M2'4D!BU%*K55F3GO+U&Z#6UCIJK!I5S"0&N\*YF57`9JK`1'2IKEU%[%VB1= M3*@=\8K0ZLV*[96:*CAAN1%_P&>\6^X0S>?(B]1K$`0^O`L#=K$(D4#8O5I$ M<;#G?+9\W_("+2Y5'79:$F14*D$MN&-5>5TCM]A87K'X9I%DTI`.-MH83"BJ MVC)$G^Y[END^/L71GLLK/#*(5WX8S)!/S[(^DL7ELP;!T=J?N):'/ZQ.'H%O M0PPF/K3!M>5-]5V6TSSK\MR/#NG4JGW-#'H.,+Z=65[L!5Y8_C<0L+^P M`MZG+:3H2D1935&-\0UOLOI6$E6)6L"K;6<@IRQG/B#J[NO4%W$2IM,F#>J, M!/ZJTB]-[TR;R&@\)]'`IOF=2:]>:A5Q[FQ$[F9*O=J##ZOB`71Y1SK9;4?V MHM1#TBJIK"K)OT\2!\P:;PEO4C%N0QI80QO/E^2`SIWR2F>0HRR'/O%E"?QL MDLO!JZ@DI)B'2VNNT1?82M.PN]FP8+>+('^/H=5;3<5%C*-Z]V#KB64P1Z$7 MM-"OB!GK0NY;D0@4W+!MM'_,"`06=$4+2<\0F3OKH^A[CH\X!F]?#FT,*WDI/^ASY`N+9=,"0^"(0D35X1C]FZ%#@'S$39]8L`E M9$X,35VOC-SEJ_O3T'/P-2`<$KJWB'@'3F@'5PL0=>?&5]X%\H*9NZ+WD3"7 M9RDY=)M7KBQ:ZFY>"@GWDAXI(1L`!].X:8QQ:'GTA&EP`SR(?!9>`8=\9@XQ M1CY[9I@J:W0`%6PT5"J1M`HZK5[,2H!4=?/20%@JWM9T!.Z"NF_W;!NC;SS_ M_&)33KW1WE">^&+4U&.Z!O`YLM@=RU/HD65/-NUK8`.RE=..OQ]6YV!JN2=> M`(,5/;LGWP(^F6"PNB5TM)TSJN2OY=&P6EG4"*)O9R3TPT-$7'2$`RAP-Z;X MFT9QUZ'A5&HE(!FZ]Y3,-C4%RG1V&OHR(#QD3>="="F"$/0J+M#2O6/LD8TB MI.9$E^4MH&+\F'B[#2W"IE8&Z`8L@34*PE[R M5<,QL(T0=BQJ?J+`>K=I,:89()]9F`3;J.D$8.4G: M%Z_K9^=G,^22>6-ZAAZP`+KNZ9+XJ/UER&=XX"2M7)HO2#XE8'7E,;,$C*?4 MM@=S.41J'?.EDQ,WDX%D*F;]3:,G.86JDD_!I&9I[-VOB0^71,IC;TG".^2+ M`5_Z9;/!4"GXY9,UE'_2SE4S9<@Z>9(_4_@C$*? MP!.]I!"5A5^"!_8G32X"%^7V;%N5;CPOCL8L-<]@K5E9 MA<+CQ\1T;]3BNXFEMSC5K-#M1#NR.#G0,]8Y=1+Z]LS"(.FQ<>5'!\J8-M]( M*^$M$2VF84R%W,L(7Q5%A M>DWRYJGS-<0!90;?HH'C0`JEY4XLZ(R]H;5@P=QZ:]*>.:W%3[MW>#60R_=; M56$?2MY!HWT\IFSF'U;KCTRB8X#!@^4[<8.6,]8U=NQ%SLV9K^D1!!UL=L3R M:)%0K'1OS+W=7O@JMF3#L/@W-+Z-)YWK:GX-:%@>E:VS+&QHN;?`GQ]JT]46 M3*T;QK,M:"5+XFVS=ABR_-Z7*,U'P8KYSLRM7$LQL%].T7(O&B;2T>CGO';R M$6JWSG""%4OREQ8UN^0PU^S_/I&)/:4*#EJUDQ;QUX[*'SW;9Z$\8M4Z5I-[ M;_SP/#H]%[VI/Z681"_?TA1WW8-S@?%J>1C]J7E[3\W%=4JD9%-2#JRGD1=$ M1?C7$'_[H+4&LXI<6VX7E9X956*EHAKK#*"I;RUFT-X@I:]]YW:BQH-&#B5- MRXD#QFPC(C4KA[*D[WRXBISAE2,HGDK@%)FUI\6\U@7+U=XO;8-8:T*+[>?@ MFT!MG.<+=E(AV]QL,"=>I&UY`I=6BK[7DLO[9NH<*'6#;*$!^XOISS#$EE$IS7?2+ZROR!^&.$#$-=#VA$H!E?:8 MQM(]J@B;6E?4Z744\#2@4*^A@B^:=EK*52?J&50T5U.EOE?>$R\"L&]^RW`D M6PUYP22-U.7>/B`I)=_\FG$CL47'"R:J[%ZA7"FT-0=7]QFN]<53Y<3:;9HX MP,J'(LJ2UQ^`9\_FEO^MP0QVEF87T]@YU%0\0D?O?.-KVM8I!&<(.?@2:'R# MJH*:T4"=5T,S7F@%/?+G;&B)ZV55PXFU M^^<92#2]X`#X)1KM&DPA'23J9EB^)R0W962^35#UH5-AP%08XL#QGH_F?!@EBJS MK"6927CG0OO4159%#:R8(-)#=L;B%*"1JDN4,CL#PH/#>G>ZE@(MSPYG*!:7 M@3:'0ZKR3CQM3NN"/%H*1*NF3=D=@8,1_>'1,O^?%W ML%)FLW/#FCK*J&&E\\"D:J_D?>UX1WXJ#Z`Q5EAQ@B&(>O'H'3(IU2BE:I3D M+$PT_"?DA@0"?W4*71+]JT(_/VSW='X#F"3JV9?=*J-QV7!#XGA.D:_,Q&0' M[:`?F$,EP;I.B!D-_!FX[N\>>O!N@(61%_5EJ#KW$0.^;/@.BJ`4J408LM?B MT[%N5&*I+#0M'K9+QJ8$F`3S(UECDXR[CG=/R6\4V/>R@3NTL99BDZ!>(^#, MCAU)50ORZ:&[X\%7P).`_WKM5)9DNG_=HV/2;A+LG_\/4$L#!!0````(``^" MKT)PQD_G%@L``/U<```1`!P`8FMY:2TR,#$S,#,S,2YXJ:FNH0M0(DM$4DF(;]^)=D&8WPC9+.>+G@"69?OG$\ZYT@ZYM,_ MBD5P@0AB4"`3#.<`-_>$_0LH@B:UIWT#@S81\JDA\`S),C)#3/Z6SR="3(]+ MI:>GIP^&K,H-S!"G#C,05P6@6#P%ZO/WOWU2@S094D,<@PXEH`/GH%(#U>IQ M[?"X_!'<#)J@6I8ENI%L\?.'9T;5.PDIA/44G60`P;!2`@&R-Q!6W$I]!`BV9#3(L/:*YD M*2ELY5JMXG?_S%=Z?ZKY2"JEN\YE7R-?0*$D`QI*B@M$;CN'%]6CY4@CR(>Z ME?]$P:H6RY5B`)B%R4,4MDJ]7B_IIW[5M9JK&E6/AY!+C2(+V8B(<\KL%AI! MQQ(GA4<'6GB$D>GW-GR8XVRJDZ.88E$U..A!R7U8.-73!@`U#2`A5$"!*?%+ MO?+I%),1/?7+9*F"?.SCOD8CH.4]5KHZ*7!L3RTU/W39A*'124&!+OH`?UAP M^$%B]*M`9C!JH61EEJ:,3N6*P)*-I<;<#M9:KRI8/2[),9%UN81<*)V^F3Q3 MAMY='CDFEW-%\Q42Z^V(,M'HW0638V*"(\1Z*Z$,:+V[4'),P[$BR5H52]4> M2$&`^G)SW8YI]5-I M6Z73ZPEX/ M7I7DMJNS)-PR9>`0&Z'6"T)**XRLKZOMN?K1@TQJ8(($EIAX!NK"+5*8K+Z& M2;"W.L@O$=3N>`WSVB:R&"V4'<-EN%:$.E8(K&4C<%&%`SH"[B!@[X9`Q\3R M>12#.PK7*&Q"/CFWZ%,,=XO'IQ%"K+"V_QK65/=`]<]3F-L1IXB[H@(%B-(_ M4ZSA@:2BA;EA4>XP)'^H1D!YNU\AQYJ$7D!_D1YMIWQ?^>60]LOIZ^(PD@#E MI"XH)F.U.@S$HA6_4WU`]6NZ=Y6?HOZC2/5K%S.1'E^M`FVB[*DT5G%+8,?" MDH5U&LJI'OUC)`G*8YQ!1N0JX*"'F,?(WC\?'2K^<];KNU\B'?F.DB`E$9QX MBR.1EGHD+0?>%\D)G,.AA7:F*0,#41244YQSI1Q)P*&.I*CQ,*&6B1C_%VC) M1@9&Q)COC%,:#Y%$I/OI2B62"^4^^FBL8]HV&5%F[WQ$-AJB>^;WWZW:`;D;=INM M]OQB\/CUI7/4F]SOW]4-\ZA2?:R]U'G=MB]LZ^*^.D:CUK3QQ3JBO7&C"4>7 M![?W;;OM[,.GC_76@V/UQK;QC9Y5:\UF_5#<"/OL4(RY^?E\7XRKMY56JR'@ MY\[M[6^-[I%1/?N]^8A)'__VL?0X*U7-5N?L<(#;^]/:0>U[^Z+BE"XZ\UFU M\D!&=]^O.[?WS:]?Z]7+SW8:E`RGEV`/;?#&"ORLTW/UY&A%[:Z!#.#!OCL67U%7*_N`$M9 M:J?2M_G9QX))OTYQN%['1[%SY#%4RUA'+@QL83TF'5VIW`LH**,C=>AJR,"H MA2U'(%,:^.82W=HLV+*CM%!NNV.9X%Q9!:I"\P54]4.#U?&@!Q?(;D`0\"[^ M2)A/#2*PJ12'9ZB/#(=A=2D?GBQ)M=)F0O1)T&MF@D)1]&&`)8Z=:\CBI\/Q MI5^:'E]6H\^2U@[S=KYZ,T)B&$G=)U>CSY.2SO92J-EQL\9-'#D9#K^KT8=, M,>=].VHVIB:6F[13\>K6)TP[MK*PU:*&/C!M$/-,.FTQ#\QWE[O$&NG72VL> MR>]/!@DR`M0]IARJ_Z1D?2JMY!CK4K=L)1_9+9?%V)Y2)@!92R-/RE5W4]PO MJ:'[2VBB?A7]=D555*Q4B[7*AV=N+M(U-X2A!'<31C>#X;=[%8SD'/88(!I$ ML.48PJEN6$*6X(N^BLN^%H@VU,SZZP%9E!-NI5135ZJI'&X/)/AFP&9@*+E* MP),!461R?M;IXC=0@Q^LJ\%[JT"/>E)8I*+%99CRQI`+]1I*`;@9U?J-D&-9 M)K<^;8%LM7P+`'JU3@J".2H76M>:2B50L&H,_4'P;+[U>2[K%@3)`Z&F,L`,S]2IN`KK5B_#&0NLPJ[(S<3=)%-F!^A M7XW<>Q$@2A=)\,(&D7*[D1ZQD M>/%B?4-X/%&\SA"#8Z0/4WC7$E6"]7/+>9_Q;6:`#Y^!OB- MSAFUNU-U/JJ4J=Y^U&=D.1(_(]!X41OFO=RF:64-J'\\C*Z0N*2:X5\[\1*VD9-6P9/N$7C3M'>HA"E6@-I)DA:_6C(PS8]$&3#&"ZCOZ+TK^AS*E@QO0[%\<=SWX8^%7QXET@A:_#UE MBC<8R],Q&5`$KMBOD:5?OE+QLPZ^]$U]#\Y=QY,_+M]*D%A-^=>0/<1T/SG4 M03K$T,E(:"Z@H5BJ,8?RI0&,Y2ZXV3][=+"8Z_N`/,NZ.>1X>^5=)\E=HPJ9 MR#C?@F\`-G$ZJTQMG:B]["&/ABL;S.2S14/^F/"H[ M+3_B9L29.)%74YNZRQRLKIN#U5CF8$UY,*4I/VK87H2DG9WN8M%E?J2.P96P MEE7N4FLM@RH_$J7@2SE%D!N([NC<(2:_1M*E,60.J#KF<@SAG4U(QKND0XF8 M6'.]\U@5V:8$"Y M;Y.J4/[I=3-LF\#VU>#3+N&4II'9MV:& MFN@J>PXS)M+;GCU+&C%'7>;^I1^7HZ]T,YC(,$N%UWJW&%X^K];#UC-A6P$2 MM;,6>_78P$M93,ZR!XB%CJ.,:D-,7GG.1V# M+(4C&?E0V7V^1(F"E43*X(DNDN3R(T4$JGAW/)A(B'PA>(ZDB`26X`:DX9A) M9]*6AD0*S_J]1GZ$B<66-+M\ZZ@MHG\%[ET5=R![4*$&-M#"-.K;X_S(O`W\ M)+7TT0P1SVQZ?V6+A\I_!D.J_*AA$[CQR[1+D+^F\R/:.JA$HQ]T%+E:G='` M$DR-"DM0'BU_%*[XL_[@`KW0_^S,_L(F9G,)$F?K%65BTM"9EY#D1^0H6$G6 M,BFW/#\G+IE0ZHFLT[?=Y%5W??X74$L!`AX#%`````@`#X*O0K6]@XV'1@`` MY?H$`!$`&````````0```*2!`````&)K>6DM,C`Q,S`S,S$N>&UL550%``,= M[9-1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`#X*O0A+7K/L'"0``YF$` M`!4`&````````0```*2!TD8``&)K>6DM,C`Q,S`S,S%?8V%L+GAM;%54!0`# M'>V3475X"P`!!"4.```$.0$``%!+`0(>`Q0````(``^"KT(+,[7STAL``(GM M`0`5`!@```````$```"D@2A0``!B:WEI+3(P,3,P,S,Q7V1E9BYX;6Q55`4` M`QWMDU%U>`L``00E#@``!#D!``!02P$"'@,4````"``/@J]"P@M\D$TV``!` MH0(`%0`8```````!````I(%);```8FMY:2TR,#$S,#,S,5]L86(N>&UL550% M``,=[9-1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`#X*O0D4"J2(.'0`` M5.P!`!4`&````````0```*2!Y:(``&)K>6DM,C`Q,S`S,S%?<')E+GAM;%54 M!0`#'>V3475X"P`!!"4.```$.0$``%!+`0(>`Q0````(``^"KT)PQD_G%@L` M`/U<```1`!@```````$```"D@4+```!B:WEI+3(P,3,P,S,Q+GAS9%54!0`# I'>V3475X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``"CRP`````` ` end XML 18 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 4 - Earnings Per Share ("EPS")
3 Months Ended
Mar. 31, 2013
Earnings Per Share [Text Block]
4.                      EARNINGS PER SHARE (“EPS”)

The Company’s basic EPS is calculated using net income available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of convertible notes and preferred stock.

The reconciliation of the numerator of the basic and diluted EPS calculations was as follows for the three month periods ended March 31, 2013 and 2012:

   
Three Months ended
March 31,
 
   
2013
   
2012
 
             
Basic Numerator:
           
             
Net (loss) income
  $ (315,579 )   $ 363,498  
                 
Basic Denominator:
    81,465,289       78,155,413  
Per Share Amount
  $ 0.00     $ 0.00  

The following table summarizes the potential weighted average shares of common stock that were included in the diluted per share calculation for the three months ended March 31, 2013 and 2012.

   
Three Months Ended
March 31,
 
   
2013
   
2012
 
             
Stock Options
    -       759  

   
Three Months ended
March 31,
 
   
2013
   
2012
 
             
Dilutive Numerator:
           
             
Net (loss) income
  $ (315,579 )   $ 363,498  
                 
Dilutive Denominator:
    81,465,289       78,156,172  
Per Share Amount
  $ 0.00*     $ 0.00*  

* Represents less than $0.01 per share

The following table sets forth the options and warrants which were excluded from the diluted per share calculation even though the exercise prices were  less than the average market price of the common shares because the effect of including these potential shares was antidilutive due to the net losses for the three months ended March 31, 2013 and 2012:

   
Three Months Ended
March 31,
 
   
2013
   
2012
 
             
Stock options
    647,660       -  
Warrants
    -       -  
                 
Total
    647,660       -  

The following table sets forth options and warrants which were excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:

   
Three Months Ended
March 31,
 
   
2013
   
2012
 
             
Stock options
    3,025,000       4,588,560  
Warrants
    8,250,000       8,250,000  
                 
Total
    11,275,000       12,838,560  

EXCEL 19 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]B93'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I7;W)K#I7;W)K#I. M86UE/@T*("`@(#QX.E=O#I%>&-E M;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?-%]%87)N:6YG#I7;W)K#I%>&-E;%=O6%B;&5?1&5T86EL/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?-U]396=M96YT7TEN9F]R;6%T:6]N7T1E M=#PO>#I.86UE/@T*("`@(#QX.E=O#I3='EL97-H965T($A2968],T0B5V]R:W-H965T&-E;"!84"!O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]B93'0O:'1M;#L@8VAA2!);F9O2`Q,BP@,C`Q,SQB'0^0DE/($M%62!)3E1%4DY!5$E/3D%, M($E.0SQS<&%N/CPO'0^,3`M43QS<&%N/CPO'0^+2TQ,BTS,3QS<&%N/CPO'0^9F%L2!# M96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,3`Q.3`S-#QS<&%N/CPO'0^665S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^3F\\2!&:6QE3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^4VUA;&QE3QS<&%N M/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF5D("AI;B!3:&%R97,I/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ-S`L,#`P+#`P,#QS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S2!O<&5R871I;F<@86-T:79I=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@(`T*("`@("`@86-C;VUP M86YY:6YG('5N875D:71E9"!I;G1E0T*("`-"B`@("`@("AC;VQL96-T:79E;'DL('1H92`F(S@R,C`[0V]M M<&%N>28C.#(R,3LI(&%N9"!A2!A8V-E<'1E9"!I;@T*(`T*("`@("`@=&AE(%5N:71E9"!3=&%T97,@;V8@ M06UE2!A8V-O=6YT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);@T*("`-"B`@("`@ M('1H92!O<&EN:6]N(&]F(&UA;F%G96UE;G0L('1H92!A8V-O;7!A;GEI;F<@ M=6YA=61I=&5D(&EN=&5R:6T-"B`@(`T*("`@("`@8V]N0T*("`- M"B`@("`@(&%D:G5S=&UE;G1S+"!C;VYS:7-T:6YG(&]N;'D@;V8@=&AO2!T:&4@0V]M<&%N>28C.#(Q-SMS#0H@ M("`@#0H@("`@("!F:6YA;F-I86P@<&]S:71I;VX@86YD('1H92!R97-U;'1S M(&]F(&ET65A0T*("`@#0H@("`@("!)6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[ M($U!4D=)3BU224=(5#H@,S9P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@ M/&9O;G0@6EN9R!C;VYS;VQI9&%T960-"B`@#0H@("`@("!F M:6YA;F-I86P@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@ M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494 M.B`P<'0[($U!4D=)3BU224=(5#H@,S9P="<@86QI9VX],T1L969T/@T*("`@ M#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4 M:&4-"B`@(`T*("`@("`@0V]M<&%N>2!H87,@:6YC=7)R960@2`D-3,@;6EL;&EO M;BX@26X@861D:71I;VXL(&)R;V%D(&-O;6UE28C.#(Q-SMS('1E8VAN;VQO9WD@ M:7,@8W)I=&EC86P@=&\-"B`@("`@#0H@("`@("!T:&4@0V]M<&%N>28C.#(Q M-SMS('-U8V-E2`D-#4R+#`P,"P@ M87,@8V]M<&%R960-"B`@(`T*("`@("`@=&\@87!P2`D.#0L M,#`P(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3(N/"]F;VYT/@T*("`@("`- M"B`@("`\+V1I=CX\8G(O/CQD:78@&EM871E M;'D@)#,Y,"PP,#`@<&5R(&UO;G1H('1O#0H@(`T*("`@("`@8V]N9'5C="8C M,38P.R8C,38P.V]P97)A=&EO;G,L(&$@;6]N=&AL>2!A;6]U;G0@=&AA="!W M92!H879E#0H@("`@(`T*("`@("`@8F5E;B!U;F%B;&4@=&\@86-H:65V92!T M:')O=6=H(')E=F5N=64@9V5N97)A=&EO;BX\+V9O;G0^#0H@("`@(`T*("`@ M(#PO9&EV/CQB6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$=7)I M;F<-"B`-"B`@("`@('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L M(#(P,3,L('1H92!#;VUP86YY(')A:7-E9`T*("`@(`T*("`@("`@<')O8V5E M9',@;V8@)#$L,CDW+#`P,"!N970@;V8@9F5E2!N;W1E(&%N9"!S:&%R97,@;V8@8V]M;6]N('-T;V-K("X-"B`-"B`@("`@ M(%-E92!.;W1E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY)9@T*("`-"B`@("`@ M('1H92!#;VUP86YY(&ES('5N86)L92!T;R!G96YE2!T;R!E>&5C=71E(&ET2!T:&4@0V]M<&%N>2P@:6X@;W)D97(@=&\@;65E="!I=',@;F5E9',L M#0H@(`T*("`@("`@;W(@=&AA="!S=6-H(&9I;F%N8VEN9R!W;W5L9"!N;W0@ M8F4@9&EL=71I=F4@=&\@97AI6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@(`T*("`@("`@86-C;VUP86YY:6YG M(&9I;F%N8VEA;"!S=&%T96UE;G1S(&AA=F4@8F5E;B!P2!A2!T;PT*("`@ M("`-"B`@("`@(&-O;G1I;G5E(&%S(&$@9V]I;F<@8V]N8V5R;BX@4F5C;W9E M2!T M;R!M965T(&ET2!B92!U;F%B;&4@=&\@8V]N=&EN=64@:6X-"B`@("`@#0H@ M("`@("!E>&ES=&5N8V4N/"]F;VYT/@T*("`@("`-"B`@("`\+V1I=CX\8G(O M/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$;&5F=#X-"B`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U!4D=)3BU224=(5#H@ M,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`@(`T*("`@("`@/&9O;G0@28C.#(Q-SMS#0H@("`-"B`@("`@ M('5N875D:71E9"!C;VYD96YS960@8V]N6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R<^#0H@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0V."4@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@ M/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@("`-"B`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0V('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#,P)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`R<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1) M3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\ M='(^#0H@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0V."4@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@ M/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@("`-"B`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$T)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`R<'@@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@ M3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&1I=B!S M='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@ M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=( M5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^,C`Q,CPO9F]N=#X-"B`@("`-"B`@("`@("`@("`@(#PO9&EV M/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@ M;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L M9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@#0H@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0V."4@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`-"B`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8X)2!S='EL93TS M1"=,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`@(`T*("`@("`@("`@("`@/&9O M;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U)SX-"B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@ M(`T*("`@("`@("`\='(@6QE/3-$)TQ)3D4M2$5)1TA4 M.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y% M+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XW-7!T M)R!A;&EG;CTS1&QE9G0^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXQ,2PQ,C$\+V9O;G0^#0H@("`@(`T*("`@("`@("`@(#PO M=&0^#0H@(`T*("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`@("`- M"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,3,E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@#0H@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0V."4@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,3AP=#L@34%21TE.+5))1TA4.B`P+C6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY297-E87)C:"P-"B`@#0H@("`@("`@("`@("`@(&1E=F5L;W!M M96YT(&%N9"!E;F=I;F5E6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A% M24=(5#H@,2XR-2<^#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@ M(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1) M3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D(&%L:6=N/3-$#L@3$E.12U(14E' M2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXD/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T* M("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@(`T*("`@ M("`@("`@("`@/&9O;G0@'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR M-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU, M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@(`T*("`@("`@ M0V]M<&%N>28C.#(Q-SMS(&)A6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U!4D=) M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`@(`T*("`@("`@/&9O M;G0@6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R<^#0H@#0H@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V."4@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T* M("`@(`T*("`@("`@("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N M,C4G/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT M/@T*("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&-O M;'-P86X],T0V('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,P)2!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`T+CAP M="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@ M#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O M;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI M9#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&1I M=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2 M24=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=% M24=(5#H@8F]L9"<^,C`Q,SPO9F]N=#X-"B`@("`-"B`@("`@("`@("`@(#PO M9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\ M=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@ M8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI M9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z M(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N M/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX- M"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@ M/&9O;G0@6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@+3$X<'0[($1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P M+CAP="<@86QI9VX],T1L969T/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5) M1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5) M1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L M969T/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,S$U+#4W.3PO9F]N=#X-"B`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F M;VYT/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\ M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@ M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0V."4@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@3$E.12U(14E'2%0Z(#$N,C4G/@T* M("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q) M3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q) M3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@ M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z M("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U! M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXX,2PT-C4L,C@Y M/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$S)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@3$E.12U(14E'2%0Z M(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO M='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@#0H@("`@("`@("`@/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V."4@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%2 M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/@T*("`@(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4 M.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R<^ M#0H@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0V."4@#L@ M3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@ M#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@("`-"B`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#,P)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R M<'@@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`R+CAP="<@86QI9VX],T1C96YT97(^#0H@("`- M"B`@("`@("`@("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T* M("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@3$E.12U(14E'2%0Z(#$N,C4G/@T* M("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@ M,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=) M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$8V5N M=&5R/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,C`Q,SPO9F]N=#X- M"B`@("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\ M+W1D/@T*("`-"B`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U M)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,3AP=#L@34%21TE.+5))1TA4.B`P+C6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY3=&]C:PT*("`@#0H@("`@("`@("`@("`@($]P=&EO;G,\+V9O M;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@ M("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)TQ)3D4M2$5)1TA4 M.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$S)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@3$E.12U( M14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!S='EL93TS1"=415A4+4%, M24=..B!R:6=H=#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@/"]T86)L93X\8G(O M/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H M/3-$.34E('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0H@("`@ M#0H@("`@("`@(#QT6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`T+CAP="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M.R!&3TY4+5=%24=(5#H@8F]L9"<^36%R8V@F(S$V,#LS,2P\+V9O;G0^#0H@ M("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D M/@T*("`-"B`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@ M("`@("`\='(^#0H@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0V."4@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@ M("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@("`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`R<'@@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@ M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=) M3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^,C`Q,CPO9F]N=#X-"B`@("`-"B`@("`@("`@("`@ M(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@ M("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@ M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0V."4@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$ M6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`-"B`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^ M#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@ M("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U) M3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`- M"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5) M1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`-"B`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@#0H@("`@("`@ M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V M."4@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5) M1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`-"B`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&1I M=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z("TQ M.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=) M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXD/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`@ M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXS-C,L-#DX/"]F;VYT/@T*(`T*("`@("`@("`@ M(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@ M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR-2<^ M#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)V)A8VMG6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^1&EL M=71I=F4-"B`@("`@#0H@("`@("`@("`@("`@($1E;F]M:6YA=&]R.CPO9F]N M=#X-"B`@("`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A% M24=(5#H@,2XR-2<^#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXW."PQ-38L,36QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=, M24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XX M<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXP+C`P*CPO9F]N=#X-"B`@("`-"B`@("`@("`@ M("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@ M)B,Q-C`[#0H@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\ M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,S9P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[ M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`@#0H@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY4:&4-"B`@(`T*("`@("`@9F]L;&]W:6YG('1A8FQE('-E=',@ M9F]R=&@@=&AE(&]P=&EO;G,@86YD('=A6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`R M+CAP="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^36%R8V@F(S$V,#LS,2P\+V9O;G0^#0H@("`-"B`@("`@("`@ M("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@ M("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=% M24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@ M("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0W,"4@#L@ M3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@ M#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@("`-"B`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$S)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R M<'@@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@3$E.12U( M14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS M1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q! M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX M<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L M9"<^,C`Q,CPO9F]N=#X-"B`@("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@ M("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@;F]W6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q M-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@#0H@("`@("`@("`@ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@ M6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4 M.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U)SX-"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&1I=B!S M='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z("TQ.'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU2 M24=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^#0H@("`@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@ M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXV-#6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@ M3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E' M2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXM/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`- M"B`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1) M3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D(&%L:6=N/3-$#L@3$E.12U(14E' M2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@3$E. M12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A% M24=(5#H@,2XR-2<^#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@ M("`\='(^#0H@("`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M M2$5)1TA4.B`Q+C(U)SX-"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$#L@ M3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T M<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@3$E.12U(14E'2%0Z(#$N M,C4G/@T*("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXM/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T* M("`-"B`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@/"]T86)L93X\8G(O/CQD:78@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@(`T*("`@("`@9F]L M;&]W:6YG('1A8FQE('-E=',@9F]R=&@@;W!T:6]N&5R8VES92!P6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R<^#0H@#0H@("`@("`@("`@ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W,"4@ M#L@3$E.12U(14E'2%0Z(#$N M,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@#L@3$E.12U(14E' M2%0Z(#$N,C4G/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[ M/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(X)2!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`R+CAP="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@ M("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1% M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U! M4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+5=%24=(5#H@8F]L9"<^,C`Q,SPO9F]N=#X-"B`@("`-"B`@("`@("`@ M("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@ M("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=% M24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP M="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@ M#L@3$E.12U( M14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@+3$X<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5)) M1TA4.B`P+C6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY3=&]C:PT* M("`@#0H@("`@("`@("`@("`@(&]P=&EO;G,\+V9O;G0^#0H@("`@(`T*("`@ M("`@("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T* M("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@3$E.12U(14E'2%0Z(#$N,C4G/@T* M("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M=#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O M;G0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXX+#(U,"PP,#`\+V9O;G0^#0H@("`-"B`@("`@ M("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@ M/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G M/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H=#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5) M1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5) M1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#6QE M/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@("`@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M(&%L:6=N/3-$#L@3$E.12U(14E'2%0Z(#$N,C4G M/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%, M24=..B!R:6=H=#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`-"B`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,BPX,S@L M-38P/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@ M("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@ M("`@/&9O;G0@3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B93'0O:'1M;#L@ M8VAA6%B;&4\8G(^/"]S=')O;F<^ M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^/&1I M=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2 M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@(`T*("`@("`@/&9O;G0@&-H86YG92!!9W)E96UE;G0\+V9O;G0^ M/"]F;VYT/@T*(`T*("`@(#PO9&EV/CQB&-H86YG92!A;&P@;V8@:&ES(&]U M='-T86YD:6YG('-H87)E2!. M;W1E(&1A=&5D(&%S(&]F($1E8V5M8F5R(#(X+"`R,#`Y(&ES2!T M:&4-"B`-"B`@("`@($-O;7!A;GD@=&\@37(N($-O;&%T;W-T:2!I;B!T:&4@ M;W)I9VEN86P@<')I;F-I<&%L(&%M;W5N="!O9@T*("`-"B`@("`@("0V-"PX M-S@@9F]R(&$@;F5W(&YO;BUC;VYV97)T:6)L92`W)2!396-U2!T:&4@0V]M<&%N>2!I;B!C87-H(&]N($1E8V5M8F5R M(#,Q+"`R,#$R+@T*("`@(`T*("`@("`@4'5R'1E;F1E9"!T;R!-87)C:"`S,2P@,C`Q,RX@26X@1F5B6%B;&4@=6YD97(@=&AE($-O M;&%T;W-T:0T*("`@(`T*("`@("`@3F]T928C,38P.R8C,38P.W=A2X\+V9O;G0^#0H@("`-"B`@("`\ M+V1I=CX\8G(O/CQD:78@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U!4D=)3BU2 M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`@(`T*("`@("`@/&9O;G0@ M2!A;F0@:7,@2!W:71H(&-E2!C;W5R6%B;&4@=6YD97(@=&AE($EN=&5R1&EG:71A;"!.;W1E('=A6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U! M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`@(`T*("`@("`@ M/&9O;G0@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXV+B8C,38P.SQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L\+V9O;G0^4U1/ M0TM(3TQ$15)3)B,X,C$W.PT*(`T*("`@("`@1$5&24-)14Y#63PO9F]N=#X- M"B`@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#,V<'0[($U!4D=)3BU224=(5#H@,S9P="<@86QI9VX] M,T1L969T/@T*(`T*("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@5$585"U$ M14-/4D%424]..B!U;F1E6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[ M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`@(`T*("`@ M("`@/&9O;G0@2!I28C.#(Q-SMS(&-O M;6UO;B!S=&]C:RD@:&%V:6YG(&$@<'5R8VAA6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#;VYC=7)R96YT;'D-"B`@#0H@("`@ M("!W:71H('1H92!C;&]S:6YG(&]F('1H92!T2!F:6YA;F-I;F<@=VET:"!A(&YU;6)E6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG M;CTS1&QE9G0^#0H@("`@(`T*("`@("`@/&9O;G0@2!I;F-U6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U!4D=)3BU2 M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`@(`T*("`@("`@/&9O;G0@ M6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@5$585"U$14-/4D%424]..B!U;F1E65A2!I;G-T2!B92!C;&%S2!I;G-T2!D M:60@;F]T(&%C8V]U;G0@9F]R#0H@(`T*("`@("`@=&AE7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`- M"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW+B8C M,38P.SQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L\ M+V9O;G0^4T5'345.5`T*("`@("`-"B`@("`@($E.1D]234%424]./"]F;VYT M/@T*(`T*("`@(#PO9&EV/CQB2P@3F]R M=&@@06UE&EM871E;'D@.3@E(&%N9"`Y-R4@;V8@=&AE($-O;7!A;GDF(S@R,3<[ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@(`T*("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#,V<'0[($U!4D=)3BU224=(5#H@-#`N-7!T)R!A;&EG;CTS1&QE M9G0^#0H@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q M,'!T)SY#87-H#0H@("`@#0H@("`@("!A;F0@8V%S:"!E<75I=F%L96YT6%B;&4L(&%C8W)U960@;&EA8FEL:71I97,L(&%N9"!N;W1E M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@ M("`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#,V<'0[($U! M4D=)3BU224=(5#H@-#5P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@/&9O M;G0@3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B93'0O:'1M;#L@8VAA MF5D(%!E6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M#0H@("`@#0H@("`@("`@(#QT6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`T+CAP="<@86QI9VX],T1C96YT97(^#0H@("`- M"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`Q+CAP="<@86QI9VX],T1C96YT97(^#0H@("`- M"B`@("`@("`@("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@ M("`@("`@("`@/&9O;G0@#L@3$E.12U( M14E'2%0Z(#$N,C4G/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q M-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A% M24=(5#H@,2XR-2<^#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U)SX-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$T)2!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR M-2<^#0H@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M)SX-"B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX- M"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXD/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`- M"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR-2<^ M#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@ M("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U) M3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X M<'0[($U!4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^#0H@("`@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H=#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$S)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@3$E.12U(14E' M2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO M='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D(&%L:6=N/3-$#L@3$E.12U( M14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`\+W1D M/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3,E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX- M"B`@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR,"PW M-#$\+V9O;G0^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@ M("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@ M("`@/&9O;G0@7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0H@("`-"B`@("`@("`@/'1R M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R<^#0H@#0H@("`@("`@("`@ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V."4@ M#L@3$E.12U(14E'2%0Z(#$N M,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@#L@3$E.12U(14E' M2%0Z(#$N,C4G/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[ M/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,P)2!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`T+CAP="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@ M("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1% M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U! M4D=)3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+5=%24=(5#H@8F]L9"<^,C`Q,SPO9F]N=#X-"B`@("`-"B`@("`@("`@ M("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@ M("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=% M24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`Q+CAP M="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@ M#L@3$E.12U( M14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@+3$X<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5)) M1TA4.B`P+CAP="<@86QI9VX],T1L969T/@T*("`@(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q) M3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q) M3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI M9VX],T1L969T/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,S$U+#4W.3PO9F]N=#X- M"B`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXI/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@ M("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^ M#0H@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0V."4@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX- M"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@3$E.12U(14E'2%0Z(#$N M,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O M;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^ M#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@ M("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U) M3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`- M"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXX,2PT M-C4L,C@Y/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@6QE/3-$)TQ)3D4M2$5)1TA4 M.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$S)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@3$E.12U( M14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@#0H@("`@("`@ M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V M."4@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1L969T/@T*("`@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX- M"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX- M"B`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^#0H@("`-"B`@("`@("`@/'1R('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R<^#0H@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0V."4@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@ M/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@("`-"B`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0V('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#,P)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`R<'@@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`R+CAP="<@86QI9VX],T1C96YT97(^ M#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N M,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@3$E.12U(14E'2%0Z(#$N M,C4G/@T*("`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A% M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[ M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N M/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,C`Q,SPO M9F]N=#X-"B`@("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@ M("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT M/@T*("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1C96YT97(^#0H@("`- M"B`@("`@("`@("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4 M.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P+C6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY3=&]C:PT*("`@#0H@("`@("`@("`@("`@($]P=&EO M;G,\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@(`T* M("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!A;&EG;CTS1')I M9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$S)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@ M3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H=#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@/"]T86)L M93X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T M:#TS1#DU)2!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`T+CAP="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M.R!&3TY4+5=%24=(5#H@8F]L9"<^36%R8V@F(S$V,#LS,2P\+V9O;G0^#0H@ M("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D M/@T*("`-"B`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@ M("`@("`\='(^#0H@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0V."4@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@ M("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@("`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)2!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`R<'@@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@ M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=) M3BU224=(5#H@,2XX<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^,C`Q,CPO9F]N=#X-"B`@("`-"B`@("`@("`@("`@ M(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@ M("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@ M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0V."4@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$ M6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`-"B`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^ M#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@ M("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U) M3D1%3E0Z("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X M<'0[($U!4D=)3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`- M"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5) M1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`-"B`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(^#0H@("`@#0H@("`@("`@ M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V M."4@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5) M1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`-"B`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&1I M=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z("TQ M.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=) M3BU224=(5#H@,"XX<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXD/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`@ M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXS-C,L-#DX/"]F;VYT/@T*(`T*("`@("`@("`@ M(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@ M("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR-2<^ M#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)V)A8VMG6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^1&EL M=71I=F4-"B`@("`@#0H@("`@("`@("`@("`@($1E;F]M:6YA=&]R.CPO9F]N M=#X-"B`@("`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A% M24=(5#H@,2XR-2<^#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXW."PQ-38L,36QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=, M24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z("TQ.'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U!4D=)3BU224=(5#H@,"XX M<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXP+C`P*CPO9F]N=#X-"B`@("`-"B`@("`@("`@ M("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@ M)B,Q-C`[#0H@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\ M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE&-L=61E M9"!F6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0H@(`T* M("`@("`@("`\='(@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@ M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=) M3BU224=(5#H@,BXX<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^5&AR964F(S$V,#M-;VYT:',F(S$V,#M%;F1E9#PO M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@ M("`@(#QD:78@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1C96YT97(^ M#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@ M(`T*("`@("`@("`@("`@/&9O;G0@#L@ M3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L M9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$S)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M)SX-"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!, M24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$ M6QE/3-$ M)V)A8VMG6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=( M5#H@,2XR-2<^#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM/"]F;VYT M/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@ M;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX- M"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@+3$X<'0[($1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4 M.B`P+C6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY787)R86YT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]- M.B!B;&%C:R`R<'@@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@3$E.12U(14E' M2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXM/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`- M"B`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1) M3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O M;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!,24Y%+4A%24=(5#H@,2XR-2<^ M#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR M-2<^#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE#L@3$E.12U(14E'2%0Z(#$N,C4[(%1% M6%0M24Y$14Y4.B`P<'0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4 M;W1A;#PO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@ M("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@86QI9VX],T1R:6=H M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@-'!X.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!, M24Y%+4A%24=(5#H@,2XR-2<^#0H@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[ M($Q)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@("`@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@ M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=) M3BU224=(5#H@,BXX<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^5&AR964F(S$V,#M-;VYT:',F(S$V,#M%;F1E9#PO M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@ M("`@(#QD:78@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P+CAP="<@86QI9VX],T1C96YT97(^ M#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@ M(`T*("`@("`@("`@("`@/&9O;G0@#L@ M3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@("`-"B`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L M9"<^)B,Q-C`[/"]F;VYT/@T*("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$S)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M)SX-"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!, M24Y%+4A%24=(5#H@,2XR-2<^#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$ M6QE/3-$ M)V)A8VMG6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=( M5#H@,2XR-2<^#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D(&%L:6=N/3-$6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@("`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\ M='(^#0H@("`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0W,"4@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@ M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z M("TQ.'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#$X<'0[($U! M4D=)3BU224=(5#H@,"XW-7!T)R!A;&EG;CTS1&QE9G0^#0H@("`@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@ M(`T*("`@("`@("`@("`@/&9O;G0@#L@3$E. M12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)V)A8VMG6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR M-2<^#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U)SX-"B`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R M:6=H=#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX- M"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@34%21TE.+5)) M1TA4.B`P<'0G/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE#L@3$E.12U(14E' M2%0Z(#$N,C4G/@T*("`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE M.R!415A4+4%,24=..B!R:6=H=#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXQ,2PR-S4L,#`P/"]F;VYT/@T*("`@(`T*("`@("`@("`@(#PO=&0^#0H@ M(`T*("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@#L@3$E.12U(14E'2%0Z(#$N,C4G/@T*("`@(`T* M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR-2<^#0H@ M(`T*("`@("`@("`@("`@/&9O;G0@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B93'0O M:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'!E;G-E'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XQ,2PQ,C$\7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&5R8VES92!03X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]B93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B93'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L92!/ M<'1I;VYS+"!796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6UE;G0@07=A'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B93'0O:'1M;#L@8VAA'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B93&UL#0I#;VYT96YT+51R M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y M<&4Z('1E>'0O:'1M;#L@8VAA&UL M;G,Z;STS1")U'1087)T7V)E-S1B,C@W7S`Q =,6%?-&4W85\Y,S XML 20 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 3 - Share Based Compensation
3 Months Ended
Mar. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
3.                      SHARE BASED COMPENSATION

The following table presents share-based compensation expenses for continuing operations included in the Company’s unaudited condensed consolidated statements of operations:

   
Three Months Ended March 31,
 
   
2013
   
2012
 
             
             
Selling, general and administrative
  $ 11,121     $ 2,223  
Research, development and engineering
    1,326       18,518  
    $ 12,447     $ 20,741  

XML 21 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Balance Sheets (USD $)
Mar. 31, 2013
Dec. 31, 2012
ASSETS    
Cash and cash equivalents $ 451,748 $ 83,989
Accounts receivable, net of allowance for doubtful accounts of $20,526 at March 31, 2013 and December 31, 2012 449,110 604,784
Due from factor 94,380 189,904
Inventory 4,351 4,186
Prepaid expenses and other 59,303 25,088
Total current assets 1,058,892 907,951
Equipment and leasehold improvements, net 18,531 24,267
Deferred finance costs 55,521  
Deposits and other assets 8,712 8,712
Intangible assets—less accumulated amortization 193,093 195,911
Total non-current assets 275,857 228,890
TOTAL ASSETS 1,334,749 1,136,841
LIABILITIES    
Accounts payable 649,308 931,276
Accrued liabilities 385,623 593,599
Deferred revenue 467,108 508,520
Note payable – related party   321,428
Total current liabilities 1,502,039 2,354,823
Note Payable 497,307  
Total non-current liabilities 497,307  
TOTAL LIABILITIES 1,999,346 2,354,823
STOCKHOLDERS’ DEFICIENCY:    
Common stock — authorized, 170,000,000 shares; issued and outstanding; 87,182,348 of $.0001 par value at March 31, 2013 and 78,155,413 December 31, 2012 8,718 7,815
Additional paid-in capital 51,930,685 51,062,624
Accumulated deficit (52,604,000) (52,288,421)
TOTAL STOCKHOLDERS’ DEFICIENCY (664,597) (1,217,982)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY $ 1,334,749 $ 1,136,841
XML 22 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 1 - Basis of Presentation
3 Months Ended
Mar. 31, 2013
Basis of Accounting [Text Block]
1.                      BASIS OF PRESENTATION

The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiary (collectively, the “Company”) and are stated in conformity with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).  The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Significant intercompany accounts and transactions have been eliminated in consolidation.

In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company’s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at December 31, 2012 was derived from the audited financial statements, but does not include all of the disclosures required by accounting principles generally accepted in the United States of America. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012 (the “Form 10-K”), filed on April 1, 2013.

Recently Issued Accounting Pronouncements

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

XML 23 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 6 - Stockholders' Deficiency (Detail) (USD $)
3 Months Ended 0 Months Ended 3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Feb. 26, 2013
InterDigital SPA [Member]
Feb. 26, 2013
Private Investor SPA [Member]
Mar. 31, 2013
Private Investor SPA [Member]
Stock Issued During Period, Shares, New Issues     4,026,935 5,000,000  
Stock Issued During Period, Sale Price Per Share (in Dollars per share)     $ 0.10 $ 0.10  
Proceeds from Issuance of Common Stock (in Dollars) $ 902,693   $ 402,693    
Purchase, Exercise or Conversion Price Per Share Threshold of Common Stock (in Dollars per share)     $ 0.10    
Proceeds from Issuance of Private Placement (in Dollars)       500,000  
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs (in Dollars)         $ 46,176
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 2,300,000 1,125,000      
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term 7 years        
Investment Options, Exercise Price (in Dollars per share) $ 0.17        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 3 years        
XML 24 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 9 - Major Customers and Accounts Receivable (Detail)
3 Months Ended
Mar. 31, 2013
Three Customers [Member]
Sales Revenue, Goods, Net [Member]
Mar. 31, 2012
Three Customers [Member]
Sales Revenue, Goods, Net [Member]
Mar. 31, 2013
One Customer [Member]
Accounts Receivable [Member]
Dec. 31, 2012
Two Customers [Member]
Accounts Receivable [Member]
Concentration Risk, Percentage 61.00% 76.00%    
Concentration Risk, Percentage 2     56.00% 88.00%
Concentration Risk, Percentage 2     56.00% 88.00%
XML 25 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 26 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 2 - Going Concern
3 Months Ended
Mar. 31, 2013
Going Concern [Text Block]
2.                      GOING CONCERN

The Company has incurred significant losses to date and at March 31, 2013,  had an accumulated deficit of approximately $53 million. In addition, broad commercial acceptance of the Company’s technology is critical to the Company’s success and ability to generate future revenues. At March 31, 2013, the Company’s total cash and cash equivalents were approximately $452,000, as compared to approximately $84,000 at December 31, 2012.

The Company has financed itself in the past through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. The Company currently requires approximately $390,000 per month to conduct  operations, a monthly amount that we have been unable to achieve through revenue generation.

During the three months ended March 31, 2013, the Company raised proceeds of $1,297,000 net of fees through the issuance of a senior secured promissory note and shares of common stock . See Notes 5 and 6.

If the Company is unable to generate sufficient revenue to meet our goals, it will need to obtain additional third-party financing to (i) conduct the sales, marketing and technical support necessary to execute its plan to substantially grow operations, increase revenue and serve a significant customer base; and (ii) provide working capital. No assurance can be given that any form of additional financing will be available on terms acceptable to the Company, that adequate financing will be obtained by the Company, in order to meet its needs, or that such financing would not be dilutive to existing shareholders.

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The matters described in the preceding paragraphs raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to meet its financing requirements on a continuing basis, and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

XML 27 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Balance Sheets (Parentheticals) (USD $)
Mar. 31, 2013
Dec. 31, 2012
Accounts receivable, allowance for doubtful accounts (in Dollars) $ 20,526 $ 20,526
Common stock, shares authorized (in Shares) 170,000,000 170,000,000
Common stock, shares issued (in Shares) 87,182,348 78,155,413
Common stock, shares outstanding (in Shares) 87,182,348 78,155,413
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
XML 28 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 2 - Going Concern (Detail) (USD $)
3 Months Ended
Mar. 31, 2013
Dec. 31, 2012
Mar. 31, 2012
Dec. 31, 2011
Retained Earnings (Accumulated Deficit) $ (52,604,000) $ (52,288,421)    
Cash and Cash Equivalents, at Carrying Value 451,748 83,989 211,003 43,437
Amount of Funds Required to Conduct Operations on Monthly Basis 390,000      
Net Proceeds from Issuance of a Senior Secured Promissory Note and Common Stock $ 1,297,000      
XML 29 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document And Entity Information
3 Months Ended
Mar. 31, 2013
May 12, 2013
Document and Entity Information [Abstract]    
Entity Registrant Name BIO KEY INTERNATIONAL INC  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   87,182,348
Amendment Flag false  
Entity Central Index Key 0001019034  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Filer Category Smaller Reporting Company  
Entity Well-known Seasoned Issuer No  
Document Period End Date Mar. 31, 2013  
Document Fiscal Year Focus 2013  
Document Fiscal Period Focus Q1  
XML 30 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 3 - Share Based Compensation (Detail) - Share-based Compensation Expenses (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Share-based compensation expense $ 12,447 $ 20,741
Selling, General and Administrative Expenses [Member]
   
Share-based compensation expense 11,121 2,223
Research and Development Expense [Member]
   
Share-based compensation expense $ 1,326 $ 18,518
XML 31 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements of Income (Unaudited) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Revenues    
Services $ 276,960 $ 395,854
License fees and other 527,683 1,014,573
804,643 1,410,427
Costs and other expenses    
Cost of services 40,715 124,017
Cost of license fees and other 77,098 57,413
117,813 181,430
Gross Profit 686,830 1,228,997
Operating Expenses    
Selling, general and administrative 732,076 604,884
Research, development and engineering 262,809 254,487
Total Operating Expenses 994,885 859,371
Operating (loss) income (308,055) 369,626
Other expenses    
Interest expense (7,524) (6,128)
Total Other expenses (7,524) (6,128)
Net (loss) income $ (315,579) $ 363,498
Basic (Loss) Income per Common Share (in Dollars per share) $ 0.00 [1] $ 0.00 [1]
Diluted (Loss) Income per Common Share (in Dollars per share) $ 0.00 [1],[2] $ 0.00 [1],[2]
Weighted Average Shares Outstanding:    
Basic (in Shares) 81,465,289 78,155,413
Diluted (in Shares) 81,465,289 78,156,172
[1] Represents less than $0.01
[2] Represents less than $0.01 per share
XML 32 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 7 - Segment Information
3 Months Ended
Mar. 31, 2013
Segment Reporting Disclosure [Text Block]
7.                      SEGMENT INFORMATION

The Company has determined that its continuing operations are one discrete segment consisting of Biometric products. Geographically, North American sales accounted for approximately 98% and 97% of the Company’s total sales for the three months ended March 31, 2013 and 2012, respectively.

XML 33 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 6 - Stockholders' Deficiency
3 Months Ended
Mar. 31, 2013
Stockholders' Equity Note Disclosure [Text Block]
6.                      STOCKHOLDERS’ DEFICIENCY

Issuances of Common Stock

Pursuant to a Securities Purchase Agreement dated February 26, 2013 by and between the Company and DRNC (the “InterDigital SPA”), the Company issued 4,026,935 shares of its common stock at a purchase price $0.10 per share, for an aggregate purchase price of $402,693. DRNC has anti-dilution rights under the InterDigital SPA that would require the Company to issue additional shares to DRNC on a full-ratchet basis if the Company, within the nine months following February 26, 2013, sells or issues any common stock or common stock equivalents (other than sales or issuances to directors, officers, employees or independent contractors in the ordinary course of business for compensation purposes and stock splits and stock dividends payable in respect of the Company’s common stock) having a purchase, exercise or conversion price per share of less than $0.10.

Concurrently with the closing of the transactions described above, the Company closed an equity financing with a number of private investors pursuant to a Securities Purchase Agreement dated February 26, 2013 by and between the Company and such private and institutional investors (the “Private Investor SPA”). Pursuant to the Private Investor SPA, the Company issued 5,000,000 shares of its common stock at a purchase price $0.10 per share, for an aggregate purchase price of $500,000.

In connection with the share issuances described above, the Company incurred costs of $46,176 which were offset against additional paid-in capital.

Issuances of Stock Options

For the three months ended March 31, 2013 and 2012, 2,300,000 and 1,125,000 stock options were granted, respectively. Terms of the options issued in 2013 include the following: term - 7 years, excercise price - $0.17, vesting - 3 years.

Derivative Liabilities

In connection with the issuances of equity instruments or debt, the Company may issue options or warrants to purchase common stock. In certain circumstances, these options or warrants may be classified as liabilities, rather than as equity. In addition, the equity instrument or debt may contain embedded derivative instruments, such as conversion options or listing requirements, which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative liability instrument. The Company accounts for derivative liability instruments under the provisions of FASB ASC 815, “Derivatives and Hedging.”

As discussed above, the Company issued shares to DRNC that contain anti-dilution rights.  The Company determined that the anti-dilution rights are embedded derivatives that must be bifurcated and recorded as derivative liabilities. In addition, the Company would be required to revalue the derivative liabilities at the end of each reporting period with the change in value reported on the statement of operations. The Company did not account for these derivative liabilities in its financial statements as it was determined to not be material.

XML 34 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 7 - Segment Information (Detail) (Geographic Concentration Risk [Member], North American [Member])
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Geographic Concentration Risk [Member] | North American [Member]
   
Concentration Risk, Percentage 98.00% 97.00%
XML 35 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 4 - Earnings Per Share ("EPS") (Detail) - Reconciliation of Numerator of Basic and Diluted EPS Calculations (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Basic Numerator:    
Net (loss) income (in Dollars) $ (315,579) $ 363,498
Dilutive Denominator: 81,465,289 78,156,172
Per Share Amount (in Dollars per share) $ 0.00 [1],[2] $ 0.00 [1],[2]
Basic Denominator: 81,465,289 78,155,413
Per Share Amount (in Dollars per share) $ 0.00 [1] $ 0.00 [1]
Stock Options   759
[1] Represents less than $0.01
[2] Represents less than $0.01 per share
XML 36 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 3 - Share Based Compensation (Tables)
3 Months Ended
Mar. 31, 2013
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
   
Three Months Ended March 31,
 
   
2013
   
2012
 
             
             
Selling, general and administrative
  $ 11,121     $ 2,223  
Research, development and engineering
    1,326       18,518  
    $ 12,447     $ 20,741  
XML 37 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 8 - Fair Values of Financial Instruments
3 Months Ended
Mar. 31, 2013
Fair Value Disclosures [Text Block]
8.                      FAIR VALUES OF FINANCIAL INSTRUMENTS                                                                                                                      

Cash and cash equivalents, accounts and notes receivable, accounts payable, accrued liabilities, and notes payable, are carried at, or approximate, fair value because of their short-term nature.

XML 38 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 9 - Major Customers and Accounts Receivable
3 Months Ended
Mar. 31, 2013
Concentration Risk Disclosure [Text Block]
9.                      MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLES

For the three months ended March 31, 2013 and 2012, three customers accounted for 61% and 76% of revenue, respectively.  At March 31, 2013, one customer accounted for 56% of accounts receivable.  At December 31, 2012, two customers accounted for 88% of accounts receivable.

XML 39 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 4 - Earnings Per Share ("EPS") (Tables)
3 Months Ended
Mar. 31, 2013
Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block]
   
Three Months ended
March 31,
 
   
2013
   
2012
 
             
Basic Numerator:
           
             
Net (loss) income
  $ (315,579 )   $ 363,498  
                 
Basic Denominator:
    81,465,289       78,155,413  
Per Share Amount
  $ 0.00     $ 0.00  
   
Three Months Ended
March 31,
 
   
2013
   
2012
 
             
Stock Options
    -       759  
   
Three Months ended
March 31,
 
   
2013
   
2012
 
             
Dilutive Numerator:
           
             
Net (loss) income
  $ (315,579 )   $ 363,498  
                 
Dilutive Denominator:
    81,465,289       78,156,172  
Per Share Amount
  $ 0.00*     $ 0.00*  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   
Three Months Ended
March 31,
 
   
2013
   
2012
 
             
Stock options
    647,660       -  
Warrants
    -       -  
                 
Total
    647,660       -  
   
Three Months Ended
March 31,
 
   
2013
   
2012
 
             
Stock options
    3,025,000       4,588,560  
Warrants
    8,250,000       8,250,000  
                 
Total
    11,275,000       12,838,560  
XML 40 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 5 - Notes Payable (Detail) (USD $)
0 Months Ended
Dec. 28, 2009
Thomas Colatosti [Member]
7% Convertible Promissory Note [Member]
Mar. 31, 2013
Colatosti Note [Member]
Dec. 31, 2012
Colatosti Note [Member]
Dec. 31, 2010
Colatosti Note [Member]
Feb. 26, 2013
InterDigital Note [Member]
Mar. 31, 2013
InterDigital Note [Member]
Debt Instrument, Interest Rate, Stated Percentage 7.00%     7.00% 7.00%  
Debt Instrument, Face Amount $ 64,878     $ 350,804 $ 497,307  
Notes Payable   0 321,428     497,307
Debt Instrument, Default Rate While a Nonpayment Default is Continuing         9.00%  
Debt Issuance Cost         $ 57,203  
XML 41 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
CASH FLOW FROM OPERATING ACTIVITIES:    
Net (loss) income $ (315,579) $ 363,498
Adjustments to reconcile net (loss) income to cash (used for) provided by operating activities:    
Depreciation 5,736 7,970
Amortization    
Intangible assets 2,818 2,817
Deferred costs 1,682  
Share-based compensation 12,447 20,741
Change in assets and liabilities:    
Accounts receivable trade 155,674 100,290
Due from factor 95,524  
Inventory (165) 1,129
Prepaid expenses and other (34,215) (8,176)
Accounts payable (281,968) (272,814)
Accrued liabilities (207,976) 18,016
Deferred revenue (41,412) (65,905)
Net cash (used for) provided by operating activities (607,434) 167,566
CASH FLOW FROM FINANCING ACTIVITIES:    
Issuance of common stock 902,693  
Repayment of note payable – related party (321,428)  
Proceeds from issuance of note payable 497,307  
Costs to issue common stock (46,176)  
Financing costs for note payable (57,203)  
Net cash provided by financing activities 975,193  
NET INCREASE IN CASH AND CASH EQUIVALENTS 367,759 167,566
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 83,989 43,437
CASH AND CASH EQUIVALENTS, END OF PERIOD 451,748 211,003
Cash paid for:    
Interest $ 51,494  
XML 42 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 5 - Notes Payable
3 Months Ended
Mar. 31, 2013
Debt Disclosure [Text Block]
5.                      NOTES PAYABLE

The 2010 Exchange Agreement

Effective as of December 31, 2010, the Company entered into a Securities Exchange Agreement (the “2010 Exchange Agreement”) with Thomas Colatosti (“Colatosti”), the Company’s Chairman of the Board. Pursuant to the 2010 Exchange Agreement, Mr. Colatosti agreed to exchange all of his outstanding shares of Series D Convertible Preferred Stock, including all accrued and unpaid dividends thereon, and the 7% Convertible Promissory Note dated as of December 28, 2009 issued by the Company to Mr. Colatosti in the original principal amount of $64,878 for a new non-convertible 7% Secured Promissory Note in the original principal amount of $350,804 (the “Colatosti Note”).

The principal and interest under the Colatosti Note was scheduled to be repaid by the Company in cash on December 31, 2012. Pursuant to a Note Amendment and Extension Agreement effective as of December 31, 2012, the maturity date of the Colatosti Note was extended to March 31, 2013. In February 2013, the principal balance and accrued interest owing under the Colatosti Note was repaid from the proceeds of the new financing (see Note 2).  At March 31, 2013 and December 31, 2012, the amount payable under the Colatosti Note  was $0 and $321,428, respectively.

2013 Note Purchase Agreement

Pursuant to a Note Purchase Agreement dated February 26, 2013 by and between the Company and DRNC (the “InterDigital NPA”). Pursuant to the InterDigital NPA, the InterDigital Note was issued in a principal amount of $497,307 and bears interest at a rate of 7% per annum, with a default rate of 9% per annum while a nonpayment default is continuing. The InterDigital Note matures on December 31, 2015, is secured by a security interest in all of the tangible and intangible assets of the Company and is subject to acceleration upon an event of default. Under the InterDigital NPA, commencing July 1, 2013, the Company is required to comply with certain financial covenants, including a leverage ratio covenant and an annual limit on capital expenditures other than in the ordinary course of business.. A portion of the proceeds from the sale of the InterDigital Note were used to repay the Colatosti Note in full, with the remaining proceeds to be used for other general corporate purposes.  At March 31, 2013, the amount payable under the InterDigital Note was $497,307.

In connection with the InterDigital NPA and InterDigital Note, the Company incurred costs totaling $57,203.  Such costs were capitalized and are being amortized over the term of the InterDigital Note on the effective interest method.

XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 36 114 1 true 19 0 false 4 false false R1.htm 000 - Disclosure - Document And Entity Information Sheet http://bio-key.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets Sheet http://bio-key.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://bio-key.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) false false R4.htm 003 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://bio-key.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Income (Unaudited) false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://bio-key.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) false false R6.htm 005 - Disclosure - Note 1 - Basis of Presentation Sheet http://bio-key.com/role/Note Note 1 - Basis of Presentation false false R7.htm 006 - Disclosure - Note 2 - Going Concern Sheet http://bio-key.com/role/Note0 Note 2 - Going Concern false false R8.htm 007 - Disclosure - Note 3 - Share Based Compensation Sheet http://bio-key.com/role/Note00 Note 3 - Share Based Compensation false false R9.htm 008 - Disclosure - Note 4 - Earnings Per Share ("EPS") Sheet http://bio-key.com/role/Note000 Note 4 - Earnings Per Share ("EPS") false false R10.htm 009 - Disclosure - Note 5 - Notes Payable Notes http://bio-key.com/role/Note0000 Note 5 - Notes Payable false false R11.htm 010 - Disclosure - Note 6 - Stockholders' Deficiency Sheet http://bio-key.com/role/Note00000 Note 6 - Stockholders' Deficiency false false R12.htm 011 - Disclosure - Note 7 - Segment Information Sheet http://bio-key.com/role/Note000000 Note 7 - Segment Information false false R13.htm 012 - Disclosure - Note 8 - Fair Values of Financial Instruments Sheet http://bio-key.com/role/Note0000000 Note 8 - Fair Values of Financial Instruments false false R14.htm 013 - Disclosure - Note 9 - Major Customers and Accounts Receivable Sheet http://bio-key.com/role/Note00000000 Note 9 - Major Customers and Accounts Receivable false false R15.htm 014 - Disclosure - Note 3 - Share Based Compensation (Tables) Sheet http://bio-key.com/role/NoteTables Note 3 - Share Based Compensation (Tables) false false R16.htm 015 - Disclosure - Note 4 - Earnings Per Share ("EPS") (Tables) Sheet http://bio-key.com/role/NoteTables0 Note 4 - Earnings Per Share ("EPS") (Tables) false false R17.htm 016 - Disclosure - Note 2 - Going Concern (Detail) Sheet http://bio-key.com/role/NoteDetail Note 2 - Going Concern (Detail) false false R18.htm 017 - Disclosure - Note 3 - Share Based Compensation (Detail) - Share-based Compensation Expenses Sheet http://bio-key.com/role/SharebasedCompensationExpensesTable Note 3 - Share Based Compensation (Detail) - Share-based Compensation Expenses false false R19.htm 018 - Disclosure - Note 4 - Earnings Per Share ("EPS") (Detail) - Reconciliation of Numerator of Basic and Diluted EPS Calculations Sheet http://bio-key.com/role/ReconciliationofNumeratorofBasicandDilutedEPSCalculationsTable Note 4 - Earnings Per Share ("EPS") (Detail) - Reconciliation of Numerator of Basic and Diluted EPS Calculations false false R20.htm 019 - Disclosure - Note 4 - Earnings Per Share ("EPS") (Detail) - Anti-dilutive Securities Sheet http://bio-key.com/role/AntidilutiveSecuritiesTable Note 4 - Earnings Per Share ("EPS") (Detail) - Anti-dilutive Securities false false R21.htm 020 - Disclosure - Note 5 - Notes Payable (Detail) Notes http://bio-key.com/role/NoteDetail0 Note 5 - Notes Payable (Detail) false false R22.htm 021 - Disclosure - Note 6 - Stockholders' Deficiency (Detail) Sheet http://bio-key.com/role/NoteDetail00 Note 6 - Stockholders' Deficiency (Detail) false false R23.htm 022 - Disclosure - Note 7 - Segment Information (Detail) Sheet http://bio-key.com/role/NoteDetail000 Note 7 - Segment Information (Detail) false false R24.htm 023 - Disclosure - Note 9 - Major Customers and Accounts Receivable (Detail) Sheet http://bio-key.com/role/NoteDetail0000 Note 9 - Major Customers and Accounts Receivable (Detail) false false All Reports Book All Reports Process Flow-Through: 001 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Process Flow-Through: 003 - Statement - Condensed Consolidated Statements of Income (Unaudited) Process Flow-Through: 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) bkyi-20130331.xml bkyi-20130331.xsd bkyi-20130331_cal.xml bkyi-20130331_def.xml bkyi-20130331_lab.xml bkyi-20130331_pre.xml true true XML 44 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 4 - Earnings Per Share ("EPS") (Detail) - Anti-dilutive Securities
3 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Exercise Price Less Than Average Market Price of Common Shares [Member] | Stock Options [Member]
   
Antidilutive securities 647,660  
Exercise Price Less Than Average Market Price of Common Shares [Member]
   
Antidilutive securities 647,660  
Exercise Price Greater Than Average Market Price of Common Shares [Member] | Stock Options [Member]
   
Antidilutive securities 3,025,000 4,588,560
Exercise Price Greater Than Average Market Price of Common Shares [Member] | Warrant [Member]
   
Antidilutive securities 8,250,000 8,250,000
Exercise Price Greater Than Average Market Price of Common Shares [Member]
   
Antidilutive securities 11,275,000 12,838,560